erlotinib hydrochloride has been researched along with Lung Neoplasms in 2456 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 505 (20.56) | 29.6817 |
| 2010's | 1662 (67.67) | 24.3611 |
| 2020's | 289 (11.77) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, J; Jiang, C; Li, H; Lin, Y; Qian, X; Xie, Y; Yin, Z; Yu, T; Zheng, S | 1 |
| Ieda, M; Nagashio, K; Sato, K; Tajiri, K | 1 |
| Dahal, A; El-Sadek, M; Emam, AM; Enriz, RD; Ibrahim, SM; Jois, SD; Kothayer, H; Singh, SS; Tosso, RD | 1 |
| Aguilar-Serra, J; Cortijo, J; Gimeno-Ballester, V; Milara, J; Pastor-Clerigues, A; Trigo-Vicente, C | 1 |
| Gao, S; Li, K; Li, X; Peng, ZY; Ren, H; Sun, X; Tang, SC; Wang, QS; Wang, R; Xiao, GD; Zhang, J | 1 |
| Chen, H; Gao, Y; Li, Z; Wang, J; Zhang, L; Zhang, P; Zhu, L | 1 |
| Chang, HC; Chang, YP; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Shen, L; Zhou, Y; Zhu, Y | 1 |
| Chen, JC; Cheng, HH; Chiang, CS; Chien, CC; Hsieh, JM; Huang, IH; Ko, JC; Lin, YW; Liu, LL; Tsao, YC; Tseng, PY; Wei, CL | 1 |
| Huang, DB; Kawashima, J; Koczywas, M; Kong, S; Kowalski, M; Neal, JW; Padda, SK; Reckamp, KL; Wakelee, HA | 1 |
| Endo, M; Harada, H; Kenmotsu, H; Ko, R; Kobayashi, H; Kodama, H; Mamesaya, N; Miyawaki, E; Miyawaki, T; Mori, K; Murakami, H; Naito, T; Nishioka, N; Omori, S; Ono, A; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Dai, JG; Gao, DC; Hou, B; Liu, QX; Lu, X; Zheng, H; Zhou, D | 1 |
| Akiyama, M; Chiba, S; Hirano, K; Maemondo, M; Nagashima, H; Sato, H; Sugai, T; Utsumi, Y; Yakuwa, K | 1 |
| Biegański, P; Godel, M; Kawano, DF; Kopecka, J; Kowalski, K; Riganti, C | 1 |
| Li, M; Luo, N; Qi, Y; Wang, M; Zhu, F | 1 |
| Azuma, K; Haratake, N; Hayashi, H; Nakagawa, K; Nakano, Y; Oki, M; Ota, K; Sakamoto, T; Seto, T; Shimokawa, M; Yamamoto, N; Yoshioka, H | 1 |
| Lee, JY; Lin, CF; Liu, SY; Lo, TK; Su, PL | 1 |
| Choowongkomon, K; Jiwacharoenchai, N; Kiriwan, D; Seetaha, S; Songtawee, N; Sousa, SF; Tabtimmai, L | 1 |
| Barrett, E; Frimodt-Moller, B; Garon, EB; Horinouchi, H; Kollmeier, J; Lipkovich, O; Nadal, E; Nakagawa, K; Novello, S; Reck, M; Shih, JY; Visseren-Grul, C; Wei, YF | 1 |
| Kagohashi, K; Satoh, H | 1 |
| Haga, Y; Hanamuro, S; Higashisaka, K; Izusawa, K; Konishi, H; Lin, Y; Nagano, K; Tsujino, H; Tsutsumi, Y; Yang, L | 1 |
| Alavala, S; Andugulapati, SB; Bathini, NB; Chella, N; Ganthala, PD; Sistla, R | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Dezfouli, AA; Dezfuli, MM; Heshmatnia, J; Lotfabadi, AS; Mirtavoos-Mahyari, H; Rismani, E; Sheikhy, K | 1 |
| Altıntop, MD; Ciftci, H; Fujita, M; Otsuka, M; Özdemir, A; Sever, B; Tateishi, H | 1 |
| Imoto, S; Miyano, S; Park, H; Yamaguchi, R | 1 |
| Mangan, MS | 1 |
| Bajan, S; Boonyaratanakornkit, V; Hutvagner, G; Kaewjanthong, P; McGowan, E; Sasano, H; Sooksai, S | 1 |
| Kibudde, S; Kirenga, BJ; Nabwana, M; Okuku, F; Orem, J; Walusansa, V | 1 |
| Gahlawat, SK; Grewal, AS; Lather, V; Saini, N | 1 |
| Agca, S; Arabaci, DH; Bilgic, SN; Domaniku, A; Kir, S; Weber, BZC | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Belani, CP; Holguin, RAP; Ma, PC; Reed, MF; Schaefer, E; Shen, C; Zhou, S | 1 |
| Bepler, G; Camidge, DR; Demedts, I; Goldman, JW; Grosch, H; Juan-Vidal, O; Mileham, K; Molina, J; Moran, T; Park, K; Smit, E; Wacheck, V; Wallin, J; Wang, XA; Wijayawardana, SR | 1 |
| Jeong, J; Kim, J | 1 |
| Chen, N; Liao, Y; Lv, W; Qiu, Y; Xiao, M; Zhang, H; Zhang, N; Zhu, S | 1 |
| Belal, A; Ma, X; O Aboelez, M; Xiang, G | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Besiroglu, M; Ozturk, A; Seker, M; Topcu, A; Turk, HM; Yasin, AI; Yurtsever, I | 1 |
| Chen, TY; Gao, YC; Liu, T; Qin, L; Ren, T; Tang, CH; Xu, K | 1 |
| Abdel-Aziz, HA; Abdelmoaz, MA; Al-Warhi, T; Albohy, A; Aljaeed, N; El Kerdawy, AM; Eldehna, WM; Elkaeed, EB; Elsayed, ZM; Said, MA | 1 |
| Berei, J; Dube, N; Eckburg, A; Gautam, S; Kuckovic, A; Lin, L; Osude, C; Patel, M; Puri, N; Rastogi, A; Smith, TJ; Sreenivassappa, SB | 1 |
| Arenare, L; Bonanno, L; Burgio, MA; Cavanna, L; Ciardiello, F; Cinieri, S; Costanzo, R; Crinò, L; D'Arcangelo, M; Dazzi, C; De Marinis, F; Di Liello, R; Esposito, G; Ferro, A; Gallo, C; Garassino, MC; Gargiulo, P; Gebbia, V; Gridelli, C; Morabito, A; Morgillo, F; Normanno, N; Papi, M; Perrone, F; Piccirillo, MC; Pozzessere, D; Proietto, M; Proto, C; Ricciardi, S; Rizzato, S; Rosetti, F; Tonini, G; Veccia, A | 1 |
| An, L; Chu, C; Duan, S; Li, L; Liu, C; Liu, Q; Wang, Z; Wu, G | 1 |
| Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Chauhan, SJ; Sahu, RP; Thyagarajan, A | 1 |
| Goto, K; Hosomi, Y; Kajihara, Y; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N | 1 |
| A El Hamd, M; Abdel-Ghany, H; Aboelez, MO; Abourehab, MAS; Belal, A; El Badry Abdel-Aziz, A; El-Remaily, MAEAA; Kamel, MS | 1 |
| Li, J; Yin, R; Yu, Y; Zou, Y | 1 |
| Choowongkomon, K; Mahalapbutr, P; Poo-Arporn, RP; Rungrotmongkol, T; Todsaporn, D | 1 |
| Li, F; Lu, Z; She, J; Sun, Q; Xia, H; Xue, D; Zhang, Y | 1 |
| Dhandha, S; Jaipuria, J; Khatri, M; Mattoo, S; Suryavanshi, M | 1 |
| Callies, S; Gao, L; Garon, EB; Nakagawa, K; Reck, M; Visseren-Grul, C; Walgren, R; Zimmermann, A | 1 |
| Abbaspour-Ravasjani, S; Asadollahi, L; Dorreyatim, SS; Hamishehkar, H; Mahoutforoush, A; Paiva-Santos, AC; Peixoto, D; Soltanfam, T; Veiga, F; Zeinali, M | 1 |
| Chalfant, CE; Darville, LNF; Haura, EB; Koomen, JM; Madanayake, TW; Robinson, TJ; Welsh, EA | 1 |
| Humphreys, IR; Ishmael, JE; Mattos, DR; McPhail, KL; Nguyen, MH; Serrill, JD; Smith, AB; Viollet, B; Wan, X | 1 |
| Asquith, CRM; Bieberich, AA; Crona, DJ; Fatig, RO; Laitinen, T; Maffuid, K; Morris, DC; Torrice, CD | 1 |
| Chen, Y; Ding, H; Huang, H; Jin, C; Liu, C; Zhang, C; Zhang, F; Zhao, Y; Zhu, L | 1 |
| Chen, M; Chen, Z; Li, F; Meng, L; Sun, J; Wang, J; Xu, Z; Yang, Q; You, Q; Yu, Y; Zhuo, W | 1 |
| Abe, S; Kusaba, Y; Naka, G; Takeda, Y; Tsukada, A | 1 |
| Chang, QZ; Chen, JC; Chiang, CS; Chien, CC; Hsieh, JM; Huang, IH; Ko, JC; Lin, YW; Liu, LL; Mu, BC; Tseng, PY | 1 |
| Bao, C; Deng, W; Huang, B; Jiang, Y; Kong, J; Li, D; Liu, L; Luo, J; Wang, K | 1 |
| Dong, W; Gong, Y; Hu, S; Li, M; Wang, C; Xie, C; Zhao, K | 1 |
| Aerts, JGJV; Dingemans, AC; Hurkmans, DP; Mathijssen, RHJ; Oomen-de Hoop, E; Paats, MS; van der Leest, CH; van Leeuwen, RW; van Thiel, ERE; Veerman, GDM | 1 |
| Alsfouk, AA; Eissa, IH; Elkady, H; Elkaeed, EB; Husein, DZ; Ibrahim, IM; Metwaly, AM; Yousef, RG | 1 |
| Bi, L; Chen, HZ; Dong, JK; Gu, WM; Lei, HM; Liang, Q; Luo, MY; Ma, P; Shen, NX; Shen, Y; Tang, YB; Wang, C; Xu, L; Zhou, Y; Zhu, L; Zhuang, G; Zou, JH | 1 |
| Chen, H; Fang, S; Hu, Z; Li, N; Liu, K; Pan, Q; Wei, Y; Xu, G; Xu, S; Zhu, L; Zhu, Y | 1 |
| Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y | 1 |
| Donald, BR; Feichtner, A; Guerin, N; Kaserer, T; Stefan, E | 1 |
| Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
| Guo, YW; Li, SW; Li, XW; Luo, C; Wang, H; Wu, Q; Xu, H; Yao, LG; Zhang, H | 1 |
| Jung, S | 1 |
| Angevin, E; Barlesi, F; Blot, V; Camidge, DR; Dunbar, M; Goldman, JW; Heist, R; Hong, DS; Kelly, K; Morgensztern, D; Motwani, M; Noon, E; Parikh, A; Spira, A; Strickler, JH; Su, WC; Vokes, E; Wu, J | 1 |
| Abbie, E; Boyne, DJ; Brenner, DR; Cheung, WY; Eaton, K; Elia-Pacitti, J; Ewara, EM; Gogna, P; Hu, LXY; Jarada, TN; O'Sullivan, DE; Pabani, A; Rose, JB; Yusuf, A | 1 |
| Chen, J; Gao, S; Keng, V; Li, N; Zhang, X; Zhao, Y | 1 |
| Boily, G; Boulanger, J; Golo, KT; Guédon, AC; Lehuédé, C; Qureshi, S; Roussafi, F; Strumpf, E; Truchon, C | 1 |
| Chang, CJ; Chen, CB; Chen, MJ; Chen, WT; Chung, WH; Fang, YF; Hsu, PC; Hui, RC; Hung, SI; Ko, HW; Ko, YS; Li, SH; Lu, CW; Lu, KL; Lu, LY; Pang, JS; Shih, FY; Tseng, LC; Wang, CL; Wang, CW; Wu, CE | 1 |
| Hu, Y; Huang, Y; Kuo, JC; Lee, RJ; Li, J; Su, F; Zhang, Z; Zhao, X | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Chang, CF; Chang, JW; Fang, YF; Hsu, PC; Huang, CY; Kuo, CS; Wu, CE; Yang, CT | 1 |
| Aredo, JV; Chaudhuri, A; Diehn, M; Guo, HH; Hui, AB; Joshi, ND; Loo, BW; Neal, JW; Padda, SK; Wakelee, HA | 1 |
| Chen, B; Cheng, Z; Ni, P; Sun, G; Wang, X; Wu, D; Yuan, T; Zhang, H; Zhang, Z | 1 |
| Cho, BC; Han, JY; Hong, MH; Kim, HR; Kim, HY; Lee, GK; Lee, KH; Lee, SH; Lee, Y; Lim, KY; Park, KU; Yoon, SJ | 1 |
| Goldman, J; John, T; Legg, D; Majem, M | 1 |
| Amelia, T; Kartasasmita, RE; Ohwada, T; Setiawan, AN; Tjahjono, DH | 1 |
| Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Lee, SH; Park, S; Sun, JM | 1 |
| Chan, CY; Chang, CM; Chen, YH; Hong, SC; Huang, CY; Liao, PC | 1 |
| Elcner, J; Fučík, J; Krzyžánek, V; Lízal, F; Mišík, O; Mravcová, L; Mravec, F; Mrázová, K; Szabová, J | 1 |
| Chen, CH; Hour, MJ; Hsieh, HH; Kuo, YH; Wu, TY | 1 |
| Aspeslagh, S; Auprih, M; Brandão, M; Cuccia, F; Dauby, N; Durieux, V; Fozza, A; Giaj-Levra, N; Verhaert, M | 1 |
| Besse, B; Cervantes, A; Cha, E; Costa, DB; Dowlati, A; Gettinger, S; Heist, R; Li, S; Ma, B; Riely, GJ; Rudin, CM; Schmid, P; Spahn, J; Villaflor, VM | 1 |
| Chen, KY; Ho, CC; Hsu, CL; Huang, CT; Liao, WY; Lin, CA; Su, TJ; Tsai, TH; Yang, CY; Yu, CJ | 1 |
| Chen, GY; Chen, KY; Liang, SK; Wei, YF; Weng, TI | 1 |
| Fan, XX; Huang, JM; Jiang, ZB; Leung, EL; Nie, XW; Shao, L; Sui, X; Wang, J; Wang, WJ; Wang, XR; Wu, QB; Xie, C; Xie, YJ; Xu, C; Yu, LL; Zhang, RN; Zhang, YZ; Zhao, ZM | 1 |
| Chen, HZ; Gong, M; Jiang, LL; Lei, HM; Liang, Q; Luo, MY; Shen, NX; Shen, Y; Wang, C; Xu, L; Zhang, KR; Zhang, MC; Zhang, R; Zhou, L; Zhu, L; Zhuang, G; Zou, JH | 1 |
| Boily, G; Boulanger, J; Pagé, É; Qureshi, S; Strumpf, E | 1 |
| Mohankumar, A; Ravisankar, R; Shivananda, N | 1 |
| Ab'Saber, AM; Baldavira, CM; Capelozzi, VL; Castelli, EC; Fabro, AT; Machado-Rugolo, J; Nagai, MA; Olivieri, EHR; Prieto, TG; Rainho, CA; Ribolla, PEM; Takagaki, T | 1 |
| Hanawa, T; Hyuga, S; Mori, E; Naoki, K; Odaguchi, H | 1 |
| Liu, M; Xiao, K; Yang, L | 1 |
| Ceccarelli, M; Garon, EB; Graham, HT; Nakagawa, K; Nishio, M; Novello, S; Paz-Ares, L; Popat, S; Reck, M; Visseren-Grul, C | 1 |
| Chen, M; Li, D; Li, H; Li, M; Shi, P; Yang, T | 1 |
| Al Hroot, J; Al-Husein, B; Mayyas, A; Zayed, A | 1 |
| Akazawa, Y; Igawa, S; Kaizuka, N; Kasajima, M; Kubota, M; Manaka, H; Mitsufuji, H; Nakahara, Y; Naoki, K; Sasaki, J; Sato, T; Yagami, Y; Yamada, K; Yamamoto, H; Yokoba, M | 1 |
| Cuan, X; Huang, Y; Luo, R; Sheng, J; Wang, X; Yang, X; Zhao, Y; Zhu, W | 1 |
| Abdelhady, H; Alanazi, MM; Aldossari, AA; Aleanizy, FS; Alkahtani, HM; Alqahtani, FY; Alsarra, IA; Fatani, WK; Haq, N; Shakeel, F | 1 |
| Costa, DB; Kobayashi, IS; Kobayashi, SS; Lee, MD; Rangachari, D; Sentana-Lledo, D; Shaffer, W; Sundararaman, S; VanderLaan, PA | 1 |
| Berger, W; Caban, M; Groza, D; Heffeter, P; Jaunecker, C; Keppler, BK; Koblmueller, B; Kowol, CR; Kryeziu, K; Mathuber, M; Mohr, T; Pirker, C; Schueffl, HH; Terenzi, A; Tolios, A | 1 |
| Chomphoo, S; Khawkhiaw, K; Ruangpratyakul, T; Saengboonmee, C; Seubwai, W; Sorin, S; Thithuan, K; Wongkham, S; Zeng, F; Zhou, Y | 1 |
| Beaver, JA; Goulart, BHL; Larkins, E; Singh, H | 1 |
| Chang, GC; Chiu, CH; Hsia, TC; Jen, MH; Lin, MC; Puri, T; Shih, JY; Su, J; Su, WC; Wang, AK; Wei, YF | 1 |
| Kosydar, R; Kwiatek, WM; Maciejewska-Prończuk, J; Oćwieja, M; Paluszkiewicz, C; Piergies, N | 1 |
| Aix, SP; Butts, BD; Garon, EB; Graham, H; Heymach, JV; Nakagawa, K; Nishio, K; Nishio, M; Novello, S; Paz-Ares, L; Popat, S; Reck, M; Visseren-Grul, C | 1 |
| Chen, JY; Ding, K; Gao, L; Lu, X; Ngan, SC; Sze, SK; Tang, G; Wang, W; Wang, X; Yao, SQ; Yuan, P | 1 |
| Antonia, SJ; Boyle, TA; Chiappori, AA; Creelan, BC; Gray, JE; Haura, EB; Kim, J; Neuger, A; Ozakinci, H; Saltos, AN; Sansil, S; Shafique, MR; Tanvetyanon, T; Ugrenovic-Petrovic, M | 1 |
| Abdullah, O; Abo Al-Hamd, MG; El-Hamamsy, MH; El-Moselhy, TF; Mehany, ABM; Sugiura, M; Tawfik, HO; Yamaguchi, K | 1 |
| Li, R; Li, S; Li, W; Zhang, F | 1 |
| Chen, YH; Deng, Y; Fu, JW; Xu, LJ; Yang, Y | 1 |
| Chang, HC; Chang, YP; Chen, YC; Chen, YM; Chuang, HY; Huang, KT; Lai, CH; Tseng, CC; Wang, CC | 1 |
| Chang, HC; Chang, YP; Chen, YM; Chuang, HY; Fang, WF; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Alahdab, A; Cinatl, J; Gohlke, L; Holdenrieder, S; Michaelis, M; Oberhofer, A; Ritter, CA; Worf, K | 1 |
| Ishibashi, N; Mitomo, H; Nonomura, R; Oshima, Y; Sagawa, M; Sasaki, T; Sugawara, T; Tabata, T | 1 |
| Chen, M; Fan, Z; Feng, H; Hou, J; Li, F; Li, J; Li, YY; Liu, B; Pan, T; Sang, Q; Su, L; Wu, X; Yan, C; Yu, B; Yu, J; Yu, Y; Zang, M; Zhu, Z | 1 |
| Cong, M; Li, C; Li, F; Pang, H; Sun, H; Xie, G; Yang, S; Zhao, W | 1 |
| Chiu, TH; Chung, FT; Fang, YF; Guo, YK; Hsu, PC; Huang, AC; Huang, CH; Ju, JS; Ko, HW; Kuo, CS; Tung, PH; Wang, CC; Yang, CT | 1 |
| Bertran-Alamillo, J; Bracht, JWP; Cardona, AF; Chaib, I; Codony-Servat, J; Filipska, M; Ito, M; Karachaliou, N; Molina, MA; Pedraz, C; Rosell, R | 1 |
| Chang, CC; Lin, CC; Lin, CY; Su, PL; Su, WC; Tseng, YL; Yen, YT | 1 |
| Chang, LC; Chang, LY; Chen, KY; Lim, CK; Shih, JY; Yu, CJ | 1 |
| Cao, Q; Chen, Y; Wang, L; Xu, L; You, X | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Ermolovich, T; Hemperly, S; Lountzis, NI; Purcell, SM; Sheikh, HA | 1 |
| Arai, D; Ikemura, S; Ishioka, K; Nakayama, S; Naoki, K; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Tani, T; Terai, H; Yasuda, H; Yoda, S | 1 |
| Edwards, A; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Lal, R; Lee, SM; Lewanski, C; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Hanafi, A; Jayusman, M; Sutandyo, N | 1 |
| Cho, WCS; Geeleher, P; Huang, RS; Lau, EYT; Lee, AM; Nath, A | 1 |
| Amri, J; Baazm, M; Karami, H; Molaee, N | 2 |
| Li, G; Sai, B; Tang, J; Wang, F; Wang, L; Xiang, J; Zhang, L; Zhang, X; Zheng, L | 1 |
| Pedraz-Valdunciel, C; Rosell, R | 1 |
| Au, KH; Chiu, CH; Enatsu, S; Frimodt-Moller, B; Garon, EB; Imamura, F; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Nishio, M; Novello, S; Park, K; Paz-Ares, L; Ponce Aix, S; Reck, M; Seto, T; Shih, JY; Visseren-Grul, C; Yoh, K; Zimmermann, A | 1 |
| Bonanno, L; Buoro, V; Calabrese, F; Cecere, FL; Conte, P; Dal Maso, A; Del Conte, A; Frega, S; Indraccolo, S; Lorenzi, M; Macerelli, M; Monteverdi, S; Nardo, G; Pasello, G; Pilotto, S; Polo, V; Roca, E; Scattolin, D; Urso, L; Zulato, E | 1 |
| Brighenti, M; Chang, GC; Cho, EK; Favaretto, A; Girard, N; Grosch, H; Gruver, AM; Hsia, TC; Kimmich, M; Kollmeier, J; Mansouri, K; Moro-Sibilot, D; Scagliotti, G; Schumann, C; Tsai, CM; Wacheck, V; Wallin, J; Wang, XA; Wijayawardana, SR | 1 |
| Chen, CY; Chen, YF; Chen, YH; Shih, JY; Yu, CJ | 1 |
| Bolan, PO; Brenan, L; Dusaj, N; Goodale, A; Johannessen, CM; Landau, DA; Piccioni, F; Schiffman, JS; Zviran, A | 1 |
| Chen, HZ; Lei, HM; Lu, LM; Shen, Y; Wang, CH; Wang, Y; Zhang, J; Zhang, KR; Zhu, L; Zhuang, GL | 1 |
| Chen, MJ; Chen, WQ; Fan, XX; Fang, SJ; Huang, XF; Mao, JT; Song, JJ; Tu, JF; Wu, FZ; Zhao, ZW; Zheng, LY | 1 |
| Bai, Y; Gu, X; Liu, X; Zhao, L; Zhou, X | 1 |
| DerSarkissian, M; Duh, MS; Fernandes, AW; Laliberté, F; Pavilack, M; Subramanian, J | 1 |
| Chella, A; Crucitta, S; Danesi, R; Del Re, M; Garassino, MC; Gianfilippo, G; Mazzoni, F; Miccoli, M; Petrini, I; Pozzessere, D; Restante, G; Rofi, E; Valleggi, S | 1 |
| Awan, NU; Goraya, AW; Hanif, A; Khokhar, MA; Nisaa Zia, NU; Qamar, S | 1 |
| Cheema, P; Cheng, Y; Chewaskulyong, B; Cho, BC; Cobo, M; Gray, JE; Hodge, R; Imamura, F; John, T; Kurata, T; Lee, KH; Lin, MC; Ohe, Y; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Saggese, M; Shah, R; Soria, JC; Tiseo, M; Todd, A; Vansteenkiste, J; Zhou, C | 1 |
| Amri, J; Karami, H; Molaee, N | 1 |
| Bilici, A; Dagel, T; Dilege, S; Ertuglu, LA; Erus, S; Kanbay, M; Kapdağlı, M; Mandel, NM; Ozdogan, E; Selcukbiricik, F; Tanju, S; Tural, D | 1 |
| Isobe, T; Okimoto, T; Sun, R; Takechi, M; Tanino, R; Tong, X; Tsubata, Y | 1 |
| Ishiki, H; Kubo, E; Satomi, E; Tateishi, A | 1 |
| Wu, YL; Yan, HH; Zhong, WZ | 1 |
| Li, Y; Owonikoko, TK; Qian, G; Ramalingam, SR; Sun, SY; Zang, H | 1 |
| Cho, BC; Gray, JE; Hovey, T; Karaseva, N; Leighl, NB; Nakagawa, K; Novello, S; Rydén, A; Walding, A | 1 |
| Ahern, E; Chan, S; Chaudhry, S; Hughes, B | 1 |
| Chen, YH; Chien, LN; Fang, WT; Hsieh, YY; Lo, YW | 1 |
| Bai, H; Fang, W; Gu, A; Han, B; Han-Zhang, H; Li, B; Li, R; Lizaso, A; Lou, Y; Xia, J; Xiong, L; Zhang, J | 1 |
| Abbasi, YF; Bera, H; Cun, D; Gajbhiye, V; Kumar, P; Lee Ping, L; Marbaniang, D; Mazumder, B; Tambe, P; Yang, M | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Miyazaki, K; Okauchi, S; Satoh, H; Yamada, H | 1 |
| Mondal, A; Nottingham, E; Rishi, AK; Safe, S; Sekar, V; Singh, M | 1 |
| Aydemir, D; Minichsdorfer, C; Otahal, A; Tomasich, E | 1 |
| Guan, R; Hu, D; Jiang, W; Li, K; Li, Y; Liao, D; Liu, L; Mansfield, AS; Wang, J; Xia, C; Xiao, L; Xiong, Y; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C | 1 |
| Ding, L; Guo, W; Zhao, S; Zhou, K | 1 |
| Cheng, F; He, B; Luo, K; Meng, G; Peng, X; Pu, Y | 1 |
| Ahangari, D; Colinet, B; Ngendahayo, P; Roquet-Gravy, PP | 1 |
| Chen, WY; Wang, EA; Wong, CH | 1 |
| Feng, S; Pang, J; Sun, Y; Wang, S; Xing, H | 1 |
| Chen, H; Gao, Y; Li, B; Li, X; Li, Z; Liu, W; Ye, J; Zheng, Y; Zhu, L | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Kusuhara, S; Mitsufuji, H; Naoki, K; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Sugimoto, A; Yokoba, M | 1 |
| Bekaii-Saab, T; Chen, X; Li, Y; Yang, X; Ye, Y; Zhang, HB; Zhang, Y; Zheng, Y | 1 |
| Abdelgalil, AA; Al-Jenoobi, FI; Al-Kahtani, HM | 1 |
| Fujio, Y; Haga, Y; Hanamuro, S; Higashisaka, K; Lin, Y; Maeda, S; Maki, A; Nagano, K; Shintani, T; Tsujino, H; Tsutsumi, Y | 1 |
| Hsu, JC; Lai, WW; Su, WC; Wang, JD; Yang, SC | 1 |
| Kovacevic, P; Kovacevic, SV; Kovacevic, T; Miljkovic, B; Stanetic, M | 1 |
| Deng, Q; He, D; Wang, F; Xie, Z; Yang, H | 1 |
| Cho, SL; Chuang, CA; Lai, CF; Liao, WY; Lin, WC | 1 |
| Chen, Y; Liu, F; Lu, T; Tang, J | 1 |
| Chen, HZ; Gu, WM; Huang, K; Lei, HM; Liang, Q; Luo, MY; Shen, Y; Zhou, L; Zhu, L; Zhuang, GL; Zou, JH | 1 |
| Amos, C; Cheng, C; Schaafsma, E; Weng, YL; Zhao, Y | 1 |
| Aono, H; Azuma, K; Bessho, A; Fukamatsu, N; Hamada, A; Hosokawa, S; Hosomi, Y; Ishii, H; Ishii, M; Itani, H; Kikuchi, N; Kunitoh, H; Kusaka, K; Miyamoto, S; Mori, Y; Nakahara, Y; Okamoto, H; Tanaka, H; Yamada, K | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Hino, M; Kobayashi, K; Kubota, K; Miyanaga, A; Nishitsuji, M; Noro, R; Seike, M; Shimokawa, T; Usuki, J; Yomota, M | 1 |
| Jénot, L; Mazieres, J; Rouquette, I | 1 |
| Chen, C; Giaccone, G; Huo, YS; Li, CG; Li, JJ; Liu, C; Liu, WR; Ma, YC; Qi, Q; Tang, Z; Tian, PF; Wang, CL; Yue, DS; Zhang, B; Zhang, H; Zhang, LM; Zhang, ZF | 1 |
| Chan Kim, S; Gong, JH; Hong, JK; Hong, SW; Jeong, HR; Jin, DH; Jung, J; Jung, SA; Ki, SY; Kim, DM; Kim, DY; Kim, EH; Kim, J; Kim, MJ; Kim, SM; Kim, TW; Koh, DI; Lee, EY; Lee, S; Lee, SH; Moon, JH; Park, SS; Park, YS; Ryu, YS; Shin, JS; Yu, HN | 1 |
| Gao, WW; Hao, JQ; Ma, T; Sun, CL; Wu, PF | 1 |
| Kong, J; Miao, F; Sheng, J; Wang, X; Xie, C | 1 |
| Gota, V; Gurjar, M; Joshi, A; Kannan, S; Nookala, M; Noronha, V; Patil, A; Patil, D; Patil, V; Prabhash, K; Shriyan, B | 1 |
| Chen, D; Chen, S; Haisma, H; Liu, B; Saber, A | 1 |
| Aerts, JGJV; Belderbos, HNA; Broerse, SD; Dingemans, AC; Hussaarts, KGAM; Koolen, SLW; Landa, KD; Mathijssen, RHJ; Oomen-de Hoop, E; Paats, MS; Peric, R; Rutten, HB; Steendam, CMJ; van der Leest, CH; van Gelder, T; van Leeuwen, RWF; Veerman, GDM | 1 |
| Irurzun-Arana, I; McDonald, TO; Michor, F; Trocóniz, IF | 1 |
| Chen, X; Deng, H; Wang, L; Wei, Y; Yi, F; Zhang, S; Zhang, W | 1 |
| Chen, T; Fang, W; Han, B; Ji, C; Li, R; Xiong, L; Zhao, W | 1 |
| Cheng, L; Gou, L; Wei, T; Zhang, J | 1 |
| Kumar, T; Pandey, M; Soni, K | 1 |
| Asai, G; Azuma, K; Fujita, Y; Fukuhara, T; Furuya, N; Gemma, PA; Hagiwara, PK; Iwasawa, S; Kobayashi, PK; Kurimoto, F; Maemondo, PM; Miyazaki, M; Morita, PS; Nagashima, H; Nakachi, I; Nukiwa, PT; Okada, PM; Saito, H; Sugawara, S; Tsubata, Y; Tsunezuka, Y; Watanabe, K; Watanabe, S; Yamaguchi, O; Yoshimori, K | 1 |
| Arrondeau, J; Blanchet, B; Csajka, C; Fabre, E; Guidi, M; Khoudour, N; Schneider, MP; Tlemsani, C; Vidal, M; Wagner, AD; Widmer, N | 1 |
| Assié, JB; Chouahnia, K; Chouaid, C; Des Guetz, G; Duchemann, B; Landre, T | 1 |
| Damhuis, RAM; Gijtenbeek, RGP; Groen, HJM; van der Wekken, AJ; van Geffen, WH | 1 |
| Morishita, M; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, K; Sakai, K; Shimizu, T; Takeda, M | 1 |
| Ebi, N; Hamada, A; Harada, T; Himeji, D; Kitazaki, T; Nosaki, K; Seto, T; Shimose, T; Shiraishi, Y; Sugio, K; Takenoyama, M; Yamanaka, T | 1 |
| Chang, MJ; Choi, HD | 1 |
| Asada, K; Fujino, H; Kagawa, Y; Kamiya, D; Kimura, M; Miyazaki, Y; Mizuno, H; Moriki, M; Sano, Y; Shirai, T; Suzuki, T; Todoroki, K; Uchino, T; Yagi, H | 1 |
| Agredo, A; Bains, M; Kasinski, AL; Pal, AS | 1 |
| Brat, K; Jakubíková, L; Šťastná, N | 1 |
| Hu, C; Xiang, Q; Zhang, J; Zhang, Q; Zhang, R; Zhou, H | 1 |
| Lei, HM; Lv, QM; Ma, CS; Shen, Y; Tang, YB; Zhang, KR; Zhang, YF; Zhu, L | 1 |
| Hu, X; Jeevithan, E; Mariadoss, AVA; Saravanakumar, K; Sathiyaseelan, A; Shin, S; Wang, MH | 1 |
| Al-Shahrour, F; Alandes, S; Alcácer, J; Aliena-Valero, A; Aparisi, S; Becker, JH; Benet, M; Borgia, JA; Carretero, J; Chuliá-Peris, L; Dalheim, AV; Fernández-Coronado, JA; García-Cañaveras, JC; Juan, O; Kaja, S; Lahoz, A; López, A; Nishimura, MI; Ollosi, S; Pulido, I; Qiu, W; Rodríguez, ML; Salom, JB; Shimamura, T; Soucheray, M; Tamayo-Torres, E | 1 |
| Li, CY; Ma, SH | 1 |
| Atagi, S; Frimodt-Moller, B; Garon, EB; Moro-Sibilot, D; Nakagawa, K; Ponce Aix, S; Reck, M; Visseren-Grul, C; Winfree, KB; Yoh, K; Zimmermann, A | 1 |
| Aoshima, Y; Asada, K; Enomoto, N; Fujisawa, T; Furuhashi, K; Hashimoto, D; Hozumi, H; Inui, N; Kaida, Y; Karayama, M; Kusagaya, H; Matsui, T; Matsuura, S; Mikamo, M; Nakamura, Y; Suda, T; Suzuki, Y; Uto, T; Yasui, H | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Arnold, SM; Chen, Q; Huang, B; Kolesar, JM; Larson, KL; Schuh, M; Tucker, T | 1 |
| Eichenfield, DZ; Orme, CM; Seidman, JS | 1 |
| Arrieta, O; Barrón, F; Catalán, R; de la Garza, J; Flores-Estrada, D; Guzmán-Vazquez, S; Lara-Mejía, L; Ramos-Ramírez, M; Soto-Molina, H | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kano, H; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Rai, K; Tabata, M; Watanabe, H | 1 |
| Dowlati, A; Guler, E; Kikano, EG; Matsunaga, F; Pfau, D; Ramaiya, NH; Smith, DA; Tirumani, SH | 1 |
| Banda, M; Inoue, M; McKim, KL; Myers, MB; Parsons, BL | 1 |
| Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC | 1 |
| Ariyasu, R; Fujita, N; Katayama, R; Kitazono, S; Nishio, M; Tadokoro, K; Uchibori, K; Yamaguchi, T; Yanagitani, N | 1 |
| Li, M; Xiang, J; Zhang, C | 1 |
| Chiu, CH; Enatsu, S; Frimodt-Moller, B; Garon, EB; Homma, G; Imamura, F; Nakagawa, K; Nishio, M; Park, K; Reck, M; Seto, T; Shih, JY; Visseren-Grul, C; Yoh, K; Zimmermann, A | 1 |
| Copur, MS; Faris, S; Horn, AJ; Lackner, R; Rodriguez, P; Zusag, T | 1 |
| Bedir, S; Celik, E; Cikman, DI; Degerli, E; Demirci, NS; Demirelli, FH; Derin, S; Karadag, M; Oruc, K; Oztas, NS; Samanci, NS | 1 |
| Chen, Y; Li, L; Liu, F; Liu, J; Lu, T; Tang, J | 1 |
| Ling, Y; Pi, Y; Tu, C; Xing, S | 1 |
| Dziadziuszko, R; Kowalski, D; Krzakowski, M; Pluzanski, A | 1 |
| Mohty, R; Tfayli, A | 1 |
| Ji, YX; Sun, L; Wang, SP; Zhao, ZM | 1 |
| Cho, SY; Choi, A; Jang, G; Jun, Y; Kim, J; Kwon, JY; Lee, A; Lee, C; Lee, J; Lee, S; Na, D | 1 |
| Huang, L; Jiang, T; Sun, Y; Wang, L; Wang, X; Wen, M; Xia, J; Yang, S; Zhang, Y; Zhang, Z | 1 |
| Liu, B; Ning, Q; Wu, L; Xia, Z; Zhang, L; Zhong, R; Zhou, X | 1 |
| Akkın, S; Benito, JM; Bilensoy, E; Demirtürk, N; Varan, G | 1 |
| Liu, Q; Luo, X; Peng, L; Tan, C; Wan, X; Yi, L; Zeng, X | 1 |
| Cheng, J; Kong, XY; Liu, Y; Luo, T; Mo, F; Song, J; Wang, Y; Zhao, D; Zhong, YF | 1 |
| Ke, L; Li, S; Meng, X; Wu, H; Yu, J; Zhang, H; Zhang, X; Zhou, H | 1 |
| Fukuoka, M; Goto, K; Nishio, M; Okamoto, I; Seto, T; Takahashi, K; Tanaka, M; Yamamoto, N; Yamanaka, T | 1 |
| Banerjee, S; Banerjee, SK; Godwin, AK; Haque, I; Huang, CH; Kawsar, HI; Motes, H; Sharma, M | 1 |
| Carbone, DP; Chen, L; Li, J; Li, R; Liao, Z; Ren, B; Sun, J; Xia, X; Yang, Z; Yisikandaer, A; Zhang, J; Zhang, Y; Zhao, R | 1 |
| Fujitaka, K; Hamai, K; Hongoh, M; Hotta, T; Ishihara, N; Ishikawa, N; Isobe, T; Kobayashi, M; Kubota, T; Nakamura, A; Nishimura, N; Sugisaka, J; Tanino, A; Tsubata, Y; Yamasaki, M | 1 |
| Ando, C; Hara, N; Higo, H; Hirabae, A; Hotta, K; Ichihara, E; Kano, H; Kato, Y; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Nakasuka, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Okawa, S; Rai, K; Tabata, M; Watanabe, H | 1 |
| Cho, HJ; Hwang, C; Jeong, DI; Kim, HJ; Lee, J; Lee, K; Lee, SY; Park, J; Seo, JH; Yang, M | 1 |
| Bahmanyar, S; Bezemer, ID; Ehrenstein, V; Enger, C; Hoti, F; Huang, K; Juuti, R; Kahlert, J; Karlsson, P; Korhonen, P; Kuiper, JG; Löfling, L; Mo, J; Nunes, AP; Rørth, M; Schachterle, SE; Sørensen, HT; Wilner, KD | 1 |
| Armas López, L; Arrieta, O; Ávila-Moreno, F; Catalán Cárdenas, R; Hernández-Cigala, N; Herrera-Solorio, AM; Mendoza Milla, C; Ortiz Quintero, B; Peralta-Arrieta, I; Pineda Villegas, P; Rodríguez Villanueva, E; Trejo Iriarte, CG; Zúñiga, J | 1 |
| Akdeniz, N; Akinci, MB; Aktas, BY; Alan, O; Avci, O; Ayhan, M; Basoglu, T; Bilgin, B; Celik, E; Cinkir, HY; Dede, DS; Demir, A; Demirkazık, A; Deniz, GI; Dogan, I; Erol, C; Gulmez, A; Gurbuz, M; Hizal, M; Ilhan, A; Karaagac, M; Karatas, F; Kilickap, S; Koca, S; Kut, E; Menevse, S; Oksuzoglu, B; Ozyukseler, DT; Paydas, S; Sakalar, T; Sen, E; Sendur, MAN; Taskaynatan, H; Tatli, AM; Yalcin, B; Yucel, S; Yumuk, F | 1 |
| Kaliki, S; Padhy, SK | 1 |
| Beijnen, JH; Huitema, ADR; Janssen, JM; Muller, M; Schellens, JHM; Steeghs, N; van den Broek, D; van den Heuvel, MM; van Duijl, TT; Verheijen, RB; Vessies, D | 1 |
| Gupta, A; Momi, G; Vaid, AK | 1 |
| Hsu, CK; Lee, CN; Po-Chao Chiu, F | 1 |
| Kaul, SC; Kumar, V; Malik, V; Sundar, D; Wadhwa, R | 1 |
| Cao, P; Chen, Z; Jiang, S; Li, J; Li, X; Liu, L; Xin, Y; Zhang, J; Zhang, L | 1 |
| Chan, JYY; Kwok, TYT; Yuen, HKL | 1 |
| Gupta, V; Kulkarni, NS; Vaidya, B | 1 |
| Chai, J; Cui, JW; Li, LY; Li, WQ | 1 |
| Au, JS; Au, KH; Cho, WCS; Kwan, CK; Li, YC; Ming, WK; You, JHS | 1 |
| Lou, E; Sperduto, PW | 1 |
| Chowbay, B; Ho, NRY; Lim, CZJ; Loh, TP; Natalia, A; Pan, S; Shao, H; Tam, JKC; Zhang, Y | 1 |
| Hou, E; Lai, L; Lu, Y; Meng, W; Tan, Z; Wei, J; Zhang, X | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Chen, HH; Fearon, D; Horton, S; Kim, YJ; McFarlane, T; Oremus, M | 1 |
| Broaddus, VC; Hong, SW; Hur, DY; Kim, SH; Kim, SM; Kim, YS; Lee, HK; Noh, MH | 1 |
| Arora, S; Bhat, ZR; Biswas, S; Joshi, G; Kumar, M; Kumar, R; Sharma, N; Singh, S; Singh, T; Tikoo, K | 1 |
| Alahdab, A; Cinatl, J; Gohlke, L; Holdenrieder, S; Kloft, C; McLaughlin, KM; Michaelis, M; Michelet, R; Ritter, CA; Saafan, H; Wass, MN; Ziemann, J | 1 |
| Choi, H; Kho, BG; Kim, MS; Kim, YC; Lee, JK; Oh, HJ; Oh, IJ; Park, CK | 1 |
| Chen, C; Lin, H; Mei, Q; Ye, L | 1 |
| Brugarolas-Masllorens, A; Catalán-Latorre, A; Escudero-Ortiz, V; Sureda, M | 1 |
| Cui, H; Dong, H; Hu, Z; Jiang, X; Li, J; Tan, K; Xue, C; Yu, Y; Zhang, J; Zhang, X; Zheng, H | 1 |
| Fujita, A; Hatsuyama, T; Inotsume, N; Mukai, Y; Sato, H; Toda, T; Wakamoto, A; Yoshida, T | 1 |
| Alonso Garcia, M; Fabre, E; Frimodt-Moller, B; Garon, EB; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Novello, S; Ponce Aix, S; Reck, M; Visseren-Grul, CM; Zimmermann, AH | 1 |
| Heo, DS; Im, SW; Jeon, YK; Keam, B; Kim, DW; Kim, M; Kim, S; Kim, TM; Ku, JL; Lee, C | 1 |
| Iwabuchi, E; Miki, Y; Okada, Y; Ono, K; Saito, R; Sasano, H; Sato, I; Sugiura, H | 1 |
| Adorno-Cruz, V; Chang, YF; Cristofanilli, M; Dashzeveg, NK; El-Shennawy, L; Jia, Y; Kawaguchi, M; Liu, H; Liu, X; Patel, D; Ramos, EK; Schuster, EJ; Taftaf, R; Zhang, Y | 1 |
| Kumar, R; Sharma, A | 1 |
| Chen, YY; Li, MH; Tang, XJ | 1 |
| Poorsargol, M; Samareh Delarami, H; Shahraki, S; Sori Nezami, Z | 1 |
| Gursoy, P | 1 |
| Adli, M; Aliyev, A; Besiroglu, M; Simsek, M; Turk, HM | 1 |
| Furusawa, S; Igai, H; Kamiyoshihara, M; Matsuura, N; Ohsawa, F; Yazawa, T | 1 |
| Clement, MS; Ebert, EBF; Meldgaard, P; Sorensen, BS | 1 |
| Frankel, P; Gandara, DR; Keer, HN; Kelly, KA; Lara, PN; Longmate, J; Mack, PC; Newman, EM; Raymond, VM; Reckamp, KL; Riess, JW; Weipert, CM | 1 |
| Alandağ, C; Merev, E; Özdemir, F | 1 |
| Dong, Y; Li, D; Li, Q; Miao, Q | 1 |
| Ando, Y; Goto, Y; Hayashi, T; Imaizumi, K; Ito, K; Kawada, K; Matsuda, H; Nishibe-Toyosato, S; Tsuge, M; Tsujii, N; Yamada, S | 1 |
| Atagi, S; Daga, H; Izumi, M; Kaneda, H; Kawaguchi, T; Matsumoto, Y; Mitsuoka, S; Nakahama, K; Nakatani, Y; Ogawa, K; Okada, A; Okishio, K; Sawa, K; Tani, Y | 1 |
| Akkın, S; Bilensoy, E; Erdoğar, N; Varan, G | 1 |
| Hirokawa, E; Nakagawa, K; Nishio, K; Sakai, K; Sato, C; Takahama, T; Takeda, M; Watanabe, S | 1 |
| Bizec, JL; Debieuvre, D; Grangeon, V; Hominal, S; Larivé, S; Le Treut, J; Molinier, O; Moreau, L; Nocent, C; Payen, T; Trédaniel, J | 1 |
| Ahn, L; Arcila, ME; Hayes, SA; Iqbal, A; Kris, MG; Luo, J; Makhnin, A; Ng, K; Riely, GJ; Tobi, Y; Yu, HA | 1 |
| Esposito, M; Glassman, L; Hannon, GJ; Huang, J; Hyman, K; Ibarra, I; Jimenez Sabinina, V; Korimerla, N; Lee, P; Lindsted, T; Lujambio, A; Miller, M; Pal, D; Safaric Tepes, P; Senturk, S; Sordella, R; Zeltsman, D | 1 |
| Boussageon, M; Pérol, M; Swalduz, A | 1 |
| Frimodt-Moller, B; Garon, EB; Nadal, E; Nakagawa, K; Nishio, M; Park, K; Paz-Ares, L; Reck, M; Seto, T; Shih, JY; Visseren-Grul, C; Wijayawardana, S; Yamamoto, N; Zimmermann, AH | 1 |
| Akrour, Y; Duchemann, B; Gaudry, S; Gibelin, A; Gonzalez, F; Jaubert, P; Moreau, AS; Oppenheimer, A; Stoclin, A; Tandjaoui-Lambiotte, Y | 1 |
| Abe, H; Domoto, Y; Hirakawa, Y; Honda, K; Miyashita, N; Nagase, T; Nakamura, M; Nangaku, M; Oda, Y; Oki, R | 1 |
| Dome, B; Kim, TY; Kim, Y; Kwon, HJ; Lee, B; Marko-Varga, G; Rezeli, M; Sugihara, Y; Szasz, AM | 1 |
| Iwamoto, T; Julian, I | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Chang, GC; Chen, JJW; Chen, KC; Chin, CS; Hsu, KH; Huang, YH; Su, KY; Tseng, JS; Yang, TY; Yu, SL | 1 |
| Chesney, J; Dougherty, SM; Imbert-Fernandez, Y; Lanceta, L; Lypova, N | 1 |
| Fujitaka, K; Hamaguchi, M; Hamaguchi, S; Hamai, K; Hotta, T; Ishikawa, N; Isobe, T; Masuda, T; Sutani, A; Tanino, A; Taniwaki, M; Tsubata, Y; Yamasaki, M | 1 |
| Chen, GY; Cheng, Y; Cui, JW; Huang, C; Li, XL; Liu, YP; Lu, S; Ma, ZY; Shu, YQ; Song, Y; Tu, HY; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Yang, N; Yu, SY; Zhong, WZ; Zhou, JY; Zhou, Q | 1 |
| Heymach, JV; Le, X; Nilsson, MB; Robichaux, JP | 1 |
| Asai, G; Azuma, K; Fujita, Y; Fukuhara, T; Furuya, N; Hagiwara, K; Iwasawa, S; Kawashima, Y; Kobayashi, K; Kurimoto, F; Maemondo, M; Miyazaki, M; Morita, S; Nagashima, H; Nakachi, I; Nukiwa, T; Okada, M; Saito, H; Seike, M; Sugawara, S; Tsubata, Y; Tsunezuka, Y; Watanabe, K; Watanabe, S; Yamaguchi, O; Yoshimori, K | 1 |
| de Vries, EGE; Giesen, D; Kol, A; Lub-de Hooge, MN; Pool, M; Terwisscha van Scheltinga, AGT | 1 |
| Aghanejad, A; Bakhtiary, Z; Barar, J; Ezzati Nazhad Dolatabadi, J; Nemati, E; Omidi, Y; Saei, AA | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Engelman, J; Gettinger, S; Jänne, PA; Lara, PN; Leach, J; Miles, DR; Subramaniam, DS; Wakelee, HA; Wax, M; West, H; Yaron, Y | 1 |
| Baty, F; Brutsche, M; Früh, M; Joerger, M; Klingbiel, D; Zappa, F | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C | 1 |
| Filiou, E; Gkiozos, I; Kainis, I; Kopitopoulou, A; Nikolaou, V; Papadavid, E; Syrigos, N | 1 |
| Aza, A; Bonastre, E; Dabad, M; Derdak, S; Esteller, M; Esteve-Codina, A; Gimenez-Xavier, P; Gomez-Lopez, G; Graña, O; Hernandez Mora, JR; Moran, S; Pisano, D; Pros, E; Salinas-Chaparro, D; Sanchez-Cespedes, M | 1 |
| He, Z; Kurata, J; Liao, J; Lin, D; Lin, J; Lin, R; Su, Y; Zou, C | 1 |
| He, M; Li, Y; Song, C; Yang, Z; Zhang, L; Zhang, X | 1 |
| Aix, SP; Barlesi, F; Bidoli, P; Camps, C; Carcereny, E; Coate, L; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; Favaretto, A; Felip, E; Froesch, P; Früh, M; Gautschi, O; Gómez-Codina, J; Hanrahan, E; Kammler, R; Karachaliou, N; Kassapian, M; Kotsakis, A; Majem, M; Massutí, B; Molina-Vila, MA; Palmero, R; Peters, S; Pless, M; Popat, S; Porta, R; Puente, J; Rabaglio, M; Rauch, D; Reguart, N; Rosell, R; Ruepp, B; Shah, R; Shames, DS; Stahel, RA; Tam, R; Thomas, M | 1 |
| Mitsudomi, T | 2 |
| Bentayeb, H; Berna, P; Dayen, C; Dewolf, M; Douadi, Y; Fourrier, M; Garoute, C; Khamis, W; Le Meunier, F; Lecuyer, E; Rousselle, F; Sadki, M; Suguenot, R | 1 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Hussmann, D; Jakobsen, KR; Luo, Y; Madsen, AT; Nielsen, AL; Sorensen, BS | 1 |
| Cho, YJ; Chung, JH; Eo, EY; Jung, MH; Kim, CH; Kim, S; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Park, JS; Park, MY; Yoon, HI | 1 |
| Alvarez-Argote, J; Dasanu, CA; Lippman, SM; Plaxe, SC | 1 |
| Berger, PB; Donzelli, M; Früh, M; Gillessen, S; Haschke, M; Joerger, M; Kloft, C; Krähenbühl, S; Parra-Guillen, ZP; Pfister, B; Winogradova, D | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Chen, JC; Chen, WC; Cheng, YT; Jian, YJ; Lin, YW; Peng, YS; Tung, CL; Wei, CL; Wu, CH; Zheng, HY | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Chuang, JC; Neal, JW | 1 |
| Argiris, A; Burns, TF; Dacic, S; Farooqui, M; Floros, T; Friedland, DM; Gaither-Davis, A; Gomez-Garcia, J; Gooding, WE; Petro, DP; Rafique, I; Siegfried, JM; Socinski, MA; Stabile, LP; Tarhini, AA; Tran, P; Villaruz, LC | 1 |
| Abraham, E; Albright, C; Alistar, AT; Bitting, RL; Blackstock, W; Chen, K; D'Agostino, RB; Desnoyers, RJ; DeYoung, B; Foley, KL; Goodman, M; Grant, SC; Kytola, V; Levine, EA; Nykter, M; Pagni, M; Pasche, B; Petro, RM; Petty, WJ; Porosnicu, M; Powell, BL; Qasem, SA; Robinson, M; Staren, ED; Thomas, A; Topaloglu, U; Vatca, M; Yang, M; Zhang, W | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Chen, Y; Deng, H; Lou, W; Wang, J; Wu, T; Zhu, KY | 1 |
| Bennouna, J; Bouquet, F; Cabart, M; de Plater, L; Decaudin, D; Joalland, MP; Lalier, L; Raimbourg, J; Savina, A; Vallette, FM | 1 |
| Hess, LM; Louder, A; Nair, R; Oton, AB; Winfree, K; Zhu, YE | 1 |
| Gu, FF; Hong, XH; Liang, JY; Liu, L; Liu, YY; Tong, F; Zeng, YL; Zhang, K | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Kim, DK; Kim, K; Kim, KS; Park, JW; Park, K; Shin, IC; Yang, KM | 1 |
| Alfonso-Bartolozzi, B; Ciufo, G; Gil-Bazo, I; Guarnieri, A; Moreno-Montañés, J | 1 |
| Fenton, M; Martin, MG; Morris, L; Schwartzberg, LS; Stein, MK; Sullivan, JL; VanderWalde, A | 1 |
| Höllhumer, R; Jacob, K; Moloney, G | 1 |
| Chan, D; Ellison, K; Heasley, LE; Hinz, TK; Hirsch, FR; Melnick, MAC; Mitsudomi, T; Politi, K; Rivard, CJ; Rozeboom, L; Suda, K; Yu, H | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Dupuis, N; Ehrnrooth, E; Felip, E; Gadgeel, S; Georgoulias, V; Göker, E; Goss, G; Guclu, SZ; Isla, D; Krämer, N; Lee, KH; Lu, S; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Archila, P; Arrieta, O; Cardona, AF; Carranza, H; Corrales, L; Cuello, M; Karachaliou, N; Martín, C; Ortiz, C; Otero, J; Pino, LE; Reguart, N; Rojas, L; Rosell, R; Vargas, C; Wills, B; Zapata, MI; Zatarain-Barrón, ZL | 1 |
| Foster, A; Patel, SH; Riely, GJ; Rimner, A; Woo, KM; Wu, AJ; Yu, HA; Zhang, Z | 1 |
| Bader, AG; Guerrero, A; Kelnar, K; Peltier, HJ; Zhao, J | 1 |
| Chang, CH; Chang, LY; Ko, JC; Lee, CH; Lee, MC; Wang, JY; Yu, CJ | 1 |
| Black, EP; Collard, JP; Krentz Gober, M; Thompson, K | 1 |
| Bohn, P; Farah, I; Guisier, F; Patout, M; Piton, N; Salaün, M; Thiberville, L; Vera, P | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Cobo, M; Dayen, C; Ehrnrooth, E; Felip, E; Fülöp, A; Gadgeel, SM; Gordon, J; Goss, GD; Gregg, R; Hirsh, V; Palmer, M; Popat, S; Soria, JC; Trigo, JM; Waller, CF; Wang, B | 1 |
| Cho, JH; Jeon, SH; Kim, HJ; Kim, JS; Kwak, SM; Lee, HL; Nam, HS; Ryu, JS | 1 |
| Chen, G; Chen, Y; Cheng, F; Liu, M; Lu, W; Pang, X; Su, H; Yu, W | 1 |
| Momin, MM; Sangshetti, JN; Zaheer, Z; Zainuddin, R | 1 |
| Ahmed, S; Blackhall, F; Chen, J; Ciuleanu, TE; Kim, JH; Mezger, J; Park, K; Poondru, S; Thomas, M; VanTornout, JM; Whitcomb, D | 1 |
| Hamid, O; Klempner, SJ; Mehta, P | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Baglivo, S; Chiari, R; Crinò, L; Ludovini, V; Messina, S; Metro, G; Rebonato, A; Ricciuti, B; Sidoni, A; Siggillino, A | 1 |
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kuwae, Y; Matsumoto, Y; Mitsuoka, S; Sawa, K; Suzumura, T; Watanabe, T; Yamamoto, N; Yoshimoto, N; Yoshimura, N | 1 |
| Bury, MJ; Gandara, DR; Hirsch, FR; Kelly, K; Kwong, M; Mack, P; Miao, J; Moon, J; Moore, DF; Nguyen, DD; Redman, M; West, HL; Wozniak, AJ | 1 |
| Gao, Y; Jia, L; Li, F; Li, T; Mei, H; Nie, H; Xie, X; Zhang, H | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, S; Zhang, W | 1 |
| Ali, SM; Carney, BJ; Costa, DB; Gowen, K; Rangachari, D; Schrock, AB; VanderLaan, PA | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Beer-Furlan, A; Hardesty, DA; Otto, B; Prevedello, DM; Priddy, B | 1 |
| Chen, Y; Han, Z; Li, S; Liu, H; Qin, Y; Zhou, X | 1 |
| Amano, T; Asahina, H; Dosaka-Akita, H; Fujita, Y; Furuta, M; Harada, T; Ikezawa, Y; Isobe, H; Kawai, Y; Kinoshita, I; Miyauchi, E; Nishihara, H; Nishimura, M; Ogi, T; Oizumi, S; Sakakibara-Konishi, J; Takamura, K; Watanabe, M; Yamada, N | 1 |
| Boughey, JC; Veeramachaneni, N; Wigle, D | 1 |
| Ahn, L; Arbour, KC; Beal, K; Daras, M; Hayes, SA; Kris, MG; Ni, A; Pao, W; Riely, GJ; Rodriguez, CR; Young, RJ; Yu, HA | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Consuegra, G; Fernandez-Penas, P; Hui, R; Liu, RC; Zhao, CY | 1 |
| Jiang, SH; Li, YQ; Song, SS; Zhang, XY | 1 |
| Bhateja, P; Dowlati, A; Sharma, N | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Aikawa, H; Fujiwara, Y; Hamada, A; Hayashi, M; Isobe, T; Ohuchi, M; Tamura, K; Tanino, R; Tsubata, Y | 1 |
| Cho, H; Levy, D | 1 |
| Goto, K; Kato, T; Khaznadar, T; Nishio, M; Okamoto, I; Seki, A; Seto, T; Shibata, M; Tajima, K; Tao, L; Yamamoto, N; Yu, W | 1 |
| Benesova, L; Celer, A; Fiala, O; Finek, J; Hosek, P; Kucera, R; Minarik, M; Nemcova, I; Pesek, M; Racek, J; Sorejs, O; Stehlik, P; Topolcan, O | 1 |
| Chen, P; Gao, X; He, Q; Li, S; Long, J; Sun, P | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Islam, R; Majid, NA; Shah, WS | 1 |
| Chen, Y; Fang, P; Sun, GP; Wang, GH; Wang, SH; Wu, PF; Wu, YQ; Zhang, LH; Zuo, G | 1 |
| Chen, Z; Feng, X; Gao, Y; He, J; Li, X; Liu, T; Lv, Z; Pan, H; Wang, Y; Xie, S; Yang, W; Yang, X; Zhang, J | 1 |
| Costa, JC; Grauslund, M; Melchior, LC; Santoni-Rugiu, E; Sørensen, JB; Urbanska, EM | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Kosloff, RA; Quinn, R; Rubin, MS; Shih, KC; Shipley, DL; Spigel, DR | 1 |
| Chang, YC; Chen, JH; Chen, YF; Cho, KH; Kuo, MY; Lu, YC; Yuan, A | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Kim, KC; Kim, S; Lee, C | 1 |
| Akerley, W; Chalmers, A; Jensen, L | 1 |
| Bai, XY; Chen, HJ; Chen, ZH; Dong, ZY; Jiang, BY; Ke, EE; Luo, DL; Mei, P; Su, J; Sun, YL; Tu, HY; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zheng, MY; Zhong, WZ; Zhou, Q | 1 |
| Aikawa, H; Hamada, A; Hayashi, M; Kawanishi, T; Masuda, C; Nishidate, M; Yamamoto, K | 1 |
| Celik, B; Demirag, MK; Elmali, M; Gulel, O | 1 |
| Wu, X | 1 |
| Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F | 1 |
| Clark, B; McCann, B | 1 |
| Tan, S; Wang, G | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| Drpa, G; Kukulj, S; Manojlovic, S; Sreter, KB | 1 |
| Akerley, W; Orlov, S; Ross, JS; Scagliotti, GV; Schwartz, B; Shepherd, FA; Shuster, D; von Pawel, J; Wang, Q | 1 |
| Chen, G; Du, KQ; Lv, TF; Song, Y; Song, ZB; Wang, WX; Xu, CW; Zhu, YC | 1 |
| Shi, KH; Tao, H; Zhou, X | 1 |
| Endo-Tsukude, C; Fujii, S; Hamada, A; Hayashi, M; Inaba, M; Isobe, T; Iwamoto, N; Kai, Y; Kashiwabara, K; Kishi, H; Kohrogi, H; Saeki, S; Saito, H; Sasaki, JI; Semba, H; Tsubata, Y; Ushijima, S | 1 |
| Dalal, R; Garon, EB; He, S; Jaime, JC; Juan, O; Kiura, K; Lee, P; Nadal, E; Nakagawa, K; Paz-Ares, L; Ponce, S; Reck, M; Widau, RC | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K | 1 |
| Garcia, C; Iderzorig, T; Kellen, J; Osude, C; Puri, N; Singh, S; Woodman, JA | 1 |
| Acker, T; Acker-Palmer, A; Cuesta, AM; Dopeso, H; Garvalov, BK; Henze, AT; Jiao, HK; Jurida, L; Kracht, M | 1 |
| Dong, X; Liu, P; Luo, J; Ren, Y; Su, D; Wang, L; Yang, X | 1 |
| Chiba, M; Gemma, A; Ishikawa, A; Kobayashi, K; Kubota, K; Kunugi, S; Noro, R; Seike, M; Zou, F | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Cao, P; Li, G; Li, Z; Sai, B; Shuai, C; Tang, J; Wang, J; Wang, X; Xiang, J; Zhang, L; Zhang, M | 1 |
| Ali, AAA; Chen, CY; Hsu, FT; Huang, HS; Kao, YC; Liu, HS; Lu, CF; Tsai, PH | 1 |
| Bosch-Barrera, J; Guerra Prió, S; Hernández Martínez, A; Izquierdo Font, A; López Brunsó, M; Mas Pueyo, HG; Roa García, D; Sais Girona, E; Toro Blanch, C | 1 |
| Augustin, M; Goepel, L; Jacobi, A; Radtke, MA | 1 |
| Daido, W; Deguchi, N; Fujihara, M; Funaishi, K; Hattori, N; Ishiyama, S; Ohashi, N; Saito, N; Sakano, A; Taniwaki, M; Yamasaki, M | 1 |
| Demuth, C; Madsen, AT; Meldgaard, P; Sorensen, BS; Weber, B; Wu, L | 1 |
| Fu, W; Lao, Y; Li, X; Meng, X; Qian, J; Tan, H; Tu, S; Xu, H; Xu, L; Xu, N; Zhang, L; Zhou, Q | 1 |
| Hsu, WH; Loong, HH; Mok, TS; Yang, JC | 1 |
| Cao, X; Chen, J; Cui, JD; Guo, XT; Li, Q | 1 |
| Bastos, BR; Brahmer, JR; Chai, F; Dietrich, MF; Gerber, DE; Hesketh, PJ; Huang, C; Johnson, ML; Kazakin, J; Kelly, RJ; Lilenbaum, RC; Neal, JW; Rosovsky, RP; Schiller, JH; Schwartz, B; Sequist, LV; Shirai, K; Socinski, MA; Subramaniam, DS; Wakelee, HA; Wang, Y | 1 |
| Choi, YD; Jang, TW; Kim, YC; Lee, JE; Lee, SY; Oh, IJ; Park, CK; Ryu, JS | 1 |
| Cai, SL; Chen, WQ; Jin, XT; Kou, GF; Li, HY; Li, P; Liu, G; Wang, Q; Yan, S; Zhang, YJ | 1 |
| Groen, HJM; Guo, Y; Li, J; Ma, J; Wang, P; Wang, Z; Yang, K; Zhang, C; Zhao, J | 1 |
| Lee, VHF; Yan, H; Zou, B | 1 |
| Bi, X; Cao, X; Guo, Z; Hong, Z; Lan, L; Luo, L; Shen, B; Sun, H; Wan, F; Xu, M; Yin, Z; Zhao, Z; Zhou, Y | 1 |
| Hebisawa, A; Hirose, T; Kitani, M; Kusaka, K; Matsui, H; Miyakawa, K; Ohta, K; Shimada, M; Tamura, A; Yokoyama, A | 1 |
| An, GJ; Choi, HG; Gautam, M; Gupta, B; Jeong, JH; Kim, JO; Pathak, S; Poudel, BK; Regmi, S; Ruttala, HB; Yong, CS | 1 |
| Cai, L; Cao, M; Hu, J; Li, C; Lu, H; Wang, X; Yan, S; Yin, H; Zhang, H | 1 |
| Chen, HZ; Dong, JK; Lei, HM; Li, WB; Liang, Q; Shen, Y; Tang, YB; Tong, Y; Wang, Y; Zhang, L; Zhang, S; Zhou, Y; Zhu, L; Zhuang, G | 1 |
| Arena, V; Barone, C; Cassano, A; D'Argento, E; Di Noia, V; Di Salvatore, M; Inno, A; Larocca, LM; Martini, M; Orlandi, A; Schinzari, G | 1 |
| Basu, S; Batus, M; Bonomi, P; Borgia, JA; Fhied, CL; Fidler, MJ; Fughhi, I; Pool, M; Roder, J; Sayidine, S | 1 |
| Norberg, E; Queiroz, AL; Vakifahmetoglu-Norberg, H | 1 |
| Li, Y; Liu, Y; Ou, Q; Shao, YW; Wang, X; Wu, X; Ying, J | 1 |
| Inoue, Y; Inui, N; Kahyo, T; Karayama, M; Maekawa, M; Suda, T; Sugimura, H; Yoshimura, K | 1 |
| Achenbach, HJ; Brueckl, WM; Ficker, JH; Schuette, W | 1 |
| Arimoto, T; Chihara, Y; Date, K; Imabayashi, T; Iwasaki, Y; Kaneko, Y; Morimoto, Y; Seko, Y; Takayama, K; Takemura, Y; Tanimura, K; Ueda, M | 1 |
| Arbour, KC; Riely, GJ | 1 |
| Burris, HA; Daniel, DB; Finney, L; Gian, VG; Greco, FA; Hainsworth, JD; Heymach, JV; Lipman, AJ; Shih, KC; Spigel, DR; Waterhouse, DM | 1 |
| Hutton, D; Li, Q; Wen, F; Zhang, P; Zheng, H | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Choi, MK; Kim, JH; Kim, SW; Kim, YC; Lee, JS; Oh, IJ; Park, K | 1 |
| Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W | 2 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Nakamura, M; Tokito, T; Yamada, K; Yanagida, E | 1 |
| Chen, KY; Chen, TT; Chuang, HC; Feng, PH; Han, CL; Huang, YC; Kuo, CH; Lee, CN; Lee, KY; Lee, WH; Lin, CF; Luo, CS; Wu, SM; Yeh, CT | 1 |
| Achenbach, J; Brugger, W; Faehling, M; Gaillard, VE; Staib, P; Steffen, U; Tessen, HW | 1 |
| Bisagni, A; Bonacini, M; Braglia, L; Croci, S; Maramotti, S; Mozzarelli, A; Paci, M; Pagano, M; Tagliavini, E; Zanelli, F | 1 |
| Fukui, T; Harada, S; Igawa, S; Kasajima, M; Katagiri, M; Kubota, M; Kusuhara, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ozawa, T; Sasaki, J; Sugita, K; Yokoba, M | 1 |
| Chang, CL; Chang, JH; Chang, YC; Chow, JM; Hsu, HL; Lin, WC; Wu, ATH; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Baglivo, S; Brambilla, M; Chiari, R; Ludovini, V; Maiettini, D; Metro, G; Rebonato, A; Reda, MS; Ricciuti, B; Sidoni, A; Siggillino, A | 1 |
| Ghaedi, K; Mojtabavi Naeini, M; Tavassoli, M | 1 |
| Dasanu, CA; Loftus, R; Sadeghi, M | 1 |
| Demirkazik, A; Gálffy, G; Kudaba, I; Markóczy, Z; Ostoros, G; Pápai-Székely, Z; Purkalne, G; Rásó, E; Sárosi, V; Somfay, A; Turay, ÜY | 1 |
| Antonia, S; Borghaei, H; Brahmer, JR; Chow, LQM; Geese, WJ; Gerber, DE; Gettinger, S; Goldman, JW; Hellmann, MD; Juergens, RA; Laurie, SA; Li, X; Rizvi, N; Shepherd, FA; Young, TC | 1 |
| Benveniste, MF; Carter, BW; de Groot, PM; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC | 1 |
| Cai, X; Lu, X; Qian, Q; Qian, W; Yu, J; Zhang, W | 1 |
| Lv, X; Wang, Z; Xu, T; Yang, J; Zhou, L; Zhu, Y | 1 |
| Aguiar, PN; de Lima Lopes, G; Del Giglio, A; Haaland, B; Park, W; San Tan, P | 1 |
| Masuda, N; Nakahara, Y; Niwa, H; Sasaki, J | 1 |
| Cheng, F; Jiang, X; Liu, M; Lu, W; Lv, J; Pang, X; Shen, X; Wang, Q; Zhao, Z | 1 |
| Chu, YB; Fu, J; He, W; Kuo, D; Wu, B; Ye, M; Zhang, YJ; Zhao, YY; Zhu, J | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Ahn, JS; Ahn, MJ; Kim, Y; Lee, SH; Park, K; Sun, JM | 1 |
| Hershberger, PA; Liu, C; Petkovich, M; Shaurova, T; Shoemaker, S; Wu, Y | 1 |
| Ardizzoni, A; Bühnemann, C; Cobo, M; Cseh, A; Ehrnrooth, E; Felip, E; Fülöp, A; Gadgeel, SM; Georgoulias, V; Gibson, N; Göker, E; Goss, GD; Guclu, S; Isla, D; Krämer, N; Lee, KH; Li, W; Lu, S; Min, YJ; Morabito, A; Solca, F; Soria, JC; Syrigos, K | 1 |
| Gandara, DR; Lara, PN; Riess, JW | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Andreas, S; Czapiewski, P; Fischer, JR; Kortsik, C; Neuser, P; Reinmuth, N; Reuss, A; Schnabel, PA; Serke, M; Thomas, M; Villalobos, M; Wolf, M | 1 |
| Cho, J; Kim, S; Park, AK | 1 |
| Abravan, A; Eide, HA; Helland, Å; Løndalen, AM; Malinen, E | 1 |
| Aigner, P; Barbacid, M; Brcic, L; Casanova, E; Dezso, K; Dome, B; Eferl, R; Grabner, B; Győrffy, B; Hidalgo, M; Hruschka, N; Laszlo, V; Lopez-Casas, PP; Mohrherr, J; Moldvay, J; Moll, HP; Moriggl, R; Musteanu, M; Penninger, J; Popper, H; Pranz, K; Schramek, D; Sibilia, M; Stiedl, P; Stoiber, D | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Ma, D; Swami, U; Zhang, J | 1 |
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Chen, H; Gao, Y; Li, Z; Lv, T; Xu, L; Zhang, Y | 1 |
| Kassie, F; Song, JM; Upadhyaya, P | 1 |
| Doki, K; Hizawa, N; Homma, M; Kaburagi, T; Kurosawa, A; Ohgami, M; Shiozawa, T | 1 |
| Amano, T; Asahina, H; Dosaka-Akita, H; Harada, M; Harada, T; Honda, R; Honjo, O; Isobe, H; Kanazawa, K; Kinoshita, I; Morikawa, N; Nakano, K; Nishimura, M; Ogi, T; Oizumi, S; Takamura, K; Takashina, T; Yamada, N; Yokouchi, H | 1 |
| Wei, Y; Xu, J; Yu, D; Zhang, W; Zhao, B | 1 |
| Chiang, CT; Choudhury, N; Demetriou, AN; Ghaffarian, K; Mumenthaler, SM; Ruderman, DL; Ung, N | 1 |
| Cao, L; Jiang, W; Liao, D; Liu, N; Xiang, D; Yang, N; Yao, D; Zhang, Y; Zhou, C | 1 |
| Jing, W; Kong, L; Wang, H; Yu, J; Zhu, H | 1 |
| Li, W; Shen, Y | 1 |
| Adams, B; Brennan, M; Dacic, S; Davenport, S; Dubinett, SM; Elashoff, D; Elashoff, RM; Garon, EB; Grogan, T; Hu, EH; Marquez-Garban, DC; Parikh, RJ; Park, DJ; Patel, R; Pietras, RJ; Press, MF; Reckamp, KL; Sadeghi, S; Siegfried, JM; Slamon, DJ; Stabile, LP; Valdes, Y; Wang, HJ; Young, PA | 1 |
| Endo, H; Imamura, F; Inoue, M; Inoue, T; Kimura, M; Kumagai, T; Kunimasa, K; Nakamura, H; Nakatsuka, S; Nishino, K; Nishio, K; Sakai, K; Tamiya, M | 1 |
| Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Karayama, M; Nakamura, Y; Suda, T; Suzuki, Y; Tsuchiya, K; Yasui, H | 1 |
| Ding, K; Hu, X; Li, QY; Li, YL; Lin, NM; Tan, BQ; Wang, F; Zhang, B; Zhang, C | 1 |
| Hollingworth, SA; McCaffrey, E; McGrath, AC; Sandhu, G; Walpole, E | 1 |
| Hanada, S; Kishi, K; Miyamoto, A; Mochizuki, S; Moriguchi, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Uruga, H | 1 |
| Chang, HY; Chen, HC; Chien, PJ; Hung, WH; Ko, JL; Lin, CH; Wang, BY | 1 |
| Akerley, W; Barlesi, F; Blackler, AR; Buttigliero, C; Favaretto, AG; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Roder, J; Santoro, A; Scagliotti, GV; Schwartz, B; Shepherd, FA; Spigel, D | 1 |
| Jassem, J | 1 |
| Atagi, S | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, SL | 1 |
| Xu, R; Zhu, J | 1 |
| Hann, SS; Huang, HD; Tang, Q; Wu, JJ; Xiao, Q; Xie, J; Yang, XB; Zheng, F | 1 |
| Chen, J; De Perrot, M; Fujino, K; Hatanaka, KC; Hatanaka, Y; Hu, HP; Jin, CS; Kaga, K; Kanno, H; Kato, T; Lee, D; Matsui, Y; Matsuno, Y; Ujiie, H; Wada, H; Weersink, RA; Wilson, BC; Wu, L; Yasufuku, K; Zheng, G | 1 |
| Chi, GY; Choi, YH; Min, TR; Park, HJ; Park, SH | 1 |
| Ceppi, M; Han, JY; Jacob, W; James, I; Kim, HS; Kim, JY; Lee, GK; Lim, KY; Shin, DH; Weisser, M | 1 |
| Archila, P; Arrieta, O; Avila, J; Bravo, M; Cardona, AF; Carranza, H; Castro, CD; Corrales, L; Martín, C; Otero, J; Pino, LE; Reguart, N; Ricaurte, LM; Rodriguez, J; Rojas, L; Rosell, R; Ruiz-Patiño, A; Vargas, C; Wills, B; Zatarain-Barrón, ZL | 1 |
| Chen, H; Gao, Y; Jia, L; Li, F; Li, Z; Lv, T; Xie, X; Zhang, H; Zhang, L; Zhang, Y | 1 |
| Chen, P; Dai, CH; Li, J; Long, WG; Shu, Y; Wu, JN; Yuan, RX; Zhu, LH; Zhu, YM | 1 |
| Kenzaka, T; Miyoshi, K; Nakaji, H | 1 |
| Hove, J; Powell, SF; Wynja, E | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Aguilar, KM; Muehlenbein, CE; Nadler, ES; Wetmore, S; Wilson, T; Winfree, KB; Zhu, YE | 1 |
| Choi, CM; Choi, YJ; Cook, S; Jin, YS; Kim, DH; Kim, JK; Lee, EY; Lee, JC; Rho, JK; Sung, KJ; Sung, YH; Yoo, SA; Yun, M | 1 |
| Fujino, H; Kajiura, K; Kondo, K; Miyoshi, H; Otani, T; Otsuka, H; Takizawa, H | 1 |
| Chinet, T; Dumenil, C; Giroux-Leprieur, E | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Abourbeh, G; Grievink, H; Itamar, B; Mishani, E; Shamni, O | 1 |
| Alama, A; Biello, F; Boccardo, S; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Rossi, G; Tagliamento, M | 1 |
| Damon, JK; Garcia, JV; Gupta, V; Kanabar, D; Kulkarni, NS; Mitragotri, S; Muth, A; Parvathaneni, V; Sarode, A; Shukla, SK; Vaidya, B | 1 |
| Aguiar-Bujanda, D; Blanco-Sanchez, MJ; Bohn-Sarmiento, U; Dueñas-Comino, A; Galvan-Ruiz, S; Hernandez-Sosa, M; Lorenzo-Barreto, JE; Mori-De Santiago, M; Ros-Sanjuan, L; Saura-Grau, S; Vargas-Prado, AM | 1 |
| Azzoli, CG; Chaft, JE; Costa, DB; Evans, TL; Govindan, R; Heist, RS; Jänne, PA; Kris, MG; Lanuti, M; Murthy, S; Muzikansky, A; Neal, JW; Pennell, NA; Rusch, VW; Sequist, LV; Shapiro, MA; Wakelee, HA | 1 |
| Zhang, W; Zhao, B | 1 |
| Cao, L; Huang, J; Jiang, Y; Li, N; Xu, B; Zhang, J; Zhao, M | 1 |
| Imamura, F; Kishi, K; Kozuki, T; Nakagawa, K; Nakagawa, S; Nishio, M; Nokihara, H; Sakai, H; Satouchi, M; Seto, T; Tahata, T | 1 |
| Liu, H; Wang, J; Wang, X; Wei, N; Zhang, F; Zhang, X | 1 |
| Chen, JS; Chen, KY; Ho, CC; Hsu, CL; Lee, JH; Liao, WY; Lin, YT; Lin, ZZ; Shih, JY; Yang, CY; Yang, JC; Yu, CJ | 1 |
| Dai, JG; Huang, HH; Liang, Y | 1 |
| Appius, A; Button, P; Hooper, G; Lee, V; Liam, CK; Lu, S; Mok, T; Palma, JF; Park, K; Schulze, K; Scudder, S; Shames, DS; Srimuninnimit, V; Wang, J; Wu, YL; Yin, AY; Zhang, G; Zhou, C | 1 |
| Agazzi, GM; Berruti, A; Bettoni, V; Borghesi, A; Caprioli, A; Farina, D; Ganeshan, B; Maroldi, R; Ravanelli, M; Roca, E; Tononcelli, E | 1 |
| Abdulla, DSY; Brandes, V; Büttner, R; Drzezga, A; Fischer, R; Galldiks, N; Grau, S; Kobe, C; Kunze, S; Merkelbach-Bruse, S; Michels, S; Nogova, L; Persigehl, T; Riedel, R; Ruge, M; Scheffler, M; Wolf, J | 1 |
| Fiore, J; Gadgeel, SM; Papadimitrakopoulou, VA; Patnaik, A; Raftopoulos, H; Saraf, S; Sequist, LV; Su, WC; Wu, CL; Yang, JC | 1 |
| Chen, JY; Ting, CH | 1 |
| Bohn, P; Brune, X; Guisier, F; Patout, M; Renard, PY; Romieu, A; Salaün, M; Sarafan-Vasseur, N; Sesboüé, R; Thiberville, L | 1 |
| Cai, H; Chen, S; Li, N; Liu, MB; Weng, L; Yang, J; Zhang, L; Zheng, B | 1 |
| Carnero, A; Cirauqui, C; Conde, E; Enguita, AB; Ferrer, I; Marrugal, Á; Molina-Pinelo, S; Ojeda-Márquez, L; Paz-Ares, L; Ponce-Aix, S; Quintanal-Villalonga, A; Suarez, R | 1 |
| Chu, YB; Gu, X; Kuo, D; Su, B; Wu, B; Zhang, Q; Zhang, YJ; Zhao, YY | 1 |
| Beau-Faller, M; Blons, H; Cadranel, J; De Fraipont, F; Escande, F; Lizard, S; Longchampt, E; Melaabi, S; Morin, F; Pignon, JP; Richard, N; Texier, M; Zalcman, G | 1 |
| Cha, PH; Cho, J; Cho, YH; Choi, KY; Han, G; Kim, T; Lee, HY; Lee, J; Lee, SK; Min, DS; Park, J; Shin, WJ; Yang, JS | 1 |
| Iwami, E; Kuroda, A; Matsuzaki, T; Nakajima, T; Sasahara, K; Terashima, T | 1 |
| Ali, SM; Atkinson, EC; Chachoua, A; Nelson, AW; Pavlick, DC; Schrock, AB | 1 |
| Chang, HL; Chong, IW; Hsu, JF; Lee, YL; Li, CY; Lin, CM; Shen, YT; Wei, PJ; Yang, CJ | 1 |
| Fujii, K; Ichiyasu, H; Ikeda, T; Imamura, K; Kashiwabara, K; Komatu, T; Maruyama, H; Saeki, S; Sakagami, T; Saruwatari, K; Shingu, N; Tomita, Y; Ushijima, S | 1 |
| Golabiewska, E; Holownia, A; Niechoda, A; Rybak, A; Zarzecki, M | 1 |
| Hashimoto, K; Kagamu, H; Kaira, K; Kobayashi, K; Miura, Y; Mouri, A; Murayama, Y; Nishihara, F; Shiono, A; Yamaguchi, O | 1 |
| Erikson, AK; Paripati, HR; Sheedy, JT; Shoudis, SN; Sio, TT; Yu, NY | 1 |
| Afaq, S; Ahmad, A; Biersack, B; Faisal, M; Farhan, M; Farooqi, AA; Malik, A; Schobert, R; Ullah, MF | 1 |
| Kong, CY; Palazzo, LL; Sheehan, DF; Tramontano, AC | 1 |
| Singh, RP; Tabasum, S | 1 |
| Grimsrud, KW; Mrugala, MM | 1 |
| An, X; Diao, XY; Feng, YF; Shao, Q; Wang, F; Wang, HY; Zhang, X | 1 |
| Bagde, A; Doddapaneni, R; Patel, K; Patki, M; Sekar, V; Singh, M | 1 |
| Goodall, S; Holleman, MS; Uyl-de Groot, CA; van der Linden, N | 1 |
| Grappasonni, I; Nguyen, BT; Nguyen, CTT; Petrelli, F; Scuri, S | 1 |
| Aguiar-Bujanda, D; Artal-Cortes, Á; DE Castro, J; Fírvida, JL; Fuentes, JC; Galán, R; Gordo, R; Oramas, J; Ortega-Granados, AL; Trigo, J | 1 |
| Baretta, Z; Basso, M; Bernardi, D; Bonanno, L; Bonetti, A; Bortolami, A; Calvetti, L; Conte, P; Corte, DD; Favaretto, A; Frega, S; Gatti, C; Giovanis, P; Gori, S; Guarneri, V; Menis, J; Oliani, C; Oniga, F; Palazzolo, G; Pasello, G; Redelotti, R; Rosetti, F; Santo, A; Toso, S; Vicario, G; Zustovich, F | 1 |
| Chen, Z; Li, F; Sun, J; Wang, J; Wang, X; Xu, Z; Yang, Q; You, Q; Yu, Y; Zheng, L; Zhou, P; Zhu, G; Zhuo, W | 1 |
| Endo, M; Gon, Y; Harada, H; Kawamura, T; Kenmotsu, H; Kobayashi, H; Mamesaya, N; Mitsuya, K; Miyawaki, E; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nakasu, Y; Omori, S; Ono, A; Takahashi, T; Wakuda, K | 1 |
| Borghaei, H; Camidge, R; Deal, A; Kavanagh, B; Kirpalani, P; Lee, C; Morris, D; Pecot, CV; Pennell, N; Stevenson, J; Stinchcombe, T; Villaruz, L; Weiss, J; West, J; Zagar, T | 1 |
| Bai, Y; Jin, YH; Li, WH; Ni, L | 1 |
| Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR | 1 |
| Hsu, JC; Wei, CF; Yang, SC | 1 |
| Chen, L; Cheng, Y; Han, B; Huang, C; Jiang, G; Li, E; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Zhong, Z; Zhou, C; Zhu, Y | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Jung, HA; Kim, Y; Lee, K; Lee, SH; Park, K; Sun, JM | 1 |
| Golembesky, A; Griebsch, I; Lim, J; Samuelsen, C; Shrestha, S; Wang, L | 2 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Hu, Y; Liu, L; Qu, J; Xiong, Y; Yang, H; Yang, N; Zhou, C | 1 |
| Fynboe Ebert, EB; Meldgaard, P; Sorensen, BS; Winther-Larsen, A | 1 |
| Ju, Q; Shao, H; Shi, H; Xu, R; Zhu, J | 1 |
| Kong, X; Lin, X; Qin, J; Wang, J; Wang, R; Xiong, Z; Zhao, H | 1 |
| Wang, Z; Wu, YL | 1 |
| Bergman, B; Branden, E; Gréen, H; Hornstra, N; Kentson, M; Koyi, H; Svedberg, A; Vikingsson, S; Vikström, A | 1 |
| Germonpré, P; Van den Wyngaert, T | 1 |
| Asai, G; Azuma, K; Fujita, Y; Fukuhara, T; Furuya, N; Gemma, A; Hagiwara, K; Iwasawa, S; Kobayashi, K; Kurimoto, F; Maemondo, M; Miyazaki, M; Morita, S; Nagashima, H; Nakachi, I; Nukiwa, T; Okada, M; Saito, H; Sugawara, S; Tsubata, Y; Tsunezuka, Y; Watanabe, K; Watanabe, S; Yamaguchi, O; Yoshimori, K | 1 |
| Yang, JC | 1 |
| Carnero, A; Enguita, AB; Ferrer, I; Marrugal, Á; Molina-Pinelo, S; Ojeda-Márquez, L; Paz-Ares, L; Ponce-Aix, S; Quintanal-Villalonga, A; Suarez, R; Yagüe, P | 1 |
| Chen, X; Duan, Y; Liao, XY; Sun, J; Wang, Y; Xu, Z; Yang, Q; Zheng, L; Zhu, B; Zhu, G | 1 |
| Bradbury, PA; Chan, KK; Chen, BE; Cheung, M; Cheung, WY; Ding, K; Hay, AE; Kornelsen, EA; Leighl, NB; Mittmann, N; Ng, RCH; Pater, JL; Tu, D | 1 |
| Guo, C; Li, R; Wu, K | 1 |
| Batra, U; Lau, SCM; Loong, HH; Mok, TSK | 1 |
| Horn, L; Jie, F; Kelly, RJ; Krivoshik, A; Shepherd, FA | 1 |
| Hann, SS; Li, X; Tang, Q; Wu, J; Wu, W; Zhao, Y; Zheng, F | 1 |
| Dekker, H; Funel, N; Giovannetti, E; Keller, K; Lardon, F; Leonetti, A; Pauwels, P; Peters, GJ; Rolfo, C; Ruijtenbeek, R; Tiseo, M; Van Der Steen, N | 1 |
| Baba, K; Hasegawa, Y; Ishioka, Y; Itoga, M; Nakagawa, H; Okudera, K; Sakamoto, H; Shiratori, T; Taima, K; Takanashi, S; Tanaka, H; Tasaka, S; Tsuchiya, J; Yasugahira, H | 1 |
| Jiang, R; Li, H; Li, X; Liu, H; Ma, R; Wang, Y; Yang, M; Zhang, M; Zhao, Y | 1 |
| López-Contreras, F; López-Muñoz, R; Martin-Martin, A; Molina-Berríos, A; Muñoz-Uribe, M; Pérez-Laines, J; Rivera-Dictter, A | 1 |
| Fintelmann, F; Geng, C; Grassberger, C; Hata, AN; Kamran, SC; Maruvka, YE; McClatchy, D; Paganetti, H; Piotrowska, Z; Sequist, LV; Willers, H | 1 |
| He, Y; Li, M; Li, Y; Tan, Z; Tu, S; Yang, J; Zhang, L; Zhou, W; Zhou, X | 1 |
| Chesney, J; Imbert-Fernandez, Y; Lypova, N; Telang, S | 1 |
| Chooback, N; Ho, C; Lau, SC; Melosky, B | 1 |
| Asselain, B; Ben Hadj Yahia, B; Brun, P; Coëtmeur, D; Coudert, M; Dayen, C; De Faverges, G; Debieuvre, D; Gally, S; Goupil, F; Grivaux, M; Hauss, PA; Locher, C; Martin, F; Moreau, L | 1 |
| Asai, K; Chiba, Y; Hayashi, H; Kasai, T; Kawaguchi, T; Kijima, T; Kimura, T; Kogure, Y; Nakagawa, K; Nakanishi, Y; Niwa, T; Oguri, T; Ono, A; Tanaka, H; Watanabe, K; Yamamoto, N; Yano, S; Yoshimura, N; Yoshioka, H | 1 |
| Hamamoto, J; Ikemura, S; Kawada, I; Kobayashi, K; Manabe, T; Masuzawa, K; Naoki, K; Oashi, A; Soejima, K; Tani, T; Terai, H; Yasuda, H | 1 |
| Atagi, S; Hirashima, T; Imamura, F; Inoue, T; Kimura, M; Kuhara, H; Kumagai, T; Kunimasa, K; Moriizumi, K; Nakahama, K; Nishino, K; Suzuki, H; Tamiya, A; Tamiya, M; Taniguchi, Y | 1 |
| Liang, F | 1 |
| Maemondo, M | 1 |
| Ayeni, D; de Miguel, FJ; Gaefele, M; Guan, T; Ho, PC; Homer, R; Kaech, S; Krystal, G; Kuhlmann, A; Levy, S; Liu, Z; Lockwood, W; Miller, B; Perry, C; Politi, K; Robles-Oteiza, C; Zelterman, D | 1 |
| Higuchi, M; Kodama, S; Koto, H; Matsuo, K; Miyazaki, M; Sasaki, Y; Wada, Y; Yamaguchi, R | 1 |
| Cikes, M; Hecimovic, A; Jakopovic, M; Jankovic Makek, M; Samarzija, M; Vukic Dugac, A | 1 |
| Higo, H; Hotta, K; Ichihara, E; Kano, H; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Matsubara, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Rai, K; Sato, A; Tabata, M; Takata, M; Tomida, S; Toyooka, S; Watanabe, H | 1 |
| Costa, DB; Jänne, PA; Kobayashi, SS; Lau, CJ; Mushajiang, M; Oxnard, GR; Paweletz, CP; Rangachari, D; Shpilsky, JE; To, C; VanderLaan, PA | 1 |
| Ahsmann, EJ; Eshuis, M; van Egmond, NH | 1 |
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Díaz-Rubio, E; González-Larriba, JL; Hernández, S; Manzano, A; Pérez, P; Puente, J; Sanz, J; Sotelo, M; Zugazagoitia, J | 1 |
| Huber, RM; Reck, M; Thomas, M | 1 |
| Chen, HJ; Cheng, YP; Chiu, HC | 1 |
| Couraud, S | 1 |
| Bastida, C; Falchook, GS; Fu, S; Hong, DS; Jiang, Y; Kurzrock, R; Morgan-Linnell, SK; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Akerley, WL; Cowie, RH; Hornberger, J; Nelson, RE; Spinella, DG | 1 |
| Alesini, D; Bria, E; Cantile, F; Ciardiello, F; Cortesi, E; Fasano, M; Morgillo, F; Passaro, A; Pellegrino, A | 1 |
| Sterman, DH | 1 |
| Altavilla, G; De Pas, TM; Rosell, R; Santarpia, M; Spaggiari, L | 1 |
| Arcila, ME; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rekhtman, N; Riely, GJ; Sima, CS; Yu, HA; Zakowski, MF | 1 |
| Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S | 1 |
| Eckert, R; Faehling, M; Griese, U; Kamp, T; Kuom, S; Ott, G; Spengler, W; Sträter, J | 1 |
| Bayne, M; Cherrett, L; Davis, R; Fenton, P; Laurence, V | 1 |
| Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Ke, S; Pan, G; Zhao, J | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Dong, Z; Kang, Y; Liu, G; Ma, X; Qian, Q; Zhang, X | 1 |
| Fukudo, M; Ikemi, Y; Inui, K; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Terada, T; Teramukai, S; Togashi, Y | 1 |
| Megahed, M; Wahl, RU | 1 |
| Giuliani, J; Marzola, M | 2 |
| Burton, L; Cowan, KJ; Hampton, GM; Hegde, PS; Lackner, MR; Li, C; Merchant, M; Parab, V; Patel, P; Penuel, E; Peterson, A; Yauch, RL | 1 |
| Beasley, MB; Cagle, PT; Chitale, DA; Dacic, S; Giaccone, G; Jenkins, RB; Kwiatkowski, DJ; Ladanyi, M; Lindeman, NI; Saldivar, JS; Squire, J; Thunnissen, E | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, JI; Kim, JY; Kim, S; Kim, TM; Koh, Y; Lee, JK; Lee, S; Lee, SH; Min, HS; Park, C; Shin, JY | 1 |
| Furukawa, T; Hamasaki, S; Itakura, S; Miyata, M; Suenaga, M; Tabata, S; Yamamoto, M | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B; Schwartz, EL; Sironi, J; Zou, Y | 1 |
| Chang, CX; Hu, RH; Li, R; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Aragane, N; Harada, T; Ichinose, Y; Kawakami, S; Kishimoto, J; Morinaga, R; Nagata, S; Nakanishi, Y; Saruwatari, K; Takayama, K; Yamada, K | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Kishi, A; Kiyohara, Y; Yamazaki, N | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Cappuzzo, F; D'Arcangelo, M | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Evans, T; Gettinger, S; Hensing, TA; Ireland, B; Socinski, MA; Stinchcombe, TE; VanDam Sequist, L | 1 |
| Agelaki, S; Agelidou, M; Christofillakis, C; Georgoulias, V; Giassas, S; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Rapti, A; Samonis, G; Souglakos, J; Vamvakas, L; Voutsina, A | 1 |
| Cho, YS; Kim, HU; Kim, JI; Nam, KH; Park, J; Yun, SK | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chen, TC; Lee, KM; Lien, CT; Lin, SY; Lu, PL | 1 |
| Bunn, PA; Paz-Ares, L; Shepherd, FA | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Essenburg, C; Kaufman, D; Lewis, S; Staal, B; Vande Woude, GF; Zhang, YW | 1 |
| Carr, LL; Jett, JR | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Arpin, D; Bringuier, PP; Couraud, S; Locatelli-Sanchez, M; Riou, R; Souquet, PJ | 1 |
| Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH | 1 |
| Belani, CP; Benner, RJ; Chachoua, A; Cuevas, JD; Eisenberg, PD; Mather, CB; Meech, SJ; Nemunaitis, JJ; Raez, LE | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, E; Lee, SH | 1 |
| Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Aoki, Y; Fujii, T; Ishii, N; Kondoh, O; Mio, T; Ono, N; Sakata, K; Suda, A; Tsukaguchi, T; Tsukuda, T; Yamazaki, T | 1 |
| Costa, C; Fujita, H; Kage, M; Kanda, R; Kawahara, A; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Sonoda, K; Uramoto, H; Watari, K | 1 |
| Jacobson, BA; Jay-Dixon, J; Kratzke, RA; Patel, MR; Sadiq, AA | 1 |
| Dziadziuszko, R; Jassem, J | 2 |
| Bettini, A; Bianchi, F; Broggini, M; Farina, G; Floriani, I; Ganzinelli, M; Garassino, MC; Giaccone, G; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Scanni, A; Tomirotti, M; Torri, V; Veronese, S | 1 |
| Altug, S; Digumarti, R; Han, B; Kim, HK; Kim, SW; Lee, DH; Lee, JS; Orlando, M; Rodrigues-Pereira, J; Sahoo, TP; Song, XQ; Wang, J; Wang, X | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Havel, L; Hrnciarik, M; Krejci, J; Minarik, M; Pesek, M; Salajka, F | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Chikamori, K; Fukuyama, T; Goto, K; Hida, T; Katakami, N; Kozuki, T; Maemondo, M; Nishio, M; Seto, T; Tamura, T; Yamamoto, N; Yoshioka, H | 1 |
| Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Gao, BL; Hang, JB; Hu, JA; Xu, ZH | 1 |
| Bedi, A; Chang, X; Chatterjee, A; Goodman, SN; Harari, PM; Hidalgo, M; Izumchenko, E; Kim, MS; Ling, S; Monitto, CL; Sidransky, D; Solis, LM; Wistuba, II | 1 |
| Izumi, Y; Nomori, H; Yamamoto, J; Yamauchi, Y | 1 |
| Aisner, DL; Berge, EM; Doebele, RC | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Chen, JQ; Giaccone, G; Goldsmith, PK; Heldman, MR; Herrmann, MA; Lee, JH; Park, KS; Wang, Y | 1 |
| Alberti, AM; Apolone, G; Cammilluzzi, E; Cesario, A; D'Angelillo, RM; De Quarto, AL; Fiore, M; Greco, C; Ippolito, E; Ramella, S; Ramponi, S; Trodella, L | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Biddinger, P; Dillard, T; Hao, Z; Patel, V | 1 |
| Amoroso, D; Chao, TY; Chung, CY; Ciuleanu, T; Groen, HJ; Heo, DS; Klingelschmitt, G; Klughammer, B; Middleton, G; Milanowski, J; Szczesna, A; Thatcher, N; Tsai, CM; Tsao, CJ; Zeaiter, A | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Koba, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Stinchcombe, TE | 1 |
| Chiu, HC; Chiu, HY | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Boisdron-Celle, M; Fey, L; Hureaux, J; Morel, A; Rieux, C; Urban, T | 1 |
| Baty, F; Betticher, D; Brutsche, M; Bubendorf, L; Cathomas, R; Crowe, S; Dröge, C; Früh, M; Gautschi, O; Pless, M; Rauch, D; Rothschild, S; Zappa, F | 1 |
| Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL | 1 |
| Shen, W; Turchi, JJ; Xu, J; Zeng, LF; Zhang, ZY | 1 |
| Barrajón-Catalán, E; Bosch-Barrera, J; Corominas-Faja, B; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A | 1 |
| Köhler, J; Schuler, M | 1 |
| Chen, CH; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
| Chen, YM; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, WS | 1 |
| Digumarthy, S; Goldberg, SB; Jackman, DM; Lennes, IT; Muzikansky, A; Oxnard, GR; Sequist, LV | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Deng, CH; Li, HQ; Li, L; Li, MY; Lu, W; Wu, Q; Zhou, TY | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Barlesi, F; Blumenschein, GR; Daniel, DB; Ervin, TJ; Godbert, B; Goldschmidt, JH; Govindan, R; Krzakowski, MJ; Orlov, SV; Patel, PH; Patel, T; Peterson, AC; Phan, SC; Ramlau, RA; Robinet, G; Spigel, DR; Wertheim, MS; Yauch, RL; Yu, W; Zha, J | 1 |
| Bowden, C; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Kressel, B; Lin, CY; Marsland, T; Miller, V; Patel, T; Polikoff, J; Rubin, M; White, L; Yang, JC | 1 |
| Baudrin, L; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Herman, D; Lavolé, A; Mennecier, B; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Pichon, E; Poudenx, M; Quoix, E; Sennelart, H; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Fukuda, M; Iida, T; Ikeda, T; Ikegami, Y; Kohno, S; Mizoguchi, K; Motoshima, K; Nagashima, S; Nakamura, Y; Sano, K; Takemoto, S; Tsukamoto, K | 1 |
| Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Abraham, I; Bustin, F; De Vos, L; Galdermans, D; Lechat, I; Van Meerbeeck, J | 1 |
| Cai, HR; Ding, JJ; Liu, L; Miao, LY; Ren, SX; Schmid-Bindert, G; Wang, YS; Zhou, CC | 1 |
| Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N | 1 |
| Mennecier, B; Quoix, A; Sakhri, L | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Fujimoto-Ouchi, K; Furugaki, K; Harada, N; Iwai, T; Moriya, Y | 1 |
| Ema, T; Enomoto, Y; Kawano, R | 1 |
| Gröschel, A; Reck, M; Reinmuth, N | 1 |
| Ahmad, A; Bao, B; Gadgeel, SM; Ginnebaugh, KR; Li, Y; Maitah, MY; Sarkar, FH | 1 |
| Bennouna, J; Dansin, E; Favrel, S; Hiret, S; Kowalski, D; Krzakowski, M; Penel, N; Tourani, JM | 1 |
| Koyama, N; Uchida, Y | 1 |
| Azuma, K; Hoshino, T; Itoh, K; Kasama-Kawaguchi, Y; Kim, J; Matsueda, S; Muta, E; Nishio, K; Sasada, T; Sugawara, S; Yamada, T; Yamashita, T; Yamashita, Y; Zhang, GL | 1 |
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Brahmer, JR; Guaglianone, PP; Hidalgo, MM; Keppen, MD; Kolesar, JM; Lee, JW; Patel, JD; Schiller, JH; Siegfried, JM; Traynor, AM | 1 |
| Song, Z; Zhang, Y | 1 |
| Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M | 1 |
| Lee, VH; Lee, VW; Schwander, B | 1 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Molina-Pinelo, S; Pastor, MD; Paz-Ares, L | 1 |
| Meng, X; Teng, FF; Yu, JM; Zhang, JD | 1 |
| Besse, B; Bonardel, G; Chargari, C; Farace, F; Gontier, E; Hadoux, J; Helissey, C; Lamand, V; Le Moulec, S; Soria, JC; Tanz, R; Vedrine, L | 1 |
| Koh, Y; Serizawa, M; Takahashi, T; Yamamoto, N | 2 |
| Liu, Z; Shi, L; Tang, J; Tong, L | 1 |
| Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR | 1 |
| Choi, CM; Choi, YJ; Kim, HR; Kim, SY; Lee, JC; Park, GM; Rho, JK; So, GS | 1 |
| Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M | 1 |
| Afonso-Afonso, FJ; Alonso-Jáudenes, G; Amenedo, M; Barón-Duarte, FJ; Campos-Balea, B; Casal Rubio, J; Fírvida-Pérez, JL; Huidobro, G; Lázaro-Quintela, M; López-Vázquez, MD; Santomé, L; Vázquez, S | 1 |
| Arcila, ME; Chaft, JE; Cohen, DW; Costa, DB; Eck, MJ; Hanna, M; Huberman, MS; Ishioka, K; Kobayashi, SS; Lathan, CS; Lucena-Araujo, AR; Meyerson, M; Moran, T; Nakayama, S; Oxnard, GR; Park, E; Riely, GJ; Sequist, LV; Sng, NJ; Soo, RA; Yamaguchi, N; Yasuda, H; Yeo, WL; Yun, CH | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Guan, Y; Jiao, S; Meng, J; Yan, X; Zhao, H | 1 |
| Afonso, J; Amenedo, M; Casal, J; Fírvida, JL; Lázaro, M; Santomé, L; Vázquez, S | 1 |
| Bannerji, R; Edelman, MJ; Jou, YM; Joy, AA; Martin, JC; Nemunaitis, J; Small, K; Statkevich, P; Stephenson, JJ; Yao, SL; Zhang, D; Zhou, H; Zhu, Y | 1 |
| Hager, H; Khalil, AA; McCulloch, T; Meldgaard, P; Mellemgaard, A; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Chan, AW; Lo, SH; To, KF; Tong, JH | 1 |
| Dhanda, R; Mallick, R; Nadler, E; Pan, IW | 1 |
| An, J; Gao, H; Li, J; Li, X; Liu, X; Liu, Y; Qin, H; Qu, L; Tang, C; Wang, W; Yang, S | 1 |
| Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 2 |
| Fang, MH; Li, RC; Yu, SY; Zheng, LJ | 1 |
| Yaqub, F | 1 |
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Liu, XQ; Qiao, TK | 1 |
| Chen, CY; Chiu, HC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Wo, TY | 1 |
| Horn, L; Lammers, PE; Lovly, CM | 1 |
| Fukihara, J; Hasegawa, Y; Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Taniguchi, H; Watanabe, N; Yokoyama, T | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Iwasaki, T; Mitsudomi, T; Mizuuchi, H; Sato, K; Suda, K; Takemoto, T | 1 |
| Cao, X; Hong, Z; Lan, L; Li, N; Luo, L; Pan, X; Shen, L; Yin, Z; Zhang, Y; Zhou, Y | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Ladanyi, M; Riely, GJ; Yu, HA | 1 |
| Li, N; Liu, QW; Ou, W; Wang, BX; Wang, SY; Yang, H; Zhang, SL | 1 |
| Camidge, DR; Campbell, AK; Engelman, JA; Gadgeel, SM; Gernhardt, D; Giaccone, G; Jänne, PA; Khuri, FR; Koczywas, M; Letrent, S; Liang, J; O'Connell, JP; Rajan, A; Reckamp, KL; Ruiz-Garcia, A; Taylor, I | 1 |
| Couturier, O; Fosse, P; Hachemi, M; Hureaux, J; Lacœuille, F; Urban, T; Vervueren, L | 1 |
| Fan, X; Jiang, L; Li, S; Liu, Z; Wu, X; Zhao, H; Zhu, F | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dong, XL; Dong, Z; Li, G; Li, XL; Mu, XY; Ni, YH; Sun, EL; Sun, J; Yi, Z | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Bernards, R; Cowell, C; de Bruin, EC; Downward, J; García-Castaño, A; Gettinger, S; Gómez-Román, J; Gong, Y; Heideman, DA; Heynen, GJ; Jiang, M; Ladanyi, M; Melnick, MA; Politi, K; Saunders, RE; Smit, EF; Varmus, H; Walther, Z; Warne, PH; Wurtz, A | 1 |
| Bader, AG; Kelnar, K; Zhao, J | 1 |
| Bohnet, S; Deppermann, KM; Eiff, MV; Fischer, JR; Heigener, DF; Koester, W; Kortsik, C; Pawel, JV; Reck, M; Schnabel, PA; Thomas, M | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Abdi, E; Button, P; Clarke, S; Clingan, P; Do, H; Dobrovic, A; Gregory, D; Michael, M; Nott, L; Solomon, B; White, SC; Zimet, A | 1 |
| Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW | 1 |
| Beltran-Alamillo, J; Benlloch, S; Bordogna, W; Botero, ML; Chen, D; de Aguirre, I; Gimenez-Capitán, A; Klughammer, B; Kovach, B; Lawrence, HJ; Mayo, C; Palma, JF; Queralt, C; Ramirez, JL; Ramón y Cajal, S; Schlegel, M; Shieh, F; Taron, M; Wu, L; Zhang, G | 1 |
| Rerknimitr, P; Rungtrakulchai, R | 1 |
| Chen, C; Cretoiu, SM; Shi, L; Wang, B; Wang, L; Wang, Q; Wang, X | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Kato, M; Kobayashi, I; Murakami, A; Nurwidya, F; Shimada, N; Shukuya, T; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Li, S; Ren, S; Zhou, C; Zhou, F | 1 |
| Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M | 1 |
| Baumann, M; Benes, CH; Chowdhury, D; Efstathiou, JA; Greninger, P; Hülskötter, M; Kern, AM; Krause, M; Pan, Y; Settleman, J; Singh, A; Wang, M; Willers, H | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z | 1 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Dafni, U; Karlis, D; Peters, S; Smit, E | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N | 1 |
| Koh, Y; Murakami, H; Serizawa, M; Takahashi, T; Watanabe, M; Yamamoto, N | 1 |
| Behringer, D; Desaiah, D; Dittrich, C; Hartmann, JT; Kazeem, G; Leschinger, MI; Papai-Szekely, Z; Sederholm, C; Vinolas, N; von Pawel, J | 1 |
| Chang, CX; Li, P; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Seto, T; Shiraishi, Y; Taguchi, K; Takenaka, T; Takenoyama, M; Takeo, S; Toyokawa, G; Toyozawa, R; Ushijima, C; Yamaguchi, M; Yoshida, T | 1 |
| Chang, JY; Hsiao, CJ; Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Fujiwara, K; Hosokawa, A; Ichiba, Y; Kajiume, S; Kiba, T; Kimoto, S; Nakano, K; Nakashima, T; Ogawa, Y; Okada, Y; Taniguchi, H | 1 |
| Bergbower, E; Dennis, PA; Dogan, I; Ekmekci, A; Gills, JJ; Kawabata, S; Rudin, CM; Wilson, W | 1 |
| Anand, S; Camargo, MF; Cascone, T; Cheresh, DA; Desgrosellier, JS; Diao, L; Elliott, KC; Franovic, A; Heymach, JV; Husain, H; Kato, S; Lesperance, J; Lippman, SM; Lowy, AM; Mielgo, A; Seguin, L; Wang, J; Weis, SM; Wistuba, II; Yebra, M | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Audigier Valette, C; Cadranel, J; Chabaud, S; Moro-Sibilot, D; Perol, D; Perol, M | 1 |
| Geissler, M; Steins, M; Thomas, M | 2 |
| Hong, W; Lin, B; Mao, W; Zhang, B; Zhang, Y | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Bexon, AS; Boyd, TE; Conkling, P; de La Bourdonnaye, G; Mita, AC; Nemunaitis, JJ; Richards, DA; Smith, DA; Wages, D | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Wu, YL; Yan, HH; Yang, JJ; Zhang, XC; Zhao, N | 1 |
| Aimiuwu, J; Blachly, JS; Gao, Y; Hicks, WJ; Li, J; Otterson, GA; Papp, A; Phelps, MA; Poi, M; Schaaf, LJ; Socinski, MA; Starrett, SL; Stinchcombe, TE; Villalona-Calero, MA; Wang, D; Wei, L; Zhao, W | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Yano, S | 1 |
| Fukai, T; Hasegawa, T; Hirasawa, Y; Ikeda, S; Kamiya, Y; Kudo, Y; Matsumura, M; Nagata, A; Shiraishi, E | 1 |
| Kuang, K; Yang, K; Yang, X | 1 |
| Aukema, TS; Burgers, SA; Klomp, HM; Rijna, H; Schaake, EE; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Garzon, F; Geater, SL; Gopalakrishna, P; Iannotti, N; Lee, V; Lim, WT; Mok, TS; Reyderman, L; Reynolds, C; Smith, D; Spira, A; Thongprasert, S; Wang, B; Xu, L | 1 |
| Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L | 1 |
| Chang, JY; Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Berger, MF; Kris, MG; Krug, LM; Ladanyi, M; Pietanza, MC; Rekhtman, N; Riely, GJ; Varghese, AM; Wang, L; Won, HH; Yu, HA; Zakowski, MF | 1 |
| Butts, CA | 1 |
| Aieta, M; Bachi, A; Barni, S; Bearz, A; Bulotta, A; Cattaneo, A; de Marinis, F; De Pas, T; Doglioni, C; Floriani, I; Foti, S; Gregorc, V; Grigorieva, J; Grossi, F; Lazzari, C; Levra, MG; Mencoboni, M; Novello, S; Petrelli, F; Roder, H; Roder, J; Torri, V; Tsypin, M; Viganò, M | 1 |
| Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T | 1 |
| Ando, M; Asami, K; Endo, T; Fukuda, M; Ibata, H; Isa, S; Kamimura, M; Kawaguchi, T; Kozuki, T; Kubo, A; Nakagawa, H; Okano, Y; Saka, H; Sakamoto, K; Soejima, Y; Takada, M; Tamura, A; Tomizawa, Y; Yoshimi, M | 1 |
| Leighl, NB; Zer, A | 1 |
| Liu, C; Qu, G; Sun, B; Wang, P; Zhang, Z; Zhou, C | 1 |
| Aukema, TS; Burgers, SA; Codrington, HE; Klomp, HM; Rijna, H; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Wakelee, HA | 1 |
| Nakanishi, Y | 1 |
| He, C; Hong, W; Lou, G; Shao, L; Song, Z; Xie, F; Zhang, B; Zhang, Y; Zheng, L | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| DiPiro, PJ; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Blumenthal, GM; Boyd, K; He, K; Jiang, X; Justice, R; Keegan, P; Khozin, S; Murgo, A; Pazdur, R | 1 |
| Aisner, DL; Berge, EM; Damek, D; Doebele, RC; Poonia, S | 1 |
| Chang, J; Hu, A; Luo, Z; Sun, S; Wang, H; Wang, J; Wu, X; Xing, K; Yu, H; Zhao, X; Zhou, X | 1 |
| Bianco, C; Giaccone, G; Lee, LC; Luo, J; Mitsudomi, T; Mok, T; Moon, YW; Okamoto, I; Park, KS; Pham, T; Raffeld, M; Rosell, R; Salomon, DS; Subramaniam, D; Wang, Y; Xi, L; Yatabe, Y | 1 |
| Lam, KC; Mok, TS | 2 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| Koh, Y; Kusuhara, M; Serizawa, M; Takahashi, T; Urakami, K; Watanabe, M; Yamaguchi, K; Yamamoto, N; Zangiacomi, V | 1 |
| Gillissen, A; Nieber, K; Oelkrug, C; Schubert, A; Simasi, J | 2 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 1 |
| Ardizzoni, A; Cappuzzo, F; Cortinovis, D; de Marinis, F; Fontanini, G; Galetta, D; Gridelli, C; Grossi, F; Iurlaro, M; Lorusso, V; Novello, S; Santo, A | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Ma, D; Mathur, G | 1 |
| Hu, G; Liu, D; Long, G; Sun, W; Wang, J | 1 |
| Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F | 1 |
| Chen, YM; Chiu, CH; Lai, SL; Lee, YC; Shih, JF; Wu, CH; Wu, WS | 1 |
| Echeveste, JI; Gúrpide, A; Labiano, T; Lozano, MD; Martín-Algarra, S; Pérez-Gracia, JL; Subtil, JC; Zudaire, I; Zulueta, JJ | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Chang, FY; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Aieta, M; Gregorc, V; Lazzari, C; Lerose, R; Tartarone, A | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Fekrat, S; Proia, AD; Rao, V; Schneider, E | 1 |
| Ayoubi, JM; Broutin, S; Couderc, LJ; Friard, S; Gil, S; Goetgheluck, J; Paci, A; Picone, O; Tcherakian, C | 1 |
| An, F; Li, M; Lin, P; Liu, J; Liu, L; Wang, P; Zhang, B; Zhao, L; Zhuang, X | 1 |
| Fernandes, J; Jampol, LM; Johnson, ML; Mets, M; Munk, MR; Patel, JD | 1 |
| Meldgaard, P; Nissen, PH; Sorensen, BS; Weber, B; Winther Larsen, A | 1 |
| De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR | 1 |
| Krainhöfer, J; Reissig, A; Steinert, M; Walther, M | 1 |
| Akay, A; Dragomir, A; Erlandsson, BE | 1 |
| Bates, A; Counsell, N; Faivre-Finn, C; Hackshaw, A; Lee, SM; Lewanski, CR; Ngai, Y; Ottensmeier, C; Patel, N; Wadsworth, C | 1 |
| Iwata, T; Kim, YH; Mishima, M; Nagai, H; Nishimura, T; Ozasa, H; Sakamori, Y; Sunadome, H | 1 |
| Arakawa, H; Fukuoka, M; Harada, R; Johkoh, T; Kudoh, S; Kusumoto, M; Sakai, F; Ueda, M | 1 |
| Calcasola, M; Cane, P; Izatt, L; Michalarea, V; Spicer, J; Tobal, K | 1 |
| Brunetti, A; De Rosa, V; Del Vecchio, S; Fonti, R; Gargiulo, S; Gramanzini, M; Greco, A; Iommelli, F; Monti, M; Ortosecco, G; Panico, M | 1 |
| McCulloch, T; Røe, OD; Szejniuk, WM | 1 |
| Blanchet, B; Cessot, A; Goldwasser, F | 1 |
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| Auliac, JB; Berard, H; Bizieux, A; Bota, S; Chouaid, C; Corre, R; Descourt, R; Falchero, L; Fournel, P; Greiller, L; Greillier, L; Labrunie, A; Le Caer, H; Marin, B; Monnet, I; Schott, R; Vergnenegre, A | 1 |
| Bosch-Barrera, J; Brunet, J; Izquierdo, A; Lorencio, C; Menéndez, JA; Porta, R; Rosell, R; Sais, E; Sirvent, JM | 1 |
| Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L | 1 |
| Jänne, PA; Paweletz, CP | 1 |
| Hayashi, H; Nakagawa, K; Nishio, K; Togashi, Y | 1 |
| Colburn, D; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Klughammer, B; Kressel, B; Marsland, T; Miller, V; Patel, T; Rubin, M; White, L; Yang, JC | 1 |
| Akiyama, Y; Fujita, K; Hirose, T; Kusumoto, S; Nakashima, M; Sasaki, Y; Shirai, T; Sugiyama, T | 1 |
| Amann, JM; Arasada, RR; Carbone, DP; Huppert, SS; Rahman, MA | 1 |
| Dome, B; Francovszky, E; Galffy, G; Hegedus, B; Losonczy, G; Ostoros, G; Sarosi, V; Tolnay, E; Torok, S | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Ahn, HK; Cho, EK; Hong, J; Kim, YS; Lee, HY; Lee, JH; Park, I; Park, J; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Blumenschein, GR; Erasmus, JJ; Gold, KA; Harun, N; Johnson, FM; Kawedia, JD; Lee, JJ; Price, J; Tang, X; Tran, HT; William, WN; Wistuba, II | 1 |
| Rosell, R | 1 |
| Atagi, S; Fukuoka, M; Goto, K; Harada, R; Hida, T; Hosomi, Y; Kato, T; Maemondo, M; Nagase, S; Nakagawa, K; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N; Yamanaka, T | 1 |
| Chao, TT; Chen, KF; Chen, PT; Chen, YL; Huang, YC; Lai, CC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Ge, N; Jiao, W; Qiu, T; Shen, Y; Tang, D; Wang, Y; Xuan, Y; Yan, G; Yao, R | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Luo, J; Shen, L; Zheng, D | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Arai, M; Hayashihara, K; Iwasawa, T; Kato, T; Ogura, T; Ohashi, K; Okudela, K; Saito, T; Satoh, H; Sekine, A; Tamura, K | 1 |
| Cecconi, M; Lane, K; Thomas, C | 1 |
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Chang, CY; Chang, GC; Chen, CY; Chen, KC; Chen, YM; Hsu, KH; Huang, MS; Su, KY; Tsai, CR; Tsai, MH; Tseng, JS; Wang, CL; Wu, CW; Yang, CT; Yang, TY; Yu, SL | 1 |
| Bai, C; Chen, S; Ning, X; Sun, Z; Wang, Y; Yang, XD; Ying, H | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Ahmed, ZA; Moatter, T; Pervez, S; Siddiqui, A | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Clause, AL; Pieters, T; Vanderheyde, K | 1 |
| Bender, C; Fichtner, I; Fröhlich, H; Herwig, R; Hülsmann, HJ; Jarahian, M; Korf, U; Kuner, R; Merk, J; Rolff, J; Sültmann, H; Thomas, M | 1 |
| Berrino, L; Capuano, A; Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F; Sasso, FC | 1 |
| Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M | 1 |
| Celik, T; Kosker, M | 1 |
| Demura, Y; Fujita, Y; Gemma, A; Harada, M; Ishii, Y; Ishimoto, O; Kobayashi, K; Maemondo, M; Matsumoto, Y; Miura, S; Morikawa, N; Okudera, K; Saijo, Y; Sato, I; Takamura, K; Usui, K | 1 |
| Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M | 1 |
| Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Fukuoka, M; Imamura, F; Komuta, K; Kudoh, S; Seki, A; Yoshioka, H | 1 |
| Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Ferrer, L; Ferretti, G; Meynet, E; Moro-Sibilot, D; Pirvu, A; Sakhri, L | 1 |
| Adler, KB; Arif, M; Chen, CH; Chiu, CL; Statt, S; Thai, P; Wu, R | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Furuyama, K; Gotanda, K; Harada, T; Ieiri, I; Iwama, E; Li, H; Nakanishi, Y; Okamoto, I; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Abdulrahman, R; Ahn, C; Bunn, PA; Camidge, DR; Choy, H; Doebele, RC; Dowell, J; Gaspar, LE; Gerber, DE; Hughes, R; Iyengar, P; Kavanagh, BD; Smith, I; Timmerman, R; Wardak, Z | 1 |
| Jabbour, SK | 1 |
| Chen, XQ; Lin, GN; Liu, DY; Liu, PP; Peng, JW; Xiao, JJ | 1 |
| Gao, HM; Gao, Z; Jia, YF; Tan, W; Tian, YL; Wang, YS; Zhang, MX; Zhang, N; Zhang, RX; Zhao, JQ | 1 |
| Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS | 1 |
| Bogart, J; Bradley, J; Hodgson, L; Jänne, PA; Katragadda, S; Kong, FM; Lilenbaum, R; Masters, G; Samuels, M; Vokes, E; Wang, X | 1 |
| Barlesi, F; Benner, RJ; Blackhall, F; Bondarenko, I; Green, S; Hsia, TC; Jassem, J; Milanowski, J; Molpus, K; Novello, S; Popat, S; Sanchez-Torres, JM; Scagliotti, GV; Shepherd, FA; Soria, JC | 1 |
| Jang, C; Li, J; Wang, J; Wu, F; Xiong, J | 1 |
| Belkina, N; Biswas, R; Chaerkady, R; Guha, U; Jacob, HK; Kim, MS; Maity, T; Pandey, A; Shaw, PG; Venugopalan, A; Zhang, X | 1 |
| Liu, Z; Mao, JH; Wang, Q; Wang, Y; Wei, G; Wen, M; Yuan, H; Zhang, P | 1 |
| Jenks, S | 1 |
| Guo, R; Huang, X; Shu, Y; Wu, H; Xiang, C; Yin, Y; Yu, Q; Yu, S; Zhang, B | 1 |
| Takeuchi, S; Yano, S | 1 |
| Agarwal, VR; Ahmed, T; Bhatia, D; Bose, J; Choudhari, S; Damre, A; Deore, V; Joshi, A; Kumar, S; Lad, VJ; Pandey, PK; Sahu, B; Sangana, R; Sharma, S; Sonawane, V; Srivastava, A; Tannu, P; Venkataraman, M; Venkatesha, VA | 1 |
| Frank, M; Golpon, H; Lange, A; Prenzler, A; von der Schulenburg, JM; Welte, T | 1 |
| Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y | 1 |
| Assaraf, YG; Azzariti, A; Giovannetti, E; Jansen, G; Kathman, I; Paradiso, A; Peters, GJ; Porcelli, L; Scheffer, GL | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS | 1 |
| Byers, L; Coombes, KR; Date, H; Diao, L; Girard, L; Giri, U; Heymach, JV; Komaki, R; Lin, SH; Menju, T; Minna, JD; Saintigny, P; Wang, J; Weinstein, JN; Wistuba, II; Wu, CC; Zhang, J | 1 |
| Sheng, Z; Zhang, Y | 1 |
| Bortlicek, Z; Bruha, F; Fiala, O; Minarik, M; Mukensnabl, P; Pesek, M; Racek, J; Svaton, M | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Arcila, ME; Hellmann, MD; Kris, MG; Reva, B; Rizvi, NA; Rusch, VW; Yu, H | 1 |
| Abe, M; Aoki, M; Fujii, T; Fujimoto-Ouchi, K; Hashimoto, E; Motegi, H; Nagahashi, S; Nakatani, N; Sakata, K; Sano, Y; Sasaki, E; Satoh, Y; Sugimoto, M; Yatabe, Y | 1 |
| West, H | 1 |
| Aparisi, F; Esquerdo, G; García-Sánchez, J; Garde, J; Giner, V; Juan, Ó; López, A; Muñoz-Langa, J; Sánchez-Hernández, A | 1 |
| Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD | 1 |
| Bugés, C; Capdevila, L; Carcereny, E; Cardona, AF; Cros, S; Moran, T; Reguart, N; Rosell, R | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Amadori, D; Burgio, MA; Calistri, D; Capelli, L; Casanova, C; Chiadini, E; Crinò, L; Dazzi, C; Delmonte, A; Dubini, A; Gamboni, A; Mariotti, M; Papi, M; Puccetti, M; Ragazzini, A; Ulivi, P; Verlicchi, A | 1 |
| Ma, H; Tian, JH; Tian, X; Wang, F; Wang, X; Wang, Y; Zhang, Y; Zhou, JG | 1 |
| Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D | 1 |
| Bantikassegn, A; Fan, PD; Guha, U; Politi, K; Song, X; Threadgill, DW; Varmus, H | 1 |
| Cohen, DE; Colozza, S; Okereke, UR | 1 |
| Liao, BC; Lin, CC; Yang, JC | 1 |
| Barberis, M; Catania, C; Conforti, F; de Marinis, F; De Pas, T; Lazzari, C; Noberasco, C; Spitaleri, G; Stufano, V; Toffalorio, F; Vecchio, F | 1 |
| Reguart, N; Remon, J | 1 |
| Chang, CH; Ho, CC; Lee, CH; Wang, JY; Yu, CJ | 1 |
| Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Abraham, RR; Girotra, M; Jones, J; Klair, JS | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Chang, FK; Chih-Hsin Yang, J; Chiu, CH; Chuang, CY; Ho, CL; Hsia, TC; Hsiao, SH; Huang, MS; Lai, CL; Lai, RS; Lee, KY; Lin, CB; Lin, YC; Perng, RP; Shih, JY; Su, WC; Tsai, CM; Wang, CC; Wu, MF; Yang, CT; Yu-Wung Yeh, D | 1 |
| Bahleda, R; Burris, H; Jiang, J; Lager, J; Liu, L; LoRusso, P; Macé, S; Martini, JF; Soria, JC | 1 |
| Fujii, A; Harada, T; Hidaka, N; Iwama, E; Kawano, Y; Li, H; Nakanishi, Y; Okamoto, I; Ota, K; Takayama, K; Wang, S | 1 |
| Hsia, TC; Kim, J; Lee, DH; Lee, JS; Orlando, M; Wang, J; Wang, X | 1 |
| Carcereny, E; de Marinis, F; Drozdowskyj, A; Dubos-Arvis, C; Passaro, A; Perez-Moreno, P; Rosell, R; Vergnenegre, A; Zeaiter, A | 1 |
| Garber, K | 1 |
| Beijnen, JH; Burgers, SA; Huitema, AD; Klomp, H; Lankheet, NA; Schaake, EE; van Pel, R | 1 |
| Boulay, G; Concannon, K; Cullen, S; Engelman, JA; Faber, AC; Haber, DA; Lockerman, EL; Maheswaran, S; Rivera, MN; Rothenberg, SM; Turke, AB | 1 |
| Berghmans, T; Grigoriu, B; Meert, AP | 1 |
| Costa, DB; Desai, NV; Folch, E; Gangadharan, SP; Huberman, MS; Karp, RS; Kent, MS; Le, X; Majid, A; Rangachari, D; VanderLaan, PA | 1 |
| Ambrosio, F; Barbato, C; Cartenì, G; Mocerino, C; Otero, M; Riccardi, F; Scagliarini, S; Vitale, MG | 1 |
| Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ | 1 |
| Slack, FJ; Stahlhut, C | 1 |
| Abera, MB; Kazanietz, MG | 1 |
| Beraldi, E; Fazli, L; Gleave, ME; Ionescu, DN; Kumano, M; Lelj-Garolla, B; Nappi, L; Rocchi, P; Zoubeidi, A | 1 |
| Aerts, JG; Boons, CC; Boven, E; Hugtenburg, JG; Moes-Ten Hove, J; Smit, EF; Swart, EL; Timmers, L; van de Ven, PM | 1 |
| Lee, JG; Wu, R | 2 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Arvold, ND; Heidari, P; Kunawudhi, A; Mahmood, U; Sequist, LV | 1 |
| Abe, M; Horiike, A; Horinouchi, H; Kuboki, Y; Kudo, K; Nakamichi, S; Nishio, M; Nokihara, H; Ohyanagi, F; Tahata, T; Takahashi, S; Tamura, T; Wakui, H; Yamada, Y; Yamamoto, N; Yanagitani, N | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| Buk, L; Jakubiak, M; Krawczyk, P; Mańdziuk, S; Milanowski, J; Pankowski, J; Wojas-Krawczyk, K | 1 |
| Acker, T; Andreas, S; Fischer, J; Grah, C; Kollmeier, J; Kortsik, C; Müller, E; Penzel, R; Reinmuth, N; Reuss, A; Schenk, M; Schnabel, P; Schröder, M; Serke, M; Thomas, M; Villalobos, M; von Eiff, M; Witt, C; Wolf, M | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Baumann, M; Brammer, I; Can, Y; Dikomey, E; Dorniok, F; Gal, A; Grob, TJ; Gurtner, K; Kasten-Pisula, U; Krause, M; Kriegs, M; Laban, S; Oertel, R; Petersen, C; Rieckmann, T; Wysocki, M | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Hirsch, FR; Hornberger, J; Li, Q; Page, RD | 1 |
| Cappuzzo, F; Pauwels, P; Rolfo, C; Van Der Steen, N | 1 |
| Liang, J; Su, N; Xie, Y | 1 |
| Li, X; Li, Y; Wang, L; Wang, Y; Wei, H; Xie, S; Yang, N | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Liao, M; Margono, B; Mok, T; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Tsai, J; Wen, W; Wu, L; Wu, YL; Yu, CJ; Zhou, C; Zhu, Y | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Betticher, DC; Brutsche, M; Bubendorf, L; Cathomas, R; Feilchenfeldt, J; Früh, M; Gautschi, O; Jaggi, R; Largiadèr, C; Leibundgut, EO; Li, Q; Mach, N; Ochsenbein, AF; Peters, S; Pilop, C; Pless, M; Rauch, D; Rothschild, SI; Savic, S; Stahel, RA; Stalder, L; Zippelius, A | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C | 1 |
| Chen, YB; Duan, SZ; Xia, YC; Yang, WT; Zhang, FQ; Zhu, RY | 1 |
| Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA | 1 |
| Fujita, Y; Kobayashi, Y; Maehara, Y; Mitsudomi, T; Mizuuchi, H; Nishio, K; Sato, K; Sekido, Y; Suda, K; Tomida, S | 1 |
| Dahlberg, SE; Jackman, DM; Jänne, PA; Johnson, BE; Lo, PC; Nishino, M; Oxnard, GR; Sequist, LV | 1 |
| Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC | 1 |
| Huang, Y; Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Horiike, A; Horinouchi, H; Kaneda, H; Murakami, H; Nagashima, M; Nakagawa, K; Nishio, M; Sekiguchi, M; Tamura, T; Yamamoto, N | 1 |
| Hou, B; Hu, W; Nie, P; Yang, Y; Zhang, T; Zou, Z | 1 |
| Bassett, P; Chicklore, S; Chua, S; Cook, GJ; Goh, V; Loi, HY; O'Brien, ME; Punwani, R; Sharma, B; Siddique, M | 1 |
| Dietrich, MF; Schiller, JH; Yan, SX | 1 |
| Fujita, S; Hata, A; Hayashi, M; Katakami, N; Kawamura, T; Takeshita, J; Tomii, K | 1 |
| Baty, F; Betticher, D; Brutsche, MH; Droege, C; Dürr, O; Franzini, A; Grigoriu, BD; Klingbiel, D; Macovei, II; Zappa, F | 1 |
| Gopal, A; Helbig, AO; Pasculescu, A; Pawson, T; Petsalaki, E; Roth, FP | 1 |
| Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Hirotani, K; Jänne, PA; Kaneda, H; Kawakami, H; Nakagawa, K; Nishio, K; Okamoto, I; Sakai, K; Takeda, M; Yonesaka, K | 1 |
| Delaney, C; Frank, S; Huang, RS | 1 |
| Feng, RT; Liu, GJ; Mei, JZ; Zhang, XJ; Zhao, JZ | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Bracke, M; Chen, G; De Grève, J; De Wever, O; Kronenberger, P; Noor, A; Singh, K; Teugels, E; Umelo, IA; Van Deun, J | 1 |
| Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Fujiwara, Y; Goto, Y; Hamada, A; Horinouchi, H; Kanda, S; Katsuya, Y; Nokihara, H; Ohe, Y; Osawa, S; Sunami, K; Takashima, Y; Tamura, T; Utsumi, H; Yamamoto, N | 1 |
| Chang, CC; Ho, JH; Hsiao, CH; Hsieh, TL; Hsu, WT; Ji, AT; Lee, OK; Tiong, TY | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Kim, H; Kim, M; Kim, S; Ku, BM; Lee, JY; Lee, MY; Lim, SH; Park, K; Sun, JM | 1 |
| Asada, K; Imokawa, S; Inoue, Y; Inui, N; Karayama, M; Kasamatsu, N; Koshimizu, N; Matsuda, H; Shirai, T; Suda, T; Yamada, T; Yokomura, K | 1 |
| Doyle, KP; Flores, EJ; Kamdar, MM; Maytal, G; Mino-Kenudson, M; Rinehart, TJ; Sequist, LV | 1 |
| Cristea, MC; Dowell, JE; Dubinett, SM; Elashoff, RM; Figlin, RA; Fishbein, MC; Gardner, BK; Koczywas, M; Milne, GL; Reckamp, KL; Wang, HJ | 1 |
| Abdul-Hai, A; Dall'Ora, M; Downward, J; Gaborit, N; Lindzen, M; Mancini, M; Salame, TM; Sevilla-Sharon, M; Yarden, Y | 1 |
| Aydiner, A; Ciftci, R; Sen, F | 1 |
| Goyal, S; Grover, A; Jamal, S; Shanker, A | 1 |
| Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kim, CK; Kim, HG; Kim, HJ; Kim, SH; Lee, J; Lee, S; Oh, SY; Park, K; Park, MJ; Park, YS; Son, C; Song, KH; Sun, JM; Yi, SY | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Chicchinelli, N; De Luca, A; Fenizia, F; Forgione, L; Franco, R; Iannaccone, A; Lambiase, M; Morabito, A; Normanno, N; Pasquale, R; Piccirillo, MC; Rocco, G; Rossi, A; Sacco, A | 1 |
| Azuma, K; Hirai, K; Inokoshi, Y; Ishida, T; Ishii, T; Kanazawa, K; Katsuura, Y; Minemura, H; Munakata, M; Oishi, A; Oshima, K; Sekine, S; Tanino, Y; Yokouchi, H | 1 |
| Chen, LH; Chen, M; Dai, YM; Ding, Y; Guan, J; Li, L; Li, QS; Li, QY; Liu, LY; Xiao, NJ; Yang, M; Zhang, C; Zhang, Y; Zhang, YW | 1 |
| Belda-Iniesta, C; de Castro-Carpeño, J; Ibañez de Cáceres, I; López-Ayllón, BD; Pernía, O; Perona, R; Rodriguez, C; Sastre, L | 1 |
| Baladandayuthapani, V; Bekele, BN; Dai, B; Jayachandran, G; Ji, L; Kawashima, H; Lara-Guerra, H; Majidi, M; Mehran, R; Meng, F; Roth, JA; Sakai, R; Wang, J; Wang, Y; Yan, S; Ying, J; Yoo, SY | 1 |
| Busch, TM; Cengel, KA; Gallagher-Colombo, SM; Miller, J; Putt, ME; Vinogradov, SA | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Cappuzzo, F; Landi, L | 1 |
| Carpentier, O; Jégu, J; Prim, N; Purohit, A; Quoix, E; Selvaggi, L; Velten, M | 1 |
| Koivunen, JP; Laurila, N | 1 |
| Adler-Reichel, S; Huber, RM; Rogowski, WH; Schremser, K; Stollenwerk, B; Tufman, AL | 1 |
| Arcila, ME; Busby, N; Kris, MG; Ladanyi, M; Nafa, K; Naidoo, J; Riely, GJ; Rodriguez, K; Sima, CS; Yu, HA | 1 |
| Chen, HL; Hsiao, FY; Lu, HM; Shen, LJ; Wei, CP | 1 |
| Chen, L; Cheng, Y; Fernando, MCL; Han, B; How, SH; Huang, C; Jiang, G; Li, E; Liam, CK; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Xia, F; Zhang, Y; Zhong, Z; Zhou, C; Zhu, Y; Zuo, Y | 1 |
| Gandara, DR; Gitlitz, B; Kelly, K; Koczywas, M; Lara, PN; Li, T; Longmate, J; Mack, PC; Reckamp, KL; Salgia, R; Socinski, MA | 1 |
| Donnini, S; Finetti, F; Giachetti, A; Hanaka, H; Radmark, O; Santi, R; Terzuoli, E; Villari, D; Ziche, M | 1 |
| Carbone, DP; Egnatchik, RA; Fessel, JP; Kaufman, JM; Park, SI; Trenary, IA; Whang, YM; Young, JD | 1 |
| Guckenberger, M | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kaneda, T; Katakami, N; Mori, M; Morita, S; Negoro, S; Nishino, K; Otsuka, T; Tachihara, M; Uchida, J; Urata, Y; Yano, Y; Yokota, S | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Berghmans, T; Meert, AP; Quoix, E | 1 |
| Bagust, A; Beale, S; Boland, A; Dickson, R; Dundar, Y; Dwan, K; Greenhalgh, J; Hockenhull, J; Marshall, E; Mullard, A; Proudlove, C; Richardson, M | 1 |
| Bange, J; Beckman, RA; Blum, S; Chen, S; Copigneaux, C; Feng, W; Freeman, DJ; Hettmann, T; Mendell, J; Nakamaru, K; Ruhe, J; Schneider, M; Tsuchihashi, Z; von Pawel, J | 1 |
| Hackshaw, A; Khan, I; Lee, SM; Morris, S | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 2 |
| Fujita, S; Hata, A; Iwasaku, M; Katakami, N; Korogi, Y; Mori, M; Morita, S; Namba, Y; Nishino, K; Nishiyama, A; Okuyama, T; Otsuka, K; Takeshita, J; Uchida, J; Yoshioka, H | 1 |
| Fuchs, BC; Gilpin, SE; Lanuti, M; Ott, HC; Ren, X; Tanabe, KK; Tapias, LF; Wei, L | 1 |
| Han, BH; Jin, B; Lou, YQ; Ren, ZH; Xu, JL; Yang, QZ; Zhou, ZR | 1 |
| Das, M; Frymoyer, A; Neal, JW; Padda, SK; Riess, JW; Wakelee, HA; Zhou, L | 1 |
| Ahn, MJ; Akinaga, S; Azuma, K; Hirashima, T; Katakami, N; Kim, SW; Kurosaki, M; Maemondo, M; Mitsudomi, T; Nakagawa, K; Nishio, M; Park, K; Takahashi, T; Tamura, T; Tsai, CM; Yamamoto, N; Yoshioka, H | 1 |
| Cui, QL; Shao, M; Shu, QJ; Ye, P | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Akerley, W; Barlesi, F; Favaretto, A; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Ross, JS; Sandler, A; Santoro, A; Scagliotti, G; Schwartz, B; Sequist, LV; Shepherd, FA; Shuster, D; Spigel, D; von Pawel, J; von Roemeling, R; Wang, Q | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Aono, H; Azuma, K; Hosomi, Y; Kato, T; Komase, Y; Kunitoh, H; Morita, S; Nakahara, Y; Nishikawa, M; Oba, MS; Okamoto, H; Okuma, Y; Sato, A; Takeoka, H; Watanabe, K; Yamada, K | 1 |
| Black, EP; Overley, CW; Ratermann, KL; Stamatkin, C | 1 |
| Bover, I; Carcereny, E; Cardenal, F; Corre, R; de Aguirre, I; de Marinis, F; Drozdowskyj, A; Felip, E; Garcia-Gomez, R; Gervais, R; Insa, A; Isla, D; Jordana-Ariza, N; Karachaliou, N; Massuti, B; Mayo-de las Casas, C; Melloni, B; Molina-Vila, MA; Morales-Espinosa, D; Moran, T; Paz-Ares, L; Ponce-Aix, S; Porta, R; Queralt, C; Ramirez-Serrano, JL; Reguart, N; Rosell, R; Sánchez, JM; Vergnenegre, A; Viteri, S | 1 |
| Hartford, A; Ji, Y; Phillips, J; Ramsey, J; Schwartz, J; Verschraegen, C | 1 |
| Sala González, MÁ | 1 |
| Leung, LS; Marmor, MF; Neal, JW; Sequist, LV; Wakelee, HA | 1 |
| Cheong, JG; Choi, J; Jung, JW; Kang, M; Kim, HJ; Kim, TY; Lee, GH; Lee, HY; Lee, JW; Nam, SH; Ryu, J | 1 |
| Bettini, A; Broggini, M; Copreni, E; Farina, G; Ganzinelli, M; Garassino, MC; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Torri, V; Veronese, S | 1 |
| Couraud, S; Gérinière, L; Laffay, L; Locatelli-Sanchez, M; Perrot, E; Souquet, PJ; Torrecillas, S | 1 |
| Asakuma, M; Fukui, T; Hamada, A; Hayashi, N; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katagiri, M; Katono, K; Kimura, M; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Saito, H; Sasaki, J; Takakura, A; Toyooka, I; Wada, M; Yamamoto, M; Yokoba, M | 1 |
| Azzoli, CG | 1 |
| Jatoi, A; Olivier, KR; Spiceland, CM | 1 |
| Cascone, T; Heymach, JV | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Caricato, M; Crucitti, P; Pezzuto, A; Russano, M; Scarlata, S; Stumbo, L; Tonini, G | 1 |
| De Maria, R; Duranti, E; Eramo, A; Fecchi, K; Gallo, E; Milella, M; Mottolese, M; Pilozzi, E; Policicchio, E; Salvati, V; Sette, G; Tartaglia, M; Visca, P | 1 |
| Di Maio, M; Scagliotti, GV | 1 |
| Boone, E; Breyne, J; De Laere, E; Dedeurwaerdere, F; Demedts, I; Oyaert, M; Vandorpe, J | 1 |
| Hanna, N; Jalal, SI; Lourdes, LS | 1 |
| Ashinuma, H; Sekine, I | 1 |
| Frechen, S; Fuhr, U; Jaehde, U; Kocher, M; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Bordogna, W; Delmar, P; Hirsch, FR; Klughammer, B; Shames, DS; Shepherd, FA; Soulières, D | 1 |
| Brandes, AA; Buttitta, F; Chella, A; Chiari, R; Crinò, L; De Pas, TM; De Tursi, M; Del Grammastro, M; Felicioni, L; Filice, G; Guglielmi, F; Ludovini, V; Malorgio, F; Marchetti, A; Palma, JF; Santoro, A | 1 |
| Han, J; Hoff, BH; Kaspersen, SJ; Sundby, E | 1 |
| Bora-Singhal, N; Chellappan, S; Nguyen, J; Perumal, D | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Nomura, S; Ohe, Y; Ohmatsu, H; Sugiyama, E; Tsuboi, M; Umemura, S; Yoh, K | 1 |
| Cui, Y; Qi, D; Tian, Y; Xin, L; Xu, J; Zhan, Z | 1 |
| Altorki, NK; Cho, EK; Crinò, L; Eberhardt, WE; Foley, MA; Hoffman, PC; Horan, JD; Kelly, K; Kim, JH; O'Brien, ME; Orlov, SV; Serwatowski, P; Shepherd, FA; Spigel, DR; Tsai, CM; Wang, J | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Chikamori, K; Goto, K; Hida, T; Katakami, N; Maemondo, M; Nishio, M; Ohishi, N; Tamura, T | 1 |
| Kau, HC; Tsai, CC | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Ayeni, D; de Stanchina, E; Goldberg, SB; Hyder, F; Meador, CB; Pao, W; Pirazzoli, V; Politi, K; Sanganahalli, BG | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Okuda, C; Otsuka, K; Takeshita, J | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Castellanos, EH; Horn, L | 1 |
| Fukumura, J; Furugaki, K; Harada, N; Iwai, T; Kurasawa, M; Mitsudomi, T; Mizuuchi, H; Moriya, Y; Suda, K; Yamamoto, K; Yanagisawa, M; Yorozu, K | 1 |
| Antoine, M; Barlesi, F; Bigay-Game, L; Cadranel, J; Friard, S; Gervais, R; Langlais, A; Lethrosne, C; Merle, P; Monnet, I; Moreau, L; Morin, F; Moro-Sibilot, D; Oliviero, G; Quoix, E; Salaun, M; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Demuth, C; Jakobsen, KR; Meldgaard, P; Nissen, PH; Sorensen, BS; Winther-Larsen, A | 1 |
| Akhter, A; Arasada, RR; Biktasova, AK; Carbone, DP; Dikov, MM; Dudimah, DF; Evans, JV; Novitskiy, SV; Park, K; Shanker, A; Tchekneva, EE; Uzhachenko, RV | 1 |
| Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P | 1 |
| Arzt, J; Busman, TA; Holen, KD; Kirschbrown, W; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA | 1 |
| Aoyama, H; Fujita, J; Furugen, M; Haranaga, S; Higa, F; Hirai, J; Kinjo, T; Miyagi, K; Saio, M; Tateyama, M; Uechi, K; Yoshimi, N | 1 |
| Goldman, JW; Hurt, KC; Koustenis, A; Paz-Ares, L; Reck, M; Shi, P | 1 |
| Novello, S | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Bai, YJ; Cheng, L; Liu, Y; Ma, H; Tian, X; Zhang, Y; Zhou, JG; Zhou, Q | 1 |
| Almeida, DR; Boldt, HC; Chin, EK; Hornick, AL; Kirkpatrick, CA | 1 |
| Boothman, DA; Dong, Y; Dowell, JE; Fattah, FJ; Gerber, DE; Leff, R; Meek, C; Priddy, LL; Sarode, V; Schiller, JH; Skelton, RA; Vo, P; Xie, Y; Zhu, H | 1 |
| Badovinac, S; Božina, N; Čučević, B; Jakopović, M; Koršić, M; Muršić, D; Roglić, M | 1 |
| Chen, D; Frias, E; Hoffman, G; Korn, J; Lantermann, AB; McAllister, G; McCutcheon, K; Meyer, MJ; Rakiec, D; Ruddy, D; Sharma, SV; Stegmeier, F | 1 |
| Fukuoka, M; Kiyohara, Y; Kudoh, S; Seki, A; Yamazaki, N | 1 |
| Alharbi, KK; Chakravarthy, S; Goud, I; Khan, IA; Lakshmi M, AM; Matam, K; Prasad, SV; Ravi, V; Shaik, NA; Sridhar, K; Syed, R; Tabassum, SN; Vijayanand, PR | 1 |
| Balabathula, P; Mandal, B; Mittal, NK; Thoma, LA; Wood, GC | 1 |
| Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Li, F; Liu, LL; Michor, F; Pao, W | 1 |
| Albus, K; Chatterjee, S; Dietlein, F; Florin, A; Franz, T; Fuhr, U; Heuckmann, JM; Heukamp, LC; Hinze, Y; König, K; Neumaier, B; Plenker, D; Rauh, D; Rokitta, D; Schöttle, J; Siobal, M; Ullrich, RT; Volz, C | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Dai, X; Jin, C; Lv, X; Xu, W | 1 |
| Cho, KM; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH | 1 |
| Bunn, PA; Hirsch, FR | 2 |
| Biscocho, J; Clarke, N; Davidson, JM; Gong, X; Kwei, KA; Pollack, JR; Sridhar, S | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Baxa, J; Bejcek, J; Ferda, J; Flohr, T; Krakorova, G; Matouskova, T; Schmidt, B; Sedlmair, M | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Anderson, H; Burkes, RL; Chu, Q; Hao, D; Ho, C; Ho, V; Lam, W; Laskin, JJ; Lee, CW; Leighl, NB; Melosky, B; Murray, N; Sun, S; Winston, R | 1 |
| Bareggi, C; Bertolini, A; Broggini, M; Caiola, E; Calcagno, A; Copreni, E; Fabbri, MA; Fagnani, D; Ganzinelli, M; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Marabese, M; Martelli, O; Pavese, I; Piva, S; Rulli, E; Sarobba, MG; Valmadre, G | 1 |
| Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Bao, X; Gan, M; Han, TY; Jin, J; Wang, J; Xie, C; Zhan, WH; Zhang, C | 1 |
| Cardinali, B; Fustaino, V; Giannini, G; Lalli, C; Papoff, G; Presutti, D; Ruberti, G; Samperna, S; Santini, S | 1 |
| Chen, X; Li, M; Li, P; Luo, X; Ma, Z; Sun, G; Wang, X; Zhai, S; Zhu, L | 1 |
| Agapito, G; Altomare, E; Arbitrio, M; Barbieri, V; Botta, C; Cannataro, M; Codispoti, S; Conforti, S; Di Martino, MT; Guzzi, PH; Iuliano, E; Scionti, F; Tagliaferri, P; Tassone, P | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Liu, YH; Zhu, WL | 1 |
| Li, J; Mansmann, UR; Ye, C | 1 |
| Bertrán-Alamillo, J; Bosch-Barrera, J; Bria, E; Carcereny, E; Chaib, I; Codony-Servat, C; Codony-Servat, J; Crisetti, E; de Marinis, F; Drozdowskyj, A; Felip, E; Felipe Cardona, A; García-Campelo, R; Gervais, R; Giménez-Capitán, A; González-Cao, M; Karachaliou, N; López-Vivanco, G; Luis Ramírez, J; Majem, M; Massuti, B; Miguel Sánchez, J; Molina-Vila, MA; Morales-Espinosa, D; Morán, T; Pilotto, S; Rosell, R; Sánchez Hernández, JJ; Santarpia, M; Sperduti, I; Teixidó, C; Vergnenegre, A; Verlicchi, A; Viteri, S | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Abou-Alfa, GK; Ang, C; Gamblin, TC; Gatalica, Z; He, R; Millis, SZ; Miura, JT; Reddy, SK; Xiu, J; Yee, NS | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Greve, G; Lübbert, M; Pantic, M; Pfeifer, D; Schiffmann, I; Schüler, J | 1 |
| Chen, G; De Grève, J; De Wever, O; Geers, C; Giron, P; Noeparast, A; Renard, M; Teugels, E; Umelo, I; Vansteenkiste, J | 1 |
| Bhosle, J; Davidson, M; Gunapala, R; Kumar, R; Lu, SK; Minchom, A; O'Brien, ME; Popat, S; Sharp, A; Yap, TA | 1 |
| Camidge, DR; Varella-Garcia, M; Womack, JP | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Gandara, DR; Hirsch, FR; Redman, M | 1 |
| Ahn, MJ; Button, P; Chan, KC; Kang, JH; Kim, SW; Lee, JS; Lin, MC; Mok, T; Park, K; Perez-Moreno, P; Sriuranpong, V; Tsai, CM; Yu, CJ | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Kucera, R; Minarik, M; Pesek, M; Svaton, M; Topolcan, O | 1 |
| Akerley, WL; Gandara, DR; Hesketh, PJ; Hirsch, FR; Lara, PN; Mack, PC; Moon, J; Redman, MW; Williamson, SK | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Kulshreshtha, D; Nanda, SS; Prakash, C; Rastogi, M | 1 |
| Amato, KR; Balko, JM; Cates, JM; Chen, J; Colvin, DC; Gray, NS; Hastings, AK; Lovly, CM; Lu, P; Meador, CB; Pao, W; Song, W; Tan, L; Wang, S; Ye, F | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
| Dong, JY; Li, YL; Lin, NM; Mao, SY; Pan, JP; Pan, YN; Sun, J; Wu, WJ; Zhang, C; Zhang, DY; Zhao, YM | 1 |
| Ma, H; Tian, X; Wang, F; Wang, Y; Zeng, XT; Zhang, Y; Zhou, JG | 1 |
| Boyer, M; Jänne, PA; Liang, J; Mok, T; O'Byrne, K; Paz-Ares, L; Ramalingam, SS; Sbar, EI; Taylor, I; Zhang, H | 1 |
| Brugger, W; Cappuzzo, F; Ciuleanu, T; Delmar, P; Klingelschmitt, G; Klughammer, B; Mok, T; Reck, M; Shames, DS; Spleiss, O; Tan, EH; Wu, L; Yin, AY | 1 |
| Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV | 1 |
| Cho-Phan, CD; Diehn, M; Myall, NJ; Neal, JW; Stehr, H; Wakelee, HA; Zhou, L; Zhou, LY | 1 |
| Asai, K; Hirata, K; Isa, S; Kawaguchi, T; Kimura, T; Kubo, A; Kudoh, S; Matsuura, K; Mitsuoka, S; Nakai, T; Oka, T; Sawa, K; Suzumura, T; Tanaka, H; Uji, M; Watanabe, T; Yoshimoto, N; Yoshimura, N | 1 |
| Chen, X; Guan, D; Liu, L; Shen, H; Shen, J; Shu, Y; Wang, M; Xu, T | 1 |
| Lee, HY; Park, SH; Seong, MA | 1 |
| Gao, H; Li, X; Wang, S; Xu, H; Yang, H | 1 |
| Boyle, T; Chan, D; He, Y; Hirsch, FR; Li, J; Li, X; Ren, S; Rivard, C; Wang, Y; Zhou, C | 1 |
| Becker, M; Fichtner, I; Hoffmann, J; Merk, J; Rolff, J | 1 |
| Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Reiser, B; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Sörgel, F; Steffens, M; Stelzer, C; Stingl, J; von Mallek, D | 1 |
| Ni, J; Zhang, L | 1 |
| Eckhardt, SG; Gadgeel, SM; Gedrich, R; Gogov, S; Juergens, RA; Macaulay, VM; McCarthy, S; Middleton, MR; Poondru, S; Rudin, CM; Stephens, AW | 1 |
| Awad, R; Nott, L | 1 |
| Bahce, I; Boellaard, R; Hendrikse, NH; Hoekstra, OS; Lammertsma, AA; Schuit, RC; Smit, EF; Voorhoeve, C; Windhorst, AD; Yaqub, M | 1 |
| Chou, SH; Han, DX; Hu, P; Ruan, RS; Tzeng, CM; Zheng, LM | 1 |
| Aerts, JG; Codrington, H; de Bruijn, P; Hussaarts, KG; IJzerman, NS; Kienhuis, E; Kloover, JS; Mathijssen, RH; Peric, R; van der Holt, B; van der Leest, C; van Gelder, T; van Leeuwen, RW | 1 |
| Ahn, MJ; Ahn, SM; Aziz, M; Bae, JS; Cho, A; Cho, J; Choi, YL; Francis, JM; Joung, JG; Kassner, M; Kim, KM; Kim, N; Koo, J; Park, AK; Park, JO; Park, K; Park, WY; Watanabe, H; Yin, HH | 1 |
| de Chabot, G; Hureaux, J; Pinquié, F; Urban, T | 1 |
| Altschuler, SJ; Evans, L; Hsu, CH; Ji, W; Koduru, PR; Morinishi, LS; Osipchuk, D; Posner, BA; Rajaram, S; Ramirez, M; Roth, MA; Steininger, RJ; Thurley, K; Wei, S; Wu, LF; Zhou, A | 1 |
| Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS | 1 |
| Backes, WH; de Lussanet, QG; de Ruysscher, D; Dingemans, AM; Groen, HJ; Houben, RM; Marcus, JT; Smit, EF; van den Boogaart, VE | 1 |
| Carcereny, E; Chouaid, C; de Marinis, F; Do, P; Felip, E; Massuti, B; Paz-Arez, L; Rosell, R; Sanchez, JM; Vergnenegre, A | 1 |
| Choy, TS; Kwong, DL; Lam, KO; Lam, PM; Lee, VH; Leung, DK; Leung, TW | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Friess, T; Kim, L; Li, M; Liu, G; Martin, P; Mascaux, C; Panchal, D; Pham, NA; Sakashita, S; Shepherd, FA; Stewart, E; Sykes, J; Tsao, MS; Wang, D | 1 |
| Aurisicchio, L; Bergantino, F; Cherubini, E; Ciliberto, G; Costantini, S; De Vitis, C; Fenizia, F; Ferrara, FF; Giarnieri, E; Giovagnoli, MR; Lambiase, M; Mancini, R; Mariotta, S; Normanno, N; Noto, A; Ricci, A; Roscilli, G; Torrisi, MR | 1 |
| Francis, DO; Garrett, CG; McWhorter, A; Misono, S; Somerville, J | 1 |
| Chen, Z; Han, J; Li, X; Ma, H; Peng, L; Sun, J; Zhang, J; Zhao, F; Zhu, H | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Chavaillon, JM; Chosidow, O; Deplanque, G; Falchero, L; Fraboulet, G; Gervais, R; Robert, C; Saal, H; Souquet, PJ; Taviot, B; Vergnenegre, A | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Kucera, R; Minarik, M; Pesek, M; Racek, J; Sorejs, O; Topolcan, O | 1 |
| Addison, CL; Al-Zahrani, KN; Dimitroulakos, J; Goss, GD; Hasim, MS; Howe, GA; Sabourin, LA; Sekhon, HS; Villeneuve, J; Xiao, B; Zhao, H | 1 |
| Brower, JV; Robins, HI | 1 |
| Fledelius, J; Meldgaard, P; Sorensen, BS; Winther-Larsen, A | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Dagogo-Jack, I; Engelman, JA; Gainor, JF; Lennerz, JK; Niederst, MJ; Sequist, LV; Shaw, AT; Stevens, S | 1 |
| Adamo, V; Alù, M; Bazan, V; Blasi, L; Bronte, G; Celesia, C; De Tursi, M; Franchina, T; Gambale, E; Laudani, A; Natoli, C; Passiglia, F; Picone, A; Rizzo, S; Russo, A; Savio, G; Sortino, G | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Bulat, T; Golić, I; Incerti, S; Keta, O; Korać, A; Petrović, I; Ristić-Fira, A | 1 |
| Chen, Z; Darling, G; de Perrot, M; Kamel-Reid, S; Keshavjee, S; Kim, L; Lara-Guerra, H; Le, LW; Leighl, NB; Liu, G; Sacher, AG; Sakashita, S; Salvarrey, A; Shepherd, FA; Tsao, MS; Waddell, TK; Yasufuku, K; Zhang, T | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Dong, X; Du, T; Li, Z; Wang, Z; Wu, G; Zhang, R | 1 |
| Amano, S; Aoyama, M; Hino, N; Inoue, S; Miyoshi, T; Mori, R; Sumitomo, H; Wada, D | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Jimenez, CR; Knol, JC; Lind, JS; Pham, TV; Rovithi, M; Smit, EF; Verheul, HM; Voortman, J | 1 |
| Alden, RS; Dahlberg, SE; Feeney, N; Jänne, PA; Mach, SL; O'Connell, A; Oxnard, GR; Paweletz, C; Sacher, AG | 1 |
| Awadalla, S; Dudek, AZ; Keshtgarpour, M; Langi, FG; Tan, WS; Zwanziger, J | 1 |
| Anayama, T; Hirohashi, K; Kume, M; Miyazaki, R; Okada, H; Orihashi, K | 1 |
| Bakar, NA; Goh, YM; Lim, SL; Mohamed, S; Mustapha, NM | 1 |
| Benesova, L; Bortlicek, Z; Buchler, T; Chloupkova, R; Fiala, O; Finek, J; Kucera, R; Minarik, M; Pesek, M; Poprach, A; Racek, J; Svaton, M; Topolcan, O | 1 |
| Au-Yeung, SC; Fei, R; Lam, AS; Poon, DC; To, KK; Wei, Y | 1 |
| García, N; Mezquita-Pérez, L; Pian, H | 1 |
| Chen, XW; Chen, ZT; Han, J; Sun, JG; Wang, J; Wang, XD; Zhao, FY | 1 |
| Honda, Y; Isozaki, H; Kiura, K; Ochi, N; Singer, JW; Takeyama, M; Takigawa, N; Yamane, H | 1 |
| Ji, SM; Li, JY; Li, L; Lu, W; Mou, ZZ; Ren, YP; Wang, LJ; Yuan, Y; Zhou, SP; Zhou, TY | 1 |
| Ciardiello, F; Crinò, L; Daniele, G; De Marinis, F; Gallo, C; Gridelli, C; Montanino, A; Morabito, A; Morgillo, F; Normanno, N; Perrone, F; Piccirillo, MC; Rossi, A | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| Castillo, J; Cong, F; Hoffman, G; Lindeman, A; Lu, B; McAllister, G; Reece-Hoyes, J; Russ, C; Schirle, M; Tallarico, J; Wang, H; Xu, W; Yang, Z; Zhang, Y | 1 |
| David, JM; Dominguez, C; Fernando, RI; Hamilton, DH; McCampbell, KK; Palena, C | 1 |
| Kim, HJ; Lee, HJ; Liebler, DC | 1 |
| Bouchet, F; Chouaïd, C; Couturier, O; Hureaux, J; Lacœuille, F; Saulnier, P; Urban, T | 1 |
| Chang, JW; Cheng, NM; Chung, HW; Fang, YD; Ho, KC; Hou, MM; Liu, YC; Su, TP; Yang, CT; Yen, TC | 1 |
| Cuderman, A; Doma, A; Grmek, M; Kern, I; Kovac, V; Rajer, M; Stanic, K; Vrankar, M; Zwitter, M | 1 |
| Atagi, S; Goto, K; Inagaki, N; Seto, T; Tajima, K; Tamura, T; Yamamoto, N | 1 |
| Azuma, K; Eida, H; Eriguchi, G; Harada, T; Kishimoto, J; Kondo, A; Nakanishi, Y; Nishida, C; Suetsugu, T; Sugio, K; Takayama, K; Takeshita, M; Uchino, J; Yamada, K | 1 |
| Fröhlich, H; Hülsmann, H; Kuner, R; Praveen, P; Sültmann, H | 1 |
| Boucher, D; Costa, DB; Dahlberg, SE; Feeney, N; Jackman, DM; Jänne, PA; Johnson, BE; O'Connell, A; Oxnard, GR; Paweletz, CP; Redig, AJ; Taibi, M; Yanagita, M | 1 |
| Enewold, L; Thomas, A | 1 |
| Dyer, O | 1 |
| Cai, F; Mao, XD; Wang, HT; Xu, J; Zhang, S | 1 |
| Cabuk, D; Cicin, I; Cinkaya, A; Erdogan, B; Hacibekiroglu, I; Hacioglu, MB; Karabulut, S; Kodaz, H; Tanriverdi, O; Tozkir, H; Turkmen, E; Uzunoglu, S | 1 |
| Giri, U; Goonatilake, R; Heymach, JV; Johnson, FM; Li, L; Mino, B; Nilsson, M; Rodriguez-Canales, J; Singh, R; Tong, P; Villalobos, P; Wang, J; Wang, L; Wang, Y; Wistuba, I | 1 |
| Boucher, D; Costa, DB; Jackman, DM; Jänne, PA; Johnson, BE; Redig, AJ; Taibi, M | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Mok, T; Perez-Moreno, P; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Wu, YL; Yu, CJ | 1 |
| Dai, Y; Hsu, PC; Hu, B; Jablons, DM; Li, H; Liu, S; Wang, YC; Xu, Z; Yang, CT; Yang, YL; You, B; You, L; Zhang, WQ | 1 |
| Bruno, R; Claret, L; Das, A; Han, K; Jin, J; Sandler, A | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Chu, JG; Li, GX; Qian, GQ; Yin, FY | 1 |
| Chen, M; Kanteti, R; Li, Y; Oh, YT; Owonikoko, TK; Ramalingam, SS; Riehm, J; Salgia, R; Shi, P; Sun, SY; Yao, W; Yue, P; Zhang, G | 1 |
| Anandharaj, A; Hong, KH; Kassie, F; Kim, JH; Kirtane, AR; Panyam, J; Song, JM; Upadhyaya, P | 1 |
| Baldari, S; Bordonaro, R; Cosentino, S; Gilardi, MC; Ippolito, M; Messa, C; Murè, G; Russo, G; Sabini, MG; Sardina, D; Soto Parra, H; Stefano, A; Valastro, LM | 1 |
| Bernatchez, C; Haymaker, C; Herrmann, AC; Hong, WK; Im, JS; Molldrem, JJ; Perez-Soler, R | 1 |
| Cai, H; Li, X; Xu, Q; Yu, S; Yuan, Y | 1 |
| Bae, E; Choi, SE; Lee, H; Lim, EA; Lim, J; Shin, YK | 1 |
| Tanday, S | 1 |
| Chen, X; Cultraro, CM; Guha, U; Lee, MJ; Lizak, MJ; Medina-Echeverz, J; Niu, G; Simpson, RM; Tomita, Y; Trepel, JB; Venugopalan, A | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Berry, G; Burt, BM; Engleman, E; Kheradmand, F; Lee, HS; Sugarbaker, DJ; Wang, DH; Wheeler, TM; Yoon, D | 1 |
| He, Y; Li, J; Ren, S; Wang, Y; Zhang, S; Zhou, C | 1 |
| Bell, D; Garber, ST; Janku, F; Khoury, L; McCutcheon, IE; Schomer, DF | 1 |
| Lee, JJ; Zang, Y | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Foo, J; Garvey, CM; Lindsay, D; Mumenthaler, SM | 1 |
| Gairard-Dory, AC; Gass-Jégu, F; Gourieux, B; Gschwend, A; Mennecier, B; Quoix, É; Tebacher-Alt, M | 1 |
| Dorokhova, E; Felip, E; Feng, J; Freudensprung, U; Gervais, R; Grange, S; Guclu, SZ; Hoiczyk, M; Mitchell, L; Perez-Moreno, PD; Reck, M; Smit, EF; Wu, YL; Zhou, C | 1 |
| Ichikado, K; Kawamura, K; Sakata, Y; Shingu, N | 1 |
| Jo, H; Kanemaru, R; Kasuga, F; Koyama, R; Morio, Y; Nagaoka, T; Shiota, S; Takahashi, K; Takekawa, H | 1 |
| Baba, T; Futaki, M; Iwasawa, T; Kato, T; Ogura, T; Sakuranaka, H; Sekine, A; Suido, A | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
| Demuth, C; Meldgaard, P; Sorensen, BS; Sorensen, SF; Weber, B | 1 |
| Ahsan, A; Bridges, A; Lawrence, TS; Mehta, R; Naughton, JP; Nyati, MK; Nyati, S; Ray, D; Ray, P; Rehemtulla, A; Sitto, M; Somnay, V; Tan, YS; Zhao, L | 1 |
| Bromberg, J; Chang, Q; Gao, SP; Kris, MG; Perez, L; Riely, GJ; Yu, HA | 1 |
| Chen, HJ; Chen, ZH; Su, J; Tu, HY; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q | 1 |
| Boudjemaa, A; Caliez, J; Chouaid, C; Jabot, L; Leroy, K; Monnet, I; Pujals, A; Rousseau-Bussac, G | 1 |
| Chikamori, K; Goto, K; Hida, T; Katakami, N; Kozuki, T; Maemondo, M; Nishio, M; Seto, T; Tajima, K; Tamura, T; Yamamoto, N; Yoshioka, H | 1 |
| Cao, X; Kothari, S; Shinde, R | 1 |
| Courtin, A; Hearn, K; Lyons, JF; Saini, HK; Smyth, T; Thompson, NT; Wallis, NG | 1 |
| Dominguez, C; Palena, C; Tsang, KY | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Ahn, MJ; Arpornwirat, W; Bazhenova, L; Chen, J; Chiappori, AA; Chow, LQ; de Lima, LG; Dechaphunkul, A; Eaton, K; Gadgeel, SM; Juergens, RA; Leighl, NB; Medley, S; Poondru, S; Rizvi, NA; Rudin, CM; Singh, M; Steinberg, J; Sunpaweravong, P | 1 |
| Alden, RS; Awad, MM; Bahcall, M; Jaklitsch, MT; Jänne, PA; Kim, ND; Kuang, Y; Lydon, CA; Oxnard, GR; Patel, JD; Paweletz, CP; Sacher, AG; Sholl, LM; Sim, T | 1 |
| Argiris, A; Brega, NM; Eaton, KD; Govindan, R; Gutierrez, ME; Ho, SN; Mita, AC; Otterson, GA; Ou, SI; Robert, F; Tan, W; Usari, T | 1 |
| Cruz, P; de Castro, J; de Lujan, L | 1 |
| Bai, J; Chang, JY; Wang, P; Yuan, Z; Zhuang, H | 1 |
| Cheng, Z; Jiang, S; Shan, F; Shao, Z | 1 |
| Du, Y; Liu, H; Ma, T; Pan, Y; Shen, Y; Zhu, Y | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 1 |
| Chen, J; Cheng, F; Li, J; Wang, J; Xing, P | 1 |
| Castillo, C; Collet-Benzaquen, D; Combemale, P; de la Fouchardière, A; Desseigne, F; Fattouh, K; Provensal, AM | 1 |
| Arai, S; Fukuda, K; Mukae, H; Nakagawa, T; Nanjo, S; Takeuchi, S; Taniguchi, H; Yamada, T; Yamaguchi, H; Yano, S | 1 |
| Homma, M; Kaburagi, T; Kurosawa, A; Ohgami, M | 1 |
| Alexandre, J; Arrondeau, J; Bigot, F; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Chapron, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Tlemsani, C; Vidal, M | 1 |
| Han, B; Jin, B; Lou, Y; Wang, H; Wu, D; Xu, J; Yang, H; Zhang, X; Zhang, Y; Zhong, H | 1 |
| Aisner, SC; Bowden, M; Carbone, DP; Dahlberg, SE; Gerstner, GJ; Huang, Y; Khalid, AA; Lerner, RE; Neal, JW; Owonikoko, TK; Ramalingam, SS; Rubin, JL; Steen, PD; Stella, PJ; Wakelee, HA | 1 |
| Choi, HG; Choi, JY; Kim, J; Kim, JO; Kim, ST; Ramasamy, T; Yong, CS; Youn, YS | 1 |
| Ding, LY; Jiang, ZL; Liu, KJ; Wu, HY; Wu, SX | 1 |
| Baladandayuthapani, V; Fang, B; Feng, M; Ji, L; Majidi, M; Mehran, R; Roth, JA; Shao, R; Song, J; Wang, J; Xiaobo, C; Zhao, Y | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Dalal, R; Garon, EB; He, S; Jaime, JC; Juan, O; Lee, P; Liu, J; Nadal, E; Nakagawa, K; Paz-Ares, L; Ponce, S; Reck, M; Treat, J | 1 |
| Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H | 1 |
| Durm, G; Hanna, N | 1 |
| Pakkala, S; Ramalingam, SS | 2 |
| Bathini, VG; Beckett, LA; Gajavelli, S; Gandara, DR; Gucalp, R; Haigentz, M; Kim, M; Lara, PN; Li, T; Pasquinelli, PB; Perez-Soler, R; Piperdi, B; Sreedhara, M; Walsh, WV; Wen, H; Xie, X; Zhou, K | 1 |
| Allegrini, G; Bidoli, P; Brighenti, M; Chella, A; DE Marinis, F; Gridelli, C; Maione, P; Migliorino, MR; Ricciardi, S; Rossi, A; Valmadre, G | 1 |
| Biernat, W; Burzykowski, T; Duchnowska, R; Dziadziuszko, R; Jassem, J; Konopa, K; Kowalczyk, A; Limon, J; Ratajska, M; Sowa, A; Suszko-Każarnowicz, M; Szczęsna, A; Szutowicz-Zielińska, E | 1 |
| Edelman, MJ; Mocci, S; Mok, T; O'Byrne, K; Paton, VE; Paz-Ares, L; Phan, S; Shames, DS; Smith, D; Spigel, DR; Yu, W | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Cicènas, S; Geater, SL; Hooper, G; Hotko, Y; Mudie, N; Petrov, P; Wu, YL; Xia, F | 1 |
| Chen, Z; Deng, W; Ke, E; Niu, F; Su, J; Wu, Y; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhao, N; Zhou, Q | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Brower, V | 1 |
| Berghmans, T; Biesma, B; Chittazhathu Kurian Kuruvilla, Y; Ciardiello, F; Coate, L; Cobo Dols, M; Collado Martin, R; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; de Hosson, S; Garde Noguera, J; Gasca-Ruchti, A; Gautschi, O; Gregorc, V; Groen, HJM; Horgan, A; Insa, A; Juan Vidal, Ó; Kassapian, M; Láng, I; López Martín, A; Mark, MT; Massutí, B; Meldgaard, P; Novello, S; Palmero Sanchez, R; Peralta, S; Peters, S; Pieterman, R; Ponce Aix, S; Rauch, D; Smit, EF; Stahel, RA; Summers, Y; Torri, V; Tsourti, Z; van den Berg, PM; van Heemst, R; van Henten, AMJ; Villa Guzmán, JC; Zielinski, CC | 1 |
| Giordano, SH; Kehl, KL; Shen, C; Simon, GR; Zhao, B; Zhou, S | 1 |
| Bruno, R; Chanu, P; Han, K; Jin, J; Jonsson, F; Stroh, M; Winter, H | 1 |
| Berse, B; Chun, D; DuVall, SL; Filipski, KK; Kelley, MJ; Kulich, S; Lynch, JA; Rivera, D; Viernes, B | 1 |
| Burich, RA; Chinn, D; Gandara, DR; Holland, WS; Kelly, K; Lara, MS; Lara, PN; Mack, PC | 1 |
| Han, L; He, J; Huang, Z; Li, W; Ma, P; Nie, F; Zhang, M | 1 |
| Bai, JP; Chen, X; Li, Y; Liu, LR; Liu, YH; Qu, X; Qu, YC; Zhang, FL; Zhang, HB; Zheng, GJ; Zhu, YJ; Zhu, YZ | 1 |
| Amano, H; Hayama, N; Hirano, S; Iikura, M; Naka, G; Nakamura, M; Nakamura, S; Sugiyama, H; Tabeta, H; Takeda, Y; Yanagisawa, A | 1 |
| Cross, J; Feldman, D; Kris, MG; Liu, LL; Michor, F; Pao, W; Riely, GJ; Rudin, CM; Sima, C; Vaitheesvaran, B; Yu, HA | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Lin, YT; Liu, YN; Shih, JY; Wu, SG; Yang, JC | 1 |
| Bailey, ST; Braas, D; Christofk, HR; Czernin, J; Demo, S; Dubinett, SM; Emberley, E; Fishbein, MC; Garon, E; Graeber, T; Gross, M; Jackson, NJ; Janes, J; Krysan, K; Lee, JT; Mackinnon, A; Magyar, C; Momcilovic, M; Pan, A; Parlati, F; Rodriguez, M; Sadeghi, S; Shackelford, DB; Walser, TC; Works, M; Zhang, W | 1 |
| Bai, XY; Chen, HJ; Jiang, BY; Su, J; Tu, HY; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hagiwara, K; Iwai, Y; Kawamura, R; Koyama, N; Koyama, S; Miwa, C; Nagai, Y; Watanabe, Y | 1 |
| Bradbury, PA; Brown, C; Cheng, N; Cosio, AP; Doherty, M; Eng, L; Gill, G; Howell, D; Labbé, C; Leighl, NB; Leung, Y; Liang, M; Liu, G; Mittmann, N; Naik, H; O'Kane, GM; Patel, D; Rett, A; Shepherd, FA; Silva Lemes, JG; Stewart, E; Xu, W | 1 |
| An, HJ; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, Y; Lim, KY; Moon, SH; Nam, BH; Yun, T | 1 |
| Ahluwalia, MS; Amini, A; Attia, A; Balasubramanian, SK; Beal, K; Boreta, LC; Braunstein, SE; Camidge, DR; Chiang, VL; Contessa, JN; Gerber, NK; Gettinger, SN; Kavanagh, BD; Lester-Coll, NH; Lockney, NA; Magnuson, WJ; Patil, T; Rana, NG; Wu, AJ; Yang, TJ; Yu, JB | 1 |
| Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y | 1 |
| Abourbeh, G; Bahce, I; Contessa, JN; Hansen, SB; Holden, D; Huang, Y; Lammertsma, AA; Mishani, E; Morris, ED; Nabulsi, NB; Petrulli, JR; Yaqub, M | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Jiang, T; Qiao, M; Ren, S; Su, C; Zhou, C; Zhou, F | 1 |
| Haratani, K; Hayashi, H; Iwasa, T; Kamiyama, E; Nakagawa, K; Ohwada, S; Shimizu, T; Yamada, H; Yonesaka, K | 1 |
| Di Maio, M; La Salvia, A; Rossi, A | 1 |
| Chang, CH; Lee, CH; Wang, JY | 1 |
| Chiba, M; Kobayashi, Y; Mitsudomi, T; Mizuuchi, H; Sato, K; Sesumi, Y; Shimoji, M; Suda, K; Takemoto, T; Tomizawa, K | 1 |
| Pi, C; Xu, CR; Zhang, YC; Zhou, Q | 1 |
| Ariyasu, R; Horiike, A; Kawashima, Y; Kitazono, S; Koyama, J; Nishikawa, S; Nishio, M; Oguri, T; Ohyanagi, F; Saiki, M; Sonoda, T; Takano, N; Yanagitani, N | 1 |
| Chen, S; Copigneaux, C; Dediu, M; Hirotani, K; Nakagawa, K; von Pawel, J; Yonesaka, K | 1 |
| Baggstrom, MQ; How, J; Laczniak, AN; Mann, J | 1 |
| Fraser, A | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 1 |
| Dongying, L; Ling, L; Yanwei, L; Yu, Z; Zhanyu, P; Zhuchen, Y | 1 |
| Boobalan, R; Chao, JI; Chen, C; Liu, KK | 1 |
| Liu, NB; Sun, J; Wang, P; Yuan, ZY; Zhao, LJ; Zhuang, HQ | 1 |
| Ahn, BN; Hong, SW; Hur, DY; Kim, D; Kim, YS; Lee, HK; Noh, MH; Park, NS; Shim, JA | 1 |
| Costa, DB; Huberman, MS; Joseph, LJ; Kobayashi, SS; Malcolm, J; Mockus, SM; Rangachari, D; Reddi, HV; Spotlow, V; VanderLaan, PA | 1 |
| Hamishehkar, H; Naseri, N; Pilehvar-Soltanahmadi, Y; Valizadeh, H; Zakeri-Milani, P | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Chen, G; Gao, C; Gao, X; Hu, J; Kuan, SF; Liu, G; Stabile, LP; Zhang, DH | 1 |
| Gettinger, S | 1 |
| Colantuoni, G; Del Gaizo, F; Falanga, M; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A | 1 |
| Enderlein, E; Gerber, PA; Homey, B | 1 |
| Yang, CH | 1 |
| Jänne, PA | 1 |
| Riely, GJ | 2 |
| Ding, K; Florescu, M; Hasan, B; Seymour, L; Shepherd, FA | 1 |
| Li, T; Ling, YH; Perez-Soler, R | 1 |
| Balleyguier, C; Besse, B; Soria, JC; Wagner, M | 1 |
| Lin, R; Ling, YH; Perez-Soler, R | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Holmes, AJ; Jänne, PA; Kang, JH; Ki, CS; Kim, HT; Kim, SW; Lee, JS; Park, BB; Park, CK; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS | 1 |
| Baselga, J; Cedres, S; Felip, E; Foernzler, D; Gatzemeier, U; Heller, A; Klughammer, B; Maacke, H; Möcks, J; Parera, M; Peralta, S; Reck, M; Rojo, F; Sala, G; Saura, C | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Altavilla, G; Arrigo, C; Galletti, G; Marabello, G; Picone, G; Pitini, VV; Santarpia, MC; Tomasello, C | 1 |
| Crinò, L; Reck, M | 1 |
| Besse, B; Osio, A; Rajpar, S | 1 |
| Braiteh, F; Johnson, FM; Kurzrock, R | 1 |
| Cutz, JC; da Cunha Santos, G; Ding, K; Kamel-Reid, S; Liu, N; Marrano, P; Sakurada, A; Seymour, L; Shepherd, FA; Squire, JA; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Brugarolas, A; Eugenieva, E; Farré, J; Fernández Morejón, FJ; González Manzano, R; Martínez Navarro, E | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Kim, SW; Lee, DH; Lee, JS; Suh, C; Yi, EJ; Yoon, DH | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Manoloukos, M; Murray, S | 1 |
| Arrieta, O; Castillo-Gonzalez, P; de la Cruz Vargas, J; De la Garza, J; Flores-Estrada, D; Gonzalez, C; Gonzalez-De la Rosa, CH; Guzman, E; Hernandez-Pedro, N; Martinez-Barrera, L; Morales-Barrera, R; Rios-Trejo, MA; Téllez, E; Treviño, S | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Epstein, D; Haley, JD; Petti, F; Sujka-Kwok, I; Thomson, S | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Bachariou, A; Chasapi, V; Papadopoulos, R | 1 |
| Burgers, JA; Haas, RL; Kappers, I; Klomp, HM; van Pel, R; Van Zandwijk, N | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Hesketh, PJ; Hirsch, FR; Mack, PC; Marchello, BT; Moon, J; Spreafico, A; Wozniak, AJ | 1 |
| Grünberg, K; Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Chin, TM; Seto, KY; Soo, RA; Wong, AS | 1 |
| Barlési, F | 2 |
| Astoul, P; Barlési, F; Breen, D; Fina, F; Martin, PM; Nanni-Metellus, I | 1 |
| Giaccone, G; Gutierrez, M; Rajan, A | 1 |
| Tamura, K | 1 |
| Dias-Santagata, DC; Lynch, TJ; Nanda, A; O'Hara, CJ; Stubbs, H; Willers, H; Zaner, KS | 1 |
| Bunn, PA; Dziadziuszko, R; Gajapathy, S; Hirsch, FR; Lin, M; O'Neill, V; Skokan, M; Varella-Garcia, M; Xiao, Y | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Bianchi, F; Neri, I; Patrizi, A | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Amoroso, D; Ardizzoni, A; Bearz, A; Belvedere, O; Brandes, AA; Cascinu, S; Crinò, L; Gridelli, C; Grossi, F; Labianca, R; Piantedosi, FV; Siena, S; Tiseo, M; Valentino, B; Venturino, P | 1 |
| Bertran-Alamillo, J; Botia, M; Carrasco, E; Castellà, E; Costa, C; Llatjós, M; Mate, JL; Mayo, C; Molina-Vila, MA; Moran, T; Pérez-Cano, M; Pradas, A; Queralt, C; Reguart, N; Rosell, R; Taron, M; Tomàs, M | 1 |
| Buhl, R; Fischer, B; Makowski, J; Meier, S; Post, F; Schad, A; Schadmand-Fischer, S; Sebastian, M; Springer, E; Taube, C; Wiewrodt, R | 1 |
| Chin, TM; Haber, DA; Lynch, TJ; Quinlan, MP; Sequist, LV; Settleman, J; Sharma, SV; Singh, A | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Copeman, M | 1 |
| Herbst, RS; Sandler, A | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Boggon, TJ; Chan, PS; Christensen, JG; Dietrich, S; Du, R; El-Telbany, A; Halmos, B; Hirashima, T; Iwasaki, T; Jiang, S; Kawahara, K; Kawase, I; Kern, JA; Kijima, T; Kobayashi, M; Ma, PC; Matsui, K; Nakagawa, K; Okamoto, N; Petri, ET; Salgia, R; Sasada, S; Suzuki, H; Tang, Z | 1 |
| Ren, SX; Yan, LH; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Balko, JM; Black, EP | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 1 |
| Azzoli, CG; Brahmer, JR; Fogle, M; Ginsberg, M; Kris, MG; Miller, VA; Milton, DT; Riely, GJ; Rizvi, NA; Rosen, N; Rudin, CM; Senturk, E; Seshan, VE; Sirotnak, FM; Solit, DB | 1 |
| Fukuoka, M; Hida, T; Katakami, N; Kawahara, M; Kubota, K; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saijo, N; Takeda, K; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bodenstein, H; Digel, W; Franke, A; Guschall, WR; Gütz, S; Heigener, D; Laack, E; Reck, M; Schmidtgen, C; Schneider, CP; Schott-von-Römer, K | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Descourt, R; Misery, L; Roguedas, AM; Rouxel, AM | 1 |
| Pavlidis, N; Pentheroudakis, G; Vassou, A; Voulgaris, E | 1 |
| Backes, H; Borgman, CL; Jacobs, AH; Koker, M; Li, H; Neumaier, B; Shapiro, GI; Shimamura, T; Sos, ML; Tawadros, S; Thomas, RK; Ullrich, RT; Waerzeggers, Y; Winkeler, A; Wolf, J; Zander, T | 1 |
| Catania, C; Curigliano, G; de Braud, F; De Carlis, L; De Pas, T; Locatelli, M; Lorizzo, K; Pelosi, G; Spitaleri, G; Toffalorio, F | 1 |
| Cardona, AF; Reguart, N; Reveiz, L | 1 |
| Acharya, J; Bottomley, DM; Lyon, C | 1 |
| Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C | 1 |
| Chouaid, C; Coudray-Omnès, C; Moser, A; Vergnenègre, A | 1 |
| Angagaw, MH; Bettano, KA; Chenard, M; Haines, BB; Reilly, JF; Sevilla, RS; Sur, C; Tong, C; Ware, C; Winkelmann, CT; Zhang, W | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH | 1 |
| Boysen, M; Longson, C; Stevens, A | 1 |
| Ailawadhi, S; Derby, L; Fetterly, G; Natarajan, R; Ramnath, N; Reid, M | 1 |
| Mehić, B; Smoljanović, V; Stanetić, M; Tinjić, L | 1 |
| Galvany, L; Herrera-Acosta, E; Iglesias, M; Márquez, G; Umbert, P; Vidal, I | 1 |
| Sakurada, A; Tsao, MS | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Dagnaes-Hansen, F; Jakobsen, S; Keiding, S; Memon, AA; Nexo, E; Sorensen, BS | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Boinpally, R; Chick, JB; Dunlop, D; Hughes, AN; Nicolson, M; O'Brien, ME; Petty, WJ; Price, A; Rankin, E; Wolf, J; Woll, PJ | 1 |
| Andrew, AS; Duell, EJ; Mason, RA; Memoli, V | 1 |
| Hanayama, K; Hirashima, T; Imamura, F; Kanazawa, S; Kinoshita, Y; Nomura, S; Sasada, S; Siomi, K; Tujimoto, M; Yamaguchi, K | 1 |
| Duchnowska, R; Grala, B; Siemiatkowska, A; Smoter, M | 1 |
| Xing, LN; Zhang, F | 1 |
| Bradley, J; Feins, RH; Gewanter, RM; Gopal, RS; Komaki, RU; Kong, FM; Langer, CJ; Lee, HK; Movsas, B; Rosenzweig, KE | 1 |
| Frenkel, EP; Gazdar, AF; Minna, JD; Peyton, M; Soh, J; Xie, Y; Zhang, W | 1 |
| Akerley, W; Arbogast, K; Bentz, JS; Boucher, KM; Walters, T | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Barletta, E; Cusano, F; Ferrara, G; Ingordo, V | 1 |
| Andreu, J; Baselga, J; Cedrés, S; del Campo, JM; Felip, E; Martínez, P; Pallisa, E; Prat, A; Quispe, I; Sala, G | 1 |
| Barkauskas, DS; Dowlati, A; Du, R; Flask, C; Gerson, S; Halmos, B; Jiang, S; Kern, JA; Lam, M; Lee, Z; Liu, L; Ma, PC; Molter, J; Richey, J; Tang, Z; Wang, Y; Wu, C | 1 |
| Deplanque, G; Deray, G; Dreno, B; Janus, N; Launay-Vacher, V; Mateus, C; Morere, JF; Robert, C; Souquet, PJ | 1 |
| Atsou, K; Chouaid, C; Hejblum, G; Vergnenegre, A | 1 |
| Ginsberg, MS; Heelan, R; Hussain, S; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rusch, VW; Zakowski, MF | 1 |
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Lu, MQ; Wang, J; Wei, Q; Wen, CH; Xu, XH; Zhou, ZT | 1 |
| Lin, CC; Yang, CH | 1 |
| Aracil, M; Jimeno, J; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Distel, RJ; Jänne, PA; Kuang, Y; Makrigiorgos, M; Rogers, A; Thiede, S; Vetrand, K; Wang, L; Yeap, BY | 1 |
| Fischer, F; Frommolt, P; Garraway, LA; Gazdar, AF; Girard, L; Heynck, S; Kashkar, H; Koker, M; Mermel, C; Meyerson, M; Michel, K; Minna, JD; Pao, W; Peifer, M; Peyton, M; Rabinovsky, R; Seeger, JM; Sos, ML; Thomas, RK; Weir, BA; Weiss, J; Zander, T | 1 |
| Karapanagiotou, EM; Merikas, I; Saif, MW; Syrigos, KN; Tsimboukis, S | 1 |
| Alexandrescu, DT; Dasanu, CA; Kauffman, CL | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Hawkins, N; Scott, DA; Thatcher, N; Woods, BS | 1 |
| Billheimer, D; Brahmer, J; Carbone, D; Chen, H; Chen, S; Dang, TP; Herbst, R; Lee, JW; Massion, P; Salmon, S; Sandler, A; Schiller, J; Shyr, Y; Tran, H; Tsao, A | 1 |
| Bousamra, M; Fan, TW; Higashi, RM; Kloecker, G; Lane, AN; Miller, DM | 1 |
| Manegold, C | 1 |
| Filipits, M; Minar, W; Pirker, R | 1 |
| Chen, ZG; Huang, DH; Khuri, FR; Peng, XH; Shin, DM; Su, L; Zhang, H | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Aubry, MC; Rickman, OB; Sanyal, B; Thomas, CF; Vohra, PK; Vrana, JA; Wigle, DA | 1 |
| Hoeller, C; Kunstfeld, R; Loewe, R; Paulitschke, V; Pehamberger, H; Pilarski, P; Schicher, N; Swoboda, A | 1 |
| Doral Stefani, S; Giorgio Saggia, M; Vicino dos Santos, EA | 1 |
| Dhruva, N; Socinski, MA | 1 |
| Kaji, A; Katayama, K; Kawahara, H; Mitsuhashi, J; Noguchi, K; Sugimoto, Y | 1 |
| Beckett, L; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, D; Perkins, N; Scudder, SA | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Becker, M; Fichtner, I; Leschber, G; Merk, J; Rolff, J | 1 |
| Mekhail, T; Pennell, NA | 1 |
| Chu, DS; Johnson, KS; Levin, F | 1 |
| Ansari, J; Hussain, SA; Palmer, DH; Rea, DW | 1 |
| Demierre, MF; Goldberg, LJ; Pongpudpunth, M | 1 |
| Brower, SL; Bush, JE; Rice, SD | 1 |
| Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Clément-Duchêne, C; Merritt, R; Wakelee, HA | 1 |
| Benedetti, G; Colucci, G; Crinò, L; Galetta, D; Latini, L | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Green, J; Hockenhull, J; Macbeth, F; McLeod, C; Proudlove, C; Stevenson, J; Walley, T | 1 |
| de Castro, J; García-Campelo, R; Isla, D; Provencio, M | 1 |
| Dorans, K | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
| Huh, K; Kim, MJ; Kim, SW; Oh, J | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Aono, N; Isa, S; Kawaguchi, T; Koh, Y; Kubo, A; Kurata, T; Nakao, K; Tachibana, K; Takada, M; Tsujino, K | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Arrieta, O; Michel, RM; Rios Trejo, MA | 1 |
| Bigelow, RL; Burke, P; Cardelli, JA; Carroll, JL; Coleman, DT; Milligan, SA; Steffan, JJ; Williams, BJ | 1 |
| Ren, S; Tang, L; Yan, L; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Admane, S; Chirieac, LR; Costa, DB; Digumarthy, SR; Heist, RS; Iafrate, AJ; Kobayashi, S; Kwak, EL; Lynch, TJ; Mark, EJ; McDermott, U; Mino-Kenudson, M; Rodig, SJ; Settleman, J; Shaw, AT; Solomon, B; Stubbs, H; Yeap, BY | 1 |
| Chang, CC; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Su, YJ | 1 |
| Cioffredi, LA; Giaccone, G; Jackman, DM; Jänne, PA; Johnson, BE; Miller, VA; Riely, GJ; Ruiz, MG; Sequist, LV; Yeap, BY | 1 |
| Hampton, T | 2 |
| Ding, J; Hu, G; Li, J; Qian, X; Wang, Z; Zhang, W | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Gazdar, AF | 3 |
| Cappuzzo, F; Hirsch, FR; Varella-Garcia, M | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, WK; Lo, AI; Wong, MK | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Kang, JH; Kim, HT; Kim, SW; Lee, J; Lee, JS; Park, BB; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS; Uhm, JE | 1 |
| Bastus, R; Bertran-Alamillo, J; Bover, I; Camps, C; Cardenal, F; Catot, S; Garcia-Campelo, R; Gonzalez-Larriba, JL; Insa, A; Isla, D; Lopez-Vivanco, G; Majem, M; Massuti, B; Mayo, C; Molina, MA; Moran, T; Moreno, MA; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M | 1 |
| Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Alì, G; Baldini, E; Boldrini, L; Camacci, T; Comin, CE; Fontanini, G; Gisfredi, S; Lucchi, M; Maddau, C; Melfi, F; Mussi, A; Servadio, A; Tibaldi, C; Ursino, S | 1 |
| Mendoza, L | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| de Stanchina, E; Goel, A; Gong, Y; Koutcher, JA; Mellinghoff, IK; Ouerfelli, O; Pao, W; Politi, KA; Regales, L; Shen, R; Spassova, M; Vivanco, I; Zakowski, MF | 1 |
| Miller, AA; Petty, WJ; Waller, LL | 1 |
| Auclair, PL; Battelli, C; Carrier, K; Emery, IF; Hayes, DM | 1 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Buttitta, F; Cappuzzo, F; Carlone, D; Ceribelli, A; Cognetti, F; Del Grammastro, M; Felicioni, L; Finocchiaro, G; Gelibter, AJ; Iacobelli, S; Irtelli, L; Malatesta, S; Marchetti, A; Mezzetti, A; Milella, M; Nuzzo, C; Perrucci, B; Sciarrotta, M | 1 |
| Da Silva, S; Decaestecker, C; Demetter, P; Mathieu, A; Salmon, I; Verbeken, E; Weynand, B | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Carlson, JJ | 1 |
| Cristofanilli, M; Esteva, FJ; Hortobagyi, GN; Hung, MC; Krishnamurthy, S; LaFortune, TA; Liu, P; Lucci, A; Singh, B; Ueno, NT; Zhang, D | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Gandara, DR; Lara, PN; Li, T; Mack, PC; Perez-Soler, R | 1 |
| Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY | 1 |
| Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Blakely, J; Houts, AC; Reyes, CM; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Beganovic, S | 1 |
| Engelman, JA; Jackman, D; Jänne, PA; Johnson, BE; Kris, MG; Lynch, T; Miller, VA; Pao, W; Riely, GJ | 1 |
| Benlloch, S; Molina, MA; Rosell, R; Taron, M; Viteri, S | 1 |
| Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Forrester, J; Lai, CJ; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Kawana, S; Mitsuishi, T; Motoki, T | 1 |
| Cattaneo, MT; Clementi, E; Ferrario, S; Filipazzi, V; Gambaro, A; Isabella, L; Oteri, A; Piazza, E; Radice, S; Tosca, N | 1 |
| Büttner, R; Heukamp, LC | 1 |
| Chen, HY; Lee, CN; Liu, HE | 1 |
| Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB | 1 |
| Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Lyseng-Williamson, KA | 1 |
| Hammersley, JR; Kanjwal, S; Taj, A | 1 |
| Eck, MJ; Yun, CH | 1 |
| Besse, B; Soria, JC; Vignot, S | 1 |
| Besse, B; Bidart, JM; Bosq, J; Lacroix, L | 1 |
| Amann, JM; Brahmer, J; Carbone, DP; Gonzalez, A; Lee, JW; Roder, H; Schiller, JH | 1 |
| Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S | 1 |
| Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M | 1 |
| Qiu, JH; Wang, J | 1 |
| Desai, RU; Rachakonda, LP; Saffra, NA | 1 |
| Ganti, AK | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Ma, PC; Manson, GV | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Neal, JW | 2 |
| Bharthuar, A; Iyer, R | 1 |
| Blumenschein, GR; Herbst, RS; Kim, ES; Lu, C; Lum, BL; Malik, M; Oh, YW; Papadimitrakopoulou, VA; Tran, HT; Zinner, RG | 1 |
| Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H | 1 |
| Carney, D; Forde, P; Murphy, C; O'Sullivan, C | 1 |
| Akimov, M; Au, JS; Baselga, J; Damyanov, D; Delmar, P; Essioux, L; Felip, E; Hillenbach, C; Klughammer, B; Kuo, HP; McLoughlin, P; Milanowski, J; Orlov, S; Pluzanska, A; Ramlau, R; Reck, M; Tan, EH; Yang, PC | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Clarke, JL; Lassman, AB; Miller, VA; Pao, W; Wu, N | 1 |
| Ramsey, SD | 1 |
| Bradbury, PA; Evans, WK; Isogai, PK; Leighl, NB; Mittmann, N; Ng, R; Seymour, L; Shepherd, FA; Tsao, MS; Tu, D; Zhu, L | 1 |
| Hatsuse, M; Morihara, K; Murakami, S; Nagata, K; Okano, A; Shimazaki, C; Shiotsu, S; Yuba, T | 1 |
| Han, YH; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y | 1 |
| Barabasz, A; Fadden, P; Foley, B; Hall, S; Huang, K; Rice, JW; Scott, A; Steed, P; Veal, JM | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Choi, PJ; Kim, KN; Lee, KN; Lee, SK; Roh, MS; Son, C; Um, SJ; Yang, DK | 1 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Hansen, O; Schytte, T | 1 |
| Borrill, J; Edwards, SJ | 1 |
| Lind, JS; Postmus, PE; Smit, EF | 1 |
| Travers, J; Workman, P | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Belani, CP; Owonikoko, TK; Ramalingam, SS | 1 |
| Athanasiou, A; Bardi, G; Chandrinou, H; Stathopoulos, GP; Trafalis, D | 1 |
| Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC | 1 |
| Chen, J; Liu, H; Xu, Y; Zhou, Q | 1 |
| Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| De Pas, TM; Delmonte, A; Gregorc, V; Spitaleri, G; Toffalorio, F | 1 |
| Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C | 1 |
| Li, LY; Wang, MZ; Xu, LY; Zhang, L; Zhang, XT; Zhang, XY; Zhong, W | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Miller, VA; Oxnard, GR | 1 |
| Camps, C; Carcereny, E; Gasco, A; Massuti, B; Moran, T; Quiroga, V; Rosell, R; Viteri, S; Wei, J | 1 |
| Ramalingam, SS; Stinchcombe, TE | 1 |
| Brugger, W; Cappuzzo, F; Cicenas, S; Ciuleanu, T; Esteban, E; Giaccone, G; Juhász, E; Klingelschmitt, G; Klughammer, B; Melezínek, I; Molinier, O; Stelmakh, L; Szczésna, A | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Besse, B; Buisine, MP; Copin, MC; Dansin, E; Ferté, C; Parent, F; Penel, N; Soria, JC | 1 |
| Fukudo, M; Inui, K; Masago, K; Mishima, M; Togashi, Y | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Eckert, R; Faehling, M; Kamp, T; Kuom, S; Schumann, C; Stoiber, KM | 1 |
| Ambrosio, R; Barbato, V; Bareschino, MA; Falanga, M; Gridelli, C; Maione, P; Rossi, A; Sacco, PC; Schettino, C | 1 |
| Ahmed, IS; Craven, RJ; Rohe, HJ; Twist, KE | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW | 1 |
| Wörmann, B | 1 |
| Fujikura, Y; Hizawa, N; Homma, S; Kurishima, K; Morishima, Y; Ota, K; Otsuka, S | 1 |
| Ji, H | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Döme, B; Ostoros, G; Strausz, J; Tímár, J | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chang, CY; Chang, SC; Chen, CY; Yu, CJ | 1 |
| Babineaux, S; Klein, R; Lawson, A; Liepa, AM; Muehlenbein, C; Schwartzberg, L; Wielage, R | 1 |
| Lin, CC; Shao, YY; Yang, CH | 1 |
| Ackerman, J; Albain, KS; Barlesi, F; Berkowitz, L; Besse, B; Gabrail, N; Hart, LL; Herbst, RS; Leighl, NB; Massarelli, E; Melnyk, O; Miller, VA; Raez, LE; Rosen, PJ; Shepherd, FA; Shun, Z; Sternas, L | 1 |
| Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
| He, C; Li, P; Ma, J; Ma, Z; Wang, H; Wang, Q; Wei, B; Zhu, H | 1 |
| Dahm-Daphi, J; Dikomey, E; Holst, K; Kasten-Pisula, U; Kriegs, M; Rieckmann, T; Saker, J | 1 |
| De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Antoniou, C; Chasapi, V; Dilana, KD; Karapanagiotou, EM; Matekovits, AE; Stratigos, AJ; Syrigos, KN; Tsimboukis, S; Vergou, T | 1 |
| Bokemeyer, C; Laack, E; Sauter, G | 1 |
| Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Costa, DB; Hamada, A; Kobayashi, S; Yeo, WL | 1 |
| Chen, J; Liu, H; Wang, Y | 1 |
| Eaton, KD; Martins, RG | 1 |
| Blum, RA; Cheng, CP; Hanifudin, A; Lim, LT | 1 |
| Bago-Horvath, Z; Berger, W; Cejka, D; Filipits, M; Haitel, A; Hayden, H; Herberger, B; Schmid, K; Sieghart, W; Werzowa, J | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H | 1 |
| Kink, JA; Raines, RT; Rutkoski, TJ; Schilling, CI; Strong, LE | 1 |
| Bertran-Alamillo, J; Cardenal, F; Cobo, M; Garrido, P; Isla, D; Lianes, P; Manegold, C; Massuti, B; Molina, MA; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Stahel, R; Taron, M; Trigo, JM | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Altorki, N; Camiolo, M; Fenoglio, S; Gao, DC; Johns, C; Kenner, L; Lindsted, T; Mittal, V; Schlederer, M; Sordella, R; Stiles, B; Yao, Z | 1 |
| Aukema, TS; Codrington, HE; Kappers, I; Klomp, HM; Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Amarshi, N; Billingsley, A; Nair, BA; Thomas, KS | 1 |
| Ghosh, G; Kron, SJ; Lee, AG; Palecek, SP; Yan, X | 1 |
| Cioffredi, LA; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Van den Abbeele, AD; Yap, JT; Yeap, BY | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Ahn, HK; Ahn, JS; Ahn, MJ; Chang, MH; Choi, YL; Jung, CK; Lee, J; Park, K; Park, YH | 1 |
| Fabian, P; Lakomý, R; Nemecek, R; Slabý, O; Stanková, M; Svoboda, M; Vyzula, R | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Murray, S | 1 |
| Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Chang, YC; Chang, YL; Hsu, YC; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC | 1 |
| Iqbal, SA; Myerson, JS; O'Brien, ME; Popat, S | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T | 1 |
| Fu, XY; Huang, Q; Li, DJ; Lu, MQ; Su, J; Xu, XH; Xue, F | 1 |
| Cheng, G; Li, L; Wu, XN; Zhang, P; Zhang, ZJ | 1 |
| Eberhardt, W | 1 |
| Altomare, G; Bidoli, P; Cazzaniga, ME; Cicchiello, F; Colombo, I; Cortinovis, DL; Crippa, A; Villa, F | 1 |
| Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Shirane, M | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Albain, KS; Atkins, JN; Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Herbst, RS; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Redman, M | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Hosomi, Y; Iguchi, M; Miyamoto, S; Ohkuma, Y; Okamura, T; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Basaki, Y; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kuwano, M; Nakashima, K; Ono, M; Uramoto, H; Yamamoto, C; Yasumoto, K | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Jones, SJ; Milenkova, T | 1 |
| Burtness, B; Psyrri, A | 1 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Minna, JD; Murudkar, C; Shay, JW; Shultz, JC; Wijesinghe, DS | 1 |
| Grygárková, Y; Havel, L; Hrnciarik, M; Kolek, V; Koubková, L; Krejcí, J; Pesek, M; Salajka, F; Skalová, B; Skricková, J; Stícha, M; Tomísková, M; Zatloukal, P | 1 |
| Katayama, T; Maehara, Y; Mitsudomi, T; Murakami, I; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Ahn, JS; Ahn, MJ; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM | 1 |
| Duchnowska, R | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Le Maître, A; Seymour, L; Shepherd, FA; Tsao, MS; Zhao, H | 1 |
| Altiok, S; Bai, Y; Eschrich, S; Fang, B; Haura, EB; Kinose, F; Koomen, J; Li, J; Lin, H; Liu, RZ; Oguz, U; Remily-Wood, ER; Zhang, G | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Ahn, JS; Ahn, MJ; Chung, MJ; Hwang, HS; Kim, TS; Lee, HY; Lee, JW; Lee, KS; Park, K; Yi, CA | 1 |
| Horger, M; Schulze, M; Spengler, W | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Dong, N; Guo, Y; Luan, HL; Sun, BC; Sun, LN; Wang, M; Zang, FL; Zhan, ZL | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Colucci, G; Galetta, D; Millaku, A; Pisconti, S; Rossi, A | 1 |
| Azzoli, CG; Brevet, M; Johnson, ML; Ladanyi, M | 1 |
| Heigener, D; Mok, T; Reck, M; Wolf, J; Wu, YL | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Lee, P | 1 |
| Cortot, AB | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Ardizzoni, A; Bartolotti, M; Boggiani, D; Bortesi, B; Bozzetti, C; Gelsomino, F; Sammarelli, G; Thai, E; Tiseo, M | 1 |
| Lin, CC; Yang, JC | 1 |
| Beijnen, JH; Fanggiday, JC; Lankheet, NA; Malingré, MM; Staaks, GH; Ter Heine, R; Van Der Westerlaken, MM | 1 |
| Heigener, DF; Reck, M | 1 |
| Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY | 1 |
| Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
| Longo, M; Merlo, V; Novello, S; Scagliotti, GV | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Boss, DS; Britten, CD; Camidge, DR; Eckhardt, SG; Engelman, JA; Garon, EB; Guo, F; Jänne, PA; Letrent, S; Liang, J; Millham, R; Schellens, JH; Taylor, I; Wong, S | 1 |
| Donev, IS; Li, Q; Matsumoto, K; Nishioka, Y; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yamori, T; Yano, S | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Ariza, A; Benlloch, S; Bertran-Alamillo, J; Bivona, TG; Carcereny, E; Cardenal, F; Cobo, M; Costa, C; de Aguirre, I; Garcia-Campelo, R; Gimenez-Capitan, A; Insa, A; Isla, D; Majem, M; Massuti, B; Mate, JL; Mayo, C; Mendez, P; Molina, MA; Moran, T; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Sawyers, CL; Simonetti, S; Taron, M; Viteri, S | 1 |
| Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Anthoine, G; Berghmans, T; CsToth, I; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Fujitaka, K; Hamada, A; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Masuda, T; Murai, H; Ohshimo, S | 1 |
| Barlesi, F; Ferry, D; Gogov, S; Goss, GD; Greco, FA; Langmuir, P; Mulatero, C; Natale, RB; Rowbottom, JA; Sunpaweravong, P; Thomas, M; Thompson, J; Thongprasert, S; Tsai, CM; Whorf, R | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Blanchet, B; Goldwasser, F; Mir, O | 2 |
| Camidge, DR; Cappuzzo, F; Varella-Garcia, M | 1 |
| Babu, VC; Harini, VV; Kumar, BS; Nargund, A; Patil Okaly, GV; Rao, R; Rao, S; Sahoo, R; Venkataswamy, E | 1 |
| Hureaux, J; Jeanfaivre, T; Le Maignan, L; Mirebeau-Prunier, D; Urban, T; Vervueren, L | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Beinert, T; Binder, D; Buckendahl, AC; Hübner, RH; Schlattmann, P; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Mountzios, G; Syrigos, KN | 1 |
| Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY | 1 |
| Friedrich, MJ | 1 |
| Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W | 1 |
| Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z | 1 |
| Hibino, M; Kudo, S; Minamiya, Y; Nakamura, M; Ogawa, J; Okuyama, M; Sasaki, Y; Tenma, K | 1 |
| Bergot, E; Creveuil, C; Lechapt, E; Levallet, G; Zalcman, G | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| De Marinis, F; Karapanagiotou, EM; Oikonomopoulos, G; Saif, MW; Syrigos, KN | 1 |
| Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A | 1 |
| Castel, M; Despas, F; Mazières, J; Pathak, A | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Akhavanfard, S; Bergethon, K; Christensen, JG; Cosper, AK; Dias-Santagata, D; Digumarthy, S; Engelman, JA; Fidias, P; Gettinger, S; Heist, RS; Iafrate, AJ; Lanuti, M; Lynch, TJ; Mark, EJ; Mino-Kenudson, M; Sequist, LV; Shaw, AT; Temel, J; Turke, AB; Vernovsky, K; Wain, JC; Waltman, BA | 1 |
| Bivona, TG; Chang, K; Costa, C; Dahlman, K; Hannon, G; Hieronymus, H; Miller, VA; Moonsamy, P; Parker, J; Rosell, R; Sawyers, CL; Taron, M | 1 |
| Murphy, M; Stordal, B | 1 |
| Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Anadkat, MJ; Hepper, DM; Wu, P | 1 |
| Tuder, RM; Winn, RA | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, H; Kim, MJ; Kim, SH; Kim, SJ; Park, SJ | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chung, WC; Gold, KA; Hittelman, WN; Kang, SM; Ki Hong, W; Kim, ES; Koo, JS; Lee, J; Ryu, SH | 1 |
| Dhillon, S; Muir, VJ | 1 |
| Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H | 1 |
| Chang, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Kern, I; Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Antoine, M; Cadranel, J; Lacave, R; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Ardizzoia, A; Bertolini, A; Cortesi, E; Fagnani, D; Farina, G; Farris, A; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Mancuso, A; Martelli, O; Moscetti, L; Pavese, I; Rulli, E; Scanni, A; Tomirotti, M; Valmadre, G | 1 |
| Crinò, L; Metro, G | 1 |
| Bagai, R; Fan, W; Flask, CA; Fu, P; Hafez-Khayyata, S; Halmos, B; Howell, S; Huang, H; Jiang, S; Koon, H; Kresak, A; Ma, PC; Morrison, B; Tang, Z; Vasanji, A; Yin, L | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| Hazama, M; Kim, YH; Niimi, M; Sakamori, Y; Tanaka, S; Yanagihara, K | 1 |
| Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Berghmans, T; Meert, AP; Sculier, JP | 1 |
| Ansari, R; Bustin, F; Flynn, P; Hainsworth, J; Hart, L; Herbst, RS; O'Connor, P; Otterson, GA; Soh, CH; Vlahovic, G | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Berg, A; Brustugun, OT; Helland, Å; Lund-Iversen, M | 1 |
| Dallas, JL; Jantz, MA; Kaye, FJ; Lightsey, JL; Sonntag, C | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Date, H; Mishima, M; Nagai, H; Niimi, M; Sasaki, T; Seo, N; Tanaka, S; Yanagihara, K; Yasuda, H | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Ma, S; Xu, Y; Zhang, Y | 1 |
| Heneberg, P | 1 |
| Gu, A; Han, B; Shen, J; Shi, C; Xiong, L | 1 |
| Chen, Y; Feng, L; Ge, W; Han, W; Jin, H; Li, J; Lin, X; Pan, H; Sun, J; Wang, X; Wang, Y | 1 |
| Baselga, J; Felip, E; Hermes, A; Klughammer, B; Reck, M; Tan, EH | 1 |
| Borget, I; Cadranel, J; Chouaid, C; Coudert, B; Daniel, C; Dansin, E; Friard, S; Madelaine, J; Madroszyk, A; Morin, F; Pignon, JP; Quoix, E; Westeel, V | 1 |
| Agustoni, F; Buzzoni, R; Ducceschi, M; Formisano, B; Gelsomino, F; Pietrantonio, F; Platania, M; Pusceddu, S; Vitali, M; Zilembo, N | 1 |
| Dallas, J; Jantz, MA; Kaye, FJ | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Okamoto, I; Takeda, M | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y; Tsuchido, Y | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, ST; Kim, SW; Lee, J; Park, K; Park, YH; Sohn, I; Sun, JM; Uhm, JE | 1 |
| Kosaka, T; Kuwano, H; Mogi, A; Yamaki, E | 1 |
| Ishida, T; Katsuura, Y; Minemura, H; Misa, K; Munakata, M; Tachihara, M; Uematsu, M | 1 |
| Chanprapaph, K; Pongcharoen, P; Vachiramon, V | 1 |
| Altavilla, G; Benecchi, S; Magri, I; Pettineo, G; Rosell, R; Salazar, MF; Santarpia, M | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Belani, CP; Blumenschein, G; Goss, G | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Correa, PD; Rizwanullah, M; Shrimali, RK | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Boons, CC; Boven, E; Hugtenburg, JG; Mangnus, D; Moes, JE; Smit, EF; Swart, EL; Timmers, L | 1 |
| Han, JY; Kim, HT; Lee, GK; Lee, JS; Lim, KY; Park, SY; Won, YW; Yoon, KA; Yun, T | 1 |
| Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS | 1 |
| Cha, MY; Chae, YJ; Kim, M; Kim, MS; Kim, YH; Lee, GS; Lee, KH; Lee, KO; Park, J; Park, SB; Song, JY; Suh, KH | 1 |
| Kagohashi, K; Kawaguchi, M; Kurishima, K; Nakayama, H; Ohara, G; Satoh, H | 1 |
| Blanchet, B; Dauphin, A; Dusser, D; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Schoemann-Thomas, A; Taieb, F; Vidal, M | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Akerley, WL; Arthur, S; Brugger, W; Chen, Y; Costa, DB; Ferrari, D; Garmey, EG; Gerber, DE; Gorbachevsky, I; Orlov, S; Ramlau, R; Schiller, JH; Schwartz, B; Sequist, LV; von Pawel, J | 1 |
| Saijo, N | 2 |
| Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Douillard, JY; Lokiec, F | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Becker, A; Crombag, L; Heideman, DA; Postmus, PE; Smit, EF; Thunnissen, FB; van Wijk, AW | 1 |
| Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ | 1 |
| Hotta, K; Kiura, K | 1 |
| Amihai, D; Gilad, Y; Gorzalczany, Y; Hammel, I; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Aziz, F; Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T | 1 |
| Bunn, PA; Camidge, DR; Camidge, R; Dziadziuszko, R; Eisen, T; Franklin, WA; Hirsch, FR; Kabbinavar, F; Martins, R; Richardson, F; Richardson, K; Rusk, J; Schnell, FM; Sternberg, DW; Varella-Garcia, M; Wacker, B | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Fujiwara, K; Kiura, K; Kudo, K; Matsuo, K; Mizuta, M; Rai, K; Sato, T; Tsushima, M; Yamadori, I; Yonei, T | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Keiding, S; Meldgaard, P; Memon, A; Nexo, E; Sorensen, BS; Sorensen, L; Weber, B; Winterdahl, M | 1 |
| Baumann, M; Benes, C; Dahm-Daphi, J; Dikomey, E; Gheorghiu, L; Krause, M; Kriegs, M; Morsbach, F; Nanda, A; Sander, D; Settleman, J; Wang, M; Willers, H | 1 |
| Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS | 1 |
| Clarke, JL; Grommes, C; Holodny, AI; Kris, MG; Lassman, AB; Miller, VA; Oxnard, GR; Pao, W | 1 |
| Li, L; Liu, JL; Su, H; Xu, CA; Zou, HW | 1 |
| Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R | 1 |
| Loo, BW; Ma, L; Meng, X; Murphy, JD; Sun, X; Yu, J | 1 |
| Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q | 1 |
| Custodio, A; de Castro, J | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Arakawa, H; Hataji, O; Johkoh, T; Kusumoto, M; Sakai, F; Taguchi, O | 1 |
| Clark, P; George, E; Rinaldi, F | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Guo, ZZ; Huang, JJ; Huang, Y; Lin, TY; Tian, Y; Xu, F; Zhang, LL | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Choi, CM; Choi, DR; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Hockenhull, J; Martin Saborido, C; Oyee, J; Ramani, VS | 1 |
| Blasinska-Morawiec, M; Brugger, W; Cappuzzo, F; Curescu, S; Manikhas, GM; Mayne, K; Mazieres, J; Sakalauskas, R; Triller, N; Trunzer, K; Ward, C; Whittom, R | 1 |
| Shepherd, FA | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Bendapudi, PK; Chen, J; Choi, P; Felsher, DW; Horng, G; Hughes, NP; Kawashima, T; Kitamura, T; Koh, S; Lin, HJ; Miller, VA; Paik, D; Schwartz, LH; Tran, PT | 1 |
| Lanuti, M; Mino-Kenudson, M; Sequist, LV; Sharma, A | 1 |
| Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Doheny, S; Hughes, D | 1 |
| Chen, C; Fujioka, N; Gupta, K; Gupta, V; Johnson, KN; Kratzke, RA; Li, Y; Nguyen, J; Niehans, G; Pasrija, T | 1 |
| Knap, MM; Madsen, HH; Meldgaard, P; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Dainton, M; Lim, E; Min, T; Nicholson, AG; O'Brien, ME; Popat, S; Swansbury, J; Vieira de Araújo, A; Wotherspoon, A | 1 |
| Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| Brownstein, CM; Chen, D; Crino, L; Eberhardt, WE; Engelman, JA; Habben, K; Jänne, PA; Liu, L; Novello, S; Ramalingam, SS; Reck, M; Schneider, CP; Spigel, DR; Steins, MB | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA | 1 |
| Benz, G; Brutsche, M; Früh, M; Putora, PM; Rodriguez, R | 1 |
| Cromwell, I; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Brugarolas, A; Evgenyeva, E; Fernández, FJ; Forteza, J; González-Manzano, R; Martínez-Navarro, EM; Rebollo, J; Sureda, M; Valenzuela, B | 1 |
| Groen, HJ; Hiltermann, TJ; Schuuring, E; Timens, W | 1 |
| Chan, AB; Lam, KC; Lee, KW; Lo, AW | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Ashley, S; Chua, S; Cook, G; Coward, JI; Gunapala, R; Myerson, JS; O'Brien, ME; Popat, S; Puglisi, M; Sharma, B; Trani, L; Wotherspoon, A | 1 |
| Cappuzzo, F; Jänne, PA; Mok, TS; Soria, JC | 1 |
| Forsyth, M; Nadler, E; Reyes, C; Satram-Hoang, S | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Alam, S; Layman, R; Lustberg, M; Reinbolt, RE; Shapiro, C | 1 |
| Guo, H; Kang, Y; Li, Y; Lin, D; Liu, Q; Tian, G; Wan, Y; Yao, Z | 1 |
| Bischoff, H; Chouaid, C; de Castro Carpeño, J; Grossi, F; Heigener, D; Nuijten, MJ; Vergnenègre, A; Walzer, S | 1 |
| Bar, J; Onn, A | 1 |
| Aleknavičius, E; Cicėnienė, A; Drobnienė, M; Grigienė, R; Lachej, N; Steponavičienė, L; Zelvienė, TP | 1 |
| Chen, YM; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Ren, SX; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Gabr, AG; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Moriya, Y; Nishioka, Y; Ogawa, H; Saijo, A; Sakaguchi, S; Sone, S; Suzuki, M; Trung, VT | 1 |
| Aftab, D; Chen, X; Chmielecki, J; Hutchinson, K; Kris, MG; Miller, V; Pao, W; Pietanza, MC; Rizvi, N; Shen, R; Stout, T; Viale, A; Zhao, Z | 1 |
| Funada, Y; Hatakeyama, Y; Hori, S; Kasai, D; Kobayashi, K; Kondoh, T; Kotani, Y; Nagano, T; Nishimura, H; Nishimura, Y | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Nambara, D; Omi, K | 1 |
| Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Cromwell, I; Malfair Taylor, SC; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Abolhoda, A; Ahn, JS; Ahn, MJ; Cui, Z; Kim, Y; Ko, J; Ou, SH; Park, K | 1 |
| Chen, ZG; Fan, S; Khuri, FR; Koo, J; Li, Y; Owonikoko, TK; Ramalingam, SS; Sun, SY; Yue, P | 1 |
| Chen, Z; Cheng, D; Ding, K; Le Maitre, A; Liu, G; Liu, N; Patel, D; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Adjei, A; Brown, A; Camidge, DR; Doebele, R; Dy, G; Fetterly, G; Franklin, W; Hirsch, FR; Jackson, MK; Lettieri, J; Lu, X; Maxson, D; Oton, A; Reynolds, M; Varella-Garcia, M; Weickhardt, A; Wynes, MW; Youssoufian, H | 1 |
| Chachoua, A; Cohen, DE; de Souza, A; Wnorowski, AM | 1 |
| Paz-Ares, L | 1 |
| Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L | 1 |
| Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M | 1 |
| Govindan, R; Subramanian, J | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Argast, GM; Davies, A; Epstein, DM; Mercado, P; Richardson, F; Sennello, R; Wacker, B; Wolf, J; Young, GD | 1 |
| Abe, T; Aoki, T; Furuya, N; Hayama, N; Hisata, J; Igawa, S; Katagiri, M; Masuda, N; Mineshita, M; Miyazawa, T; Tajiri, S; Urano, T | 1 |
| Kaira, K; Yamamoto, N | 1 |
| Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Akazawa, Y; Imamura, F; Kumagai, T; Nishino, K; Okyuama, T; Uchida, J | 1 |
| Del Vecchio, S; Iommelli, F; Salvatore, M; Speranza, A; Zannetti, A | 1 |
| Higashino, M; Hiraishi, Y; Hirano, S; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Naka, G; Nakamichi, S; Sugiyama, H; Takeda, Y | 1 |
| Fujiu, K; Kobayashi, N; Miyamoto, H; Suzuki, H | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Lin, TC; Wu, PY | 1 |
| Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J | 1 |
| Bai, H; Han, B | 1 |
| Chang, JW; Chang, NJ; Chen, CH; Cheng, HY; Chung, FT; Hou, MM; Hsieh, JJ; Hsu, T; Huang, SF; Kuo, HP; Lin, HC; Lin, YC; Ou, LY; Tsai, YH; Wang, CL; Wang, HM; Yang, CT; Yu, CT | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Jeong, SH; Kim, J; Kim, S; Ku, B; Lee, DW | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Bengtsson, T; Hicks, RJ; Peterson, A; Port, RE | 1 |
| Chang, GC; Chen, HY; Chen, KC; Hsu, KH; Tseng, JS; Yang, TY | 1 |
| Egawa, K; Matsushita, H; Miura, H; Osawa, T; Takahashi, T; Tsubouchi, Y; Yuyama, K | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Ghosh, G; Kron, SJ; Lian, X; Palecek, SP | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 1 |
| Hirsh, V; Novello, S; Sandler, AB; Scagliotti, GV; Schiller, JH; Schwartz, B; Sequist, LV; Soria, JC; von Pawel, J; Von Roemeling, R | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J | 1 |
| Fujii, S; Hamada, A; Inaba, M; Isobe, T; Iwamoto, N; Kai, Y; Kashiwabara, K; Kishi, H; Kohrogi, H; Saeki, S; Saito, H; Sasaki, J; Semba, H; Tsubata, Y; Urata, M; Ushijima, S | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D | 1 |
| Amler, LC; Atwal, S; Fine, BM; Hampton, GM; Hicks, RJ; Hughes, BG; Lackner, MR; Liu, W; Pirzkall, A; Punnoose, EA; Raja, R | 1 |
| Kim, JH; Klingelschmitt, G; Ng, C; Park, K; Wu, YL; Zaatar, A | 1 |
| Chien, CR; Hsia, TC; Lin, CC | 1 |
| Hirata, K; Kimura, T; Kudoh, S; Manabe, M; Mitsuoka, S; Takeda, A; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Bunn, PA; Hirsch, FR; Jotte, RM; Konduri, K; Neubauer, MA; Ruxer, RL; Spira, AI; Varella-Garcia, M; Witta, SE | 1 |
| Dittmann, K; Huber, SM; Mayer, C; Misovic, M; Rodemann, HP | 1 |
| Arango, N; Bonilla, C; Cuello, J; Llinás, N; Rivas, G; Rubiano, J | 1 |
| Albert, I; Azzoli, CG; Bodkin, D; Iannotti, NO; Jiang, PY; Juhász, E; Kelly, K; Koutsoukos, T; Patel, JD; Pereira, JR; Weems, G; Zatloukal, P | 1 |
| Juergens, R; Levine, MN | 1 |
| Capelletti, M; Crawford, J; Edelman, MJ; Gu, L; Jänne, PA; Kratzke, R; Miller, VA; Socinski, MA; Stinchcombe, TE; Villalona-Calero, MA; Vokes, EE; Wang, X | 1 |
| Kita, K; Mano, H; Matsumoto, K; Nakade, J; Nakagawa, T; Nakamura, T; Nanjo, S; Soda, M; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Ayoola, A; Barochia, A; Belani, CP; Belani, K | 1 |
| Hamatani, Y; Kim, YH; Masago, K; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Kaneko, F; Oyama, N; Togashi, A; Yamamoto, T | 1 |
| Molina, JJ; Molina-Prat, N; Morral, M; Quintana, R; Saint-Jean, A; Sainz de la Maza, M; Torras, J | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Fallet, V; Lacave, R; Lavolé, A; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Bertran-Alamillo, J; Costa, C; Giménez-Capitán, A; Mayo, C; Molina-Vila, MÁ; Rosell, R | 1 |
| Chauhan, S; Gupta, M; Gupta, MK; Kesari, AA; Madabhavi, I; Rastogi, M; Revannasiddaiah, S; Seam, RK | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Brewster, M; Cedrés, S; Dean, E; Felip, E; Galdermans, D; Martínez, P; McNally, V; Ranson, M; Ross, G | 1 |
| Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N | 1 |
| Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
| Guo, Z; Li, J | 1 |
| Au, JS; Cheng, CK; Merimsky, O; Reck, M; von Pawel, J | 1 |
| Mason, DP | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| Nakamura-Wakatsuki, T; Yamamoto, T | 1 |
| Asrani, K; Bremner, R; Cheng, E; Hostetter, G; Inge, L; Jameson, NM; Kingsley, CB; Loftus, JC; Tran, NL; Weiss, GJ; Whitsett, TG; Winkles, JA | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Albano, T; Arnovitz, P; Burstein, D; Dhawan, NS; Difeo, A; Farrington, C; Galsky, M; Izadmehr, S; Katz, S; Mazhar, S; Melville, H; Narla, G; Ohlmeyer, M; Okrent, R; Politi, K; Rana, H; Sangodkar, J; Singh, VJ; Yuan, E; Zhang, D | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Fukuda, A; Sonoda, T; Takenaka, T; Yamagata, M | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Le Caer, H; Locher, C; Monnet, I; Vergnenegre, A | 1 |
| El-Modir, A; Stevenson, R | 1 |
| Ashizawa, J; Deguchi, Y; Hashimoto, R; Hitani, K; Hori, Y; Maeno, T; Shiba, T; Ubuka, M | 1 |
| Keshtgarpour, M; Ma, PC; Pennell, NA; Yin, L | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| Harada, D; Ichihara, E; Kiura, K; Kubo, T; Ninomiya, T; Ochi, N; Ohashi, K; Takata, S; Takeda, H; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Cappuzzo, F | 3 |
| Perez-Soler, R; Piperdi, B | 1 |
| Califano, R; D'arcangelo, M; Mok, TS | 1 |
| Dietlein, M; Kahraman, D; Kobe, C; Neumaier, B; Nogova, L; Scheffler, M; Thomas, R; Wolf, J; Zander, T | 1 |
| Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Abdel-Rahman, M; Arcila, M; Au, V; Bivona, TG; Boggon, TJ; Choi, CM; Choi, YJ; Costa, C; Halmos, B; Jang, SJ; Kim, SW; Kim, WS; Ladanyi, M; LaFramboise, T; Lee, DH; Lee, JC; Lee, JS; Levine, AD; Lin, L; Ma, PC; Miller, VA; Moonsamy, P; Olivas, V; Park, YS; Rho, JK; Rosell, R; Sawyers, C; Taron, M; Wang, X; Zhang, Z | 1 |
| Burgers, JA; Codrington, HE; Kappers, I; Klomp, HM; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Barrios, CH; Blackhall, F; Bover, I; Boyer, M; Campbell, AK; Frank, R; Krzakowski, M; Letrent, SP; Liang, JQ; O'Connell, J; Park, K; Ramalingam, SS; Rosell, R; Ruiz-Garcia, A; Seog Heo, D; Talbot, DC; Taylor, I | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Gu, H; Li, X; Liu, S; Wang, D | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Girard, L; Heymach, JV; Johnson, FM; Lippman, SM; Minna, JD; Peng, S; Saintigny, P; Sen, B; Wistuba, II; Zhang, L | 1 |
| Dong, XR; Huang, J; Liu, L; Lu, HD | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Abe, H; Arao, T; Azuma, K; Hayashi, K; Kage, M; Kanda, R; Kawahara, A; Kubo, T; Kuwano, M; Murakami, Y; Nishio, K; Ono, M; Rosell, R; Sonoda, K; Tabara, K; Tahira, T; Yoshinaga, A | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Li, H; Ren, XB; Wang, CL; Wang, M; Yu, JP; Zhang, LM; Zhao, J | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Horn, L; Lovly, CM | 1 |
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H | 1 |
| Chen, RC; Halle, J; Higginson, DS; Marks, LB; Morris, DE; Pham, E; Rosenman, JG; Socinski, MA; Stefanescu, M; Tracton, G | 1 |
| Jänne, PA; Oxnard, GR | 1 |
| Shi, YK | 1 |
| An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Jin, C; Li, W; Li, Y; Ren, S; Zhang, D; Zhao, Z | 1 |
| Ali, K; Kumar, I; Saeed, MU; Usman-Saeed, M | 1 |
| Kris, MG; Ladanyi, M; Moreira, AL; Paik, PK; Rekhtman, N; Sima, CS; Varghese, AM | 1 |
| Chen, HM; Kuo, R; Lai, MS; Lin, ZZ; Shao, YY; Shau, WY; Yang, JC | 1 |
| Abell, F; Boyer, M; De Souza, P; Horwood, K; Johnston, M; Millward, M; Pavlakis, N; Rischin, D; Stein, B | 1 |
| Gao, G; Ren, S; Wu, X; Zhou, C | 1 |
| Beculic, H; Dervisevic, S; Imsirovic, B; Mekic-Abazovic, A | 1 |
| Benešová, L; Bortlíček, Z; Brůha, F; Fiala, O; Fínek, J; Krejčí, J; Minárik, M; Pešek, M | 1 |
| Cei, M; Mumoli, N; Vitale, J | 1 |
| Daw, H; Haddad, A; Petrosyan, F; Spiro, T | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Cai, J; Chen, T; Chen, Y; Deng, J; Du, Z; Li, Q; Lu, J; Shan, B; Song, X; Wery, JP; Yang, M; Zhang, L | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Arcila, ME; de Stanchina, E; Janjigian, YY; Kris, MG; Ladanyi, M; Melnick, MA; Miller, VA; Nebhan, CA; Ohashi, K; Pao, W; Pirazzoli, V; Politi, K; Riely, GJ; Song, X; Spitzler, PJ; Takezawa, K | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Carlson, JJ; Yeung, K | 1 |
| Hashemi-Sadraei, N; Pennell, NA | 1 |
| Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Chmielecki, J; Foo, J; Michor, F; Pao, W | 1 |
| Ackerman, A; Costa, DB; Goldstein, MA; Kobayashi, S | 1 |
| Crvenkova, S; Dimovski, A; Ivkovski, Lj; Kaeva, B | 1 |
| Busch, TM; Cengel, KA; Edmonds, C; Gallagher-Colombo, SM; Hagan, S | 1 |
| Jiang, SJ; Ma, XB; Zhang, QC; Zhang, S | 1 |
| Katsura, Y; Ko, R; Koyama, R; Minakata, K; Murakami, A; Muraki, K; Namba, Y; Ohashi, R; Sakuraba, S; Shukuya, T; Takahashi, F; Takahashi, K; Yagishita, S | 1 |
| Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F | 1 |
| Clark, P; Dillon, B; Knight, H; Naidoo, B | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Blackstock, AW; Decker, RH; Gettinger, SN; Khandani, A; Lankford, S; Moore, DT; Morris, DE; Petty, WJ; Schwartz, G; Socinski, MA; Stinchcombe, TE | 1 |
| Chen, YM; Chiang, CL; Chiu, CH; Chou, TY; Lai, SL; Lee, YC; Shih, JF; Tsai, CM | 1 |
| Hallek, M; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Carbone, DP; Ding, K; Grigorieva, J; Roder, H; Roder, J; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Bianchi, L; Lisi, P; Minotti, V; Stingeni, L | 1 |
| Edelman, MJ; Mok, T; O'Byrne, K; Paz-Ares, L; Rittweger, K; Spigel, DR; Thurm, H; Yu, W | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J | 1 |
| Bivona, TG; Blakely, CM | 1 |
| Riely, GJ; Yu, HA | 1 |
| Boshoff, C; Bulley, S; Chao, D; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Khan, I; Lal, R; Lee, SM; Lewanski, C; Marshall, E; Middleton, G; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Chen, HJ; Dong, S; Huang, YS; Jiang, BY; Liao, RQ; Nie, Q; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Bortlíček, Z; Coupková, H; Grygárková, Y; Havel, L; Hejduk, K; Hrnčiarik, M; Kolek, V; Košatová, K; Koubková, L; Pešek, M; Roubec, J; Salajka, F; Sixtová, D; Skřičková, J; Spelda, S; Tomíšková, M; Zatloukal, P; Zemanová, M | 1 |
| Baghdadi, TA; Bhatia, S; Hanna, N; Harb, W; Jalal, SI; Johnson, C; McClean, J; Riggs, H; Taber, D; Yu, M | 1 |
| Baty, F; Brutsche, M; Bubendorf, L; Carbone, D; Crowe, S; Dingemans, AM; Gautschi, O; Grigorieva, J; Hsu Schmitz, SF; Na, KJ; Peters, S; Pless, M; Roder, H; Roder, J; Smit, E; Stahel, R; Zappa, F | 1 |
| Bidkhori, G; Masoudi-Nejad, A; Moeini, A | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Bahce, I; Heideman, DA; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Postmus, PE; Schuit, RC; Smit, EF; Thunnissen, E; van der Veldt, AA; Windhorst, AD; Yaqub, M | 1 |
| Chen, SS; Falchook, GS; Fok, JY; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, SA; Stephen, B; Tsimberidou, AM; Wheler, JJ | 1 |
| Alesini, D; Cortesi, E; Passaro, A; Pochesci, A | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX | 1 |
| Beijnen, JH; Burgers, JA; Huitema, AD; Lankheet, NA; Rosing, H; Schaake, EE; Schellens, JH | 1 |
| Chambers, CR; Sheikh, N | 1 |
| Guirgis, HM | 1 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Arakawa, K; Fukatsu, M; Kataoka, K; Katsuno, S; Kimura, T; Kondoh, Y; Nakamura, N; Nishiyama, O; Takashima, N; Taniguchi, H; Umemura, T; Watanabe, N | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Cioffi, P; Fanizza, C; Giglioni, A; Grappasonni, I; Marotta, V; Natoli, C; Petrelli, F | 1 |
| Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X | 1 |
| Baqir, W; Husband, A; Mahony, M; Todd, A; Williamson, S | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Barocelli, E; Bonelli, M; Carbognani, P; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Graiani, G; La Monica, S; Madeddu, D; Mozzoni, P; Mutti, A; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Hirashima, T; Kawase, I; Kitai, K; Morishita, N; Okamoto, N; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, M; Yamadori, T | 1 |
| Bailey, AS; Canepa, HM; Costa, DB; Goldstein, MA; Huberman, MS; Kobayashi, S; Nakayama, S; Yamaguchi, N | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Baik, CS; Chow, LQ; Eaton, KD; Pritchard, CC | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Chen, Z; Han, R; Sun, L; Wang, J; Wang, X; Zhang, J; Zhao, J; Zhong, D | 1 |
| Gridelli, C; Maione, P; Rossi, A | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M | 1 |
| Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Chen, Y; Sun, C; Zhang, X | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T | 1 |
| Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Gonzalez, D; Nicholson, AG; Nutting, CM; O'Brien, M; Popat, S; Wotherspoon, A | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Angelini, F; Bianchetti, S; Gamucci, T; Gemma, D; Grande, R; Mansueto, G; Narducci, F; Sperduti, I; Trombetta, G | 1 |
| Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Endo, H; Higashiyama, M; Imamura, F; Inoue, M; Kondo, J; Kumagai, T; Nishizawa, Y; Okami, J; Okuyama, H; Takehara, T; Uchida, J | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Bridge, S; Dharamshi, K; Jäkel, A; Johns, A; Modha, R; Plested, M | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Duyster, J; Kancha, RK; Kunst, PW; Reinten, RJ; van der Ven, WH; van Noesel, CJ; van Noesel, J; van Os, TA; Weegenaar, J | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Augustin, A; Avila, DW; Duchateau-Nguyen, G; Essioux, L; Golling, S; Hermann, JC; Klughammer, B; Lamerz, J; Langen, H; Meistermann, H; Scheiblich, S; Tzouros, M | 1 |
| Kuiper, JL; Smit, EF | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Fang, Z; Li, B; Zang, YS | 1 |
| Khan, I; Sarker, SJ; Whitehead, A | 1 |
| Sánchez De Cos Escuín, J | 1 |
| Couzin, J | 1 |
| Baselga, J; Hammond, LA | 1 |
| Tamura, T | 2 |
| Lorusso, PM | 1 |
| Muguruma, H; Sone, S; Yano, S | 2 |
| Herbst, RS | 1 |
| Bonomi, P | 2 |
| DeGrendele, H | 1 |
| Goldman, B | 1 |
| Bunn, PA; Herbst, RS | 1 |
| Gatzemeier, U | 1 |
| Hidalgo, M | 1 |
| Sandler, A | 2 |
| Soulières, D | 1 |
| Pérez-Soler, R | 5 |
| Averbuch, S; Blackledge, G | 1 |
| Fayette, J; Le Chevalier, T; Soria, JC | 1 |
| Belani, CP; Ramalingam, S | 1 |
| Langer, CJ | 2 |
| Thomas, M | 1 |
| Choy, H; Kim, DW | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Kobayashi, K | 1 |
| McNeil, C | 1 |
| Cheng, ZW; Gao, JM; Zhang, L | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Price, N; Reddy, GK | 1 |
| Bonomi, P; Chachoua, A; Clark, GM; Hammond, LA; Huberman, M; Karp, D; Pérez-Soler, R; Rigas, J; Rowinsky, EK; Santabárbara, P | 1 |
| Chocholska, S; Krawczyk, P; Milanowski, J | 1 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Vastag, B | 1 |
| Adjei, A; Belani, CP | 1 |
| Fuster, LM; Sandler, AB | 1 |
| Patel, JD | 1 |
| Belani, CP | 1 |
| Akita, H | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Twombly, R | 2 |
| Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Blumenschein, G; Carbone, DP; Eberhard, DA; Henderson, T; Herbst, RS; Hong, WK; Johnson, DH; Kelley, SK; Kim, ES; Lee, JJ; Liu, DD; Mass, R; Mininberg, E; Ramies, DA; Sandler, A; Seshagiri, S; Tran, H; Truong, MT; Tsao, A; Xie, D | 1 |
| Miller, VA; Pao, W | 1 |
| Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S | 1 |
| Edelman, MJ | 1 |
| Giaccone, G | 2 |
| Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Byrne, BJ; Garst, J | 1 |
| Costello, G; Holloway, B; Speake, G | 1 |
| Blackhall, FH; Rehman, S; Thatcher, N | 1 |
| Blackhall, F; Danson, S; Papakotoulas, PI; Thatcher, N | 1 |
| Buter, J; Giaccone, G | 2 |
| Dowell, J; Minna, JD | 1 |
| Haber, DA; Settleman, J | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Bezjak, A; Campos, D; Ciuleanu, T; Clark, G; Dediu, M; Findlay, B; Hirsh, V; Johnston, D; Maoleekoonpiroj, S; Martins, R; Rodrigues Pereira, J; Santabárbara, P; Seymour, L; Shepherd, FA; Smylie, M; Tan, EH; Thongprasert, S; Tu, D; van Kooten, M | 1 |
| Doroshow, JH | 1 |
| Cutz, JC; da Cunha Santos, G; Daneshmand, M; Ding, K; Kamel-Reid, S; Lagarde, A; Liu, N; Lorimer, I; Marrano, P; Pater, J; Richardson, F; Sakurada, A; Seymour, L; Shepherd, FA; Squire, J; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Ready, N | 1 |
| Friess, T; Hasmann, M; Scheuer, W | 1 |
| Gandara, DR; Gumerlock, PH | 1 |
| Amler, LC; Eberhard, DA; Goddard, AD; Heldens, SL; Herbst, RS; Hillan, KJ; Ince, WL; Jänne, PA; Januario, T; Johnson, BE; Johnson, DH; Klein, P; Miller, VA; Ostland, MA; Ramies, DA; Sebisanovic, D; Seshagiri, S; Stinson, JA; Zhang, YR | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Engelman, JA; Jänne, PA | 1 |
| Chen, YF; Cohen, MH; Johnson, JR; Pazdur, R; Sridhara, R | 1 |
| Comis, RL | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Harper, P; Spicer, J | 1 |
| Ganti, AK; Potti, A | 1 |
| Govindan, R; Pillot, G; Viswanathan, A | 1 |
| Benson, K; Booth, B; Chen, YF; Chidambaram, N; Cohen, M; Duan, J; Gobburu, J; Hsieh, LS; Johnson, JR; Leighton, J; Pazdur, R; Sridhara, R; Williams, GM; Zimmerman, P | 1 |
| Beijnen, JH; Schellens, JH; Siegel-Lakhai, WS | 1 |
| Leighl, NB; Nematollahi, M; Shepherd, FA; Tsao, WS; Zawisza, DL | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Brown, E; Buck, E; Gibson, N; Griffin, G; Haley, JD; Iwata, KK; Petti, F; Ramnarine, N; Thomson, S | 1 |
| Garfield, DH | 1 |
| Bitran, JD; Nabhan, C | 1 |
| Ladanyi, M; Miller, VA; Pao, W | 1 |
| Ohe, Y; Takano, T | 1 |
| D'Amico, TA | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Kris, M | 1 |
| Kabasawa, K; Kawasaki, N; Nakamura, H; Taguchi, M | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Apolone, G; Garattini, S; La Vecchia, C | 1 |
| Smith, J | 1 |
| Reddy, GK | 1 |
| Rivera, MP; Silvestri, GA | 1 |
| Garfield, D; Kashef, G | 1 |
| Cardiff, RD | 1 |
| Amler, LC; Cavet, G; Eberhard, DA; Fu, L; Januario, T; Lin, CY; Modrusan, Z; O'Neill, V; Pham, TQ; Seshagiri, S; Soriano, R; Stinson, J; Yauch, RL; Zhu, W | 1 |
| Chan, SK; Gullick, WJ; Hill, ME | 1 |
| Baldwin, PD; Lundberg, AS; Tammaro, KA | 1 |
| Boshoff, C; Falzon, M; Lai, CS; Lee, SM | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Journagan, S; Obadiah, J | 1 |
| Buttitta, F; Felicioni, L; Marchetti, A | 1 |
| Gatzemeier, U; Kranich, AL; Reck, M; Steinbach, AK | 1 |
| Polk, B | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Chuai, S; Kris, MG; Ladanyi, M; McDonough, T; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rusch, VW; Sarkaria, IS; Singh, B; Venkatraman, ES; Wilson, RK | 1 |
| Shepherd, FA; Tsao, MS | 1 |
| He, YM; Lai, RS; Shen, LS; Xie, L; Zhu, CL | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Reck, M | 2 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Dowell, JE; Minna, JD | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Garfield, D | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Goodin, S | 1 |
| Pérol, M | 1 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
| Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK | 1 |
| Mitra, SS; Simcock, R | 1 |
| Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C | 1 |
| Blackhall, F; Ranson, M; Thatcher, N | 1 |
| Cecere, F; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Arteaga, CL | 1 |
| von Eyben, FE | 1 |
| Sandler, AB | 1 |
| Bang, SI; Choi, YJ; Kim, DK; Kim, JH; Kim, MH; Nam, DH; Nam, SJ; Son, MJ; Song, HS; Yang, JH | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Ramalingam, S; Sandler, AB | 1 |
| Gadgeel, SM | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Clark, GM; Ding, K; Santabarbara, P; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Costa, DB; Huberman, MS | 1 |
| Glatt, KA; Greulich, H; Ji, H; Lowell, AM; Meyerson, M; Minami, Y; Shah, K; Shapiro, GI; Shimamura, T; Thomas, RK; Wong, KK | 1 |
| Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY | 1 |
| Cozzani, E; Parodi, A; Santoro, F | 1 |
| Herbst, R; Sandler, A | 1 |
| Amler, LC; Goddard, AD; Hillan, KJ | 1 |
| Bach, JP; Faoro, C; Gorg, C; Kiessling, AM; Kleinhans, A; Neubauer, A; Riera-Knorrenschild, J; Schwella, N; Wagner, HJ | 1 |
| Azzoli, CG; Dunne, M; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Rizvi, NA; Venkatraman, E | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M | 1 |
| Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK | 1 |
| Ali, MA; Cao, C; Choy, H; Kim, JC; Mukhopadhyay, P; Nandi, A; Saha, D | 1 |
| Gerdes, S; Mrowietz, U | 1 |
| Hong, WK; Kim, ES; Lee, HY; Morgillo, F; Woo, JK | 1 |
| Ahmed, SM; Salgia, R | 1 |
| Kato, T; Nishio, K | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Bunn, PA | 2 |
| Gallegos Ruiz, M; Giaccone, G; Janne, P; Le Chevalier, T; Oulid-Aissa, D; Rodriguez, JA; Smit, E; Soria, JC; Thatcher, N | 1 |
| Adamoli, L; Catania, C; De Pas, TM; Goldhirsch, A; Manzotti, M; Nolè, F; Pelosi, G | 1 |
| Vansteenkiste, J | 1 |
| Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF | 1 |
| Pao, W | 1 |
| Balko, JM; Black, EP; Haura, EB; Potti, A; Saunders, C; Stromberg, A | 1 |
| Döme, B; Ostoros, G | 1 |
| Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F | 1 |
| Pujol, JL | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H | 1 |
| Borras, AM; Fidias, P; Freidlin, B; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, NI; Lucca, J; Lynch, TJ; Meyerson, M; Ostler, PA; Rabin, MS; Skarin, AT; Temel, J; Yeap, BY | 1 |
| Grenier, J; Soria, JC | 1 |
| Chou, LS; Garey, J; Kim, E; Oishi, K | 1 |
| Achille, M; Gallegos-Ruiz, M; Giaccone, G; Soria, JC | 1 |
| Guitart, J; Lacouture, ME; Lai, SE; Luu, M; Patel, J | 1 |
| Akita, RW; Schaefer, G; Shao, L; Totpal, K | 1 |
| Fidias, P; Haber, DA; Jänne, PA; Johnson, BE; Joshi, VA; Kucherlapati, R; Lynch, TJ; Meyerson, M; Muzikansky, A; Sequist, LV | 1 |
| Bell, DW; Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| van de Vijver, MJ; van Zandwijk, N | 1 |
| Serke, M | 1 |
| Gabizon, A; Gipps, M; Grenader, T; Shavit, L | 1 |
| Evans, WK; Feld, R; Mackay, JA; Shepherd, FA; Sridhar, SS | 1 |
| Bedano, PM; Hanna, NH | 1 |
| Clark, GM; Culbertson, JL; Savoie, M; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Carser, JE; Summers, YJ | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Galetta, D; Gridelli, C; Maione, P; Rossi, A | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Ho, C; Lara, PN; Lau, DH | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Chowbay, B; Goh, JW; Lee, P; Mancer, K; Tan, PH; Toh, CK | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R; Weber, TK; Yuan, Z | 1 |
| Bergot, E; Richard, N; Zalcman, G | 1 |
| Esmaili, A; Vahid, B | 1 |
| Fujisaka, Y; Horiike, A; Murakami, H; Shimoyama, T; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Chen, TH; Feng, W; Glatt, KA; Greulich, H; Ji, H; Jiang, J; Lee, JC; Meyerson, M; Minami, Y; Shapiro, G; Shimamura, T; Wong, KK; Woo, MS; Yanagisawa, H; Yuza, Y | 1 |
| Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC | 1 |
| Bragg, J; Pomeranz, MK | 1 |
| Hwang, C; Lacouture, ME; Marymont, MH; Patel, J | 1 |
| Dancey, JE | 1 |
| Goldman, ID; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY | 1 |
| Paz-Ares, L; Rosell, R; Sanchez, JJ; Taron, M | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Di Todaro, F; Gaudenzi, P; Manfredini, R; Morandi, P; Nielsen, I; Salmi, R | 1 |
| Costa, DB | 1 |
| Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Brahmer, J; Juergens, R | 1 |
| Calhoun, R; Gandara, DR; Jablons, D; Wakelee, H | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Argiris, A; Grandis, JR; Karamouzis, MV | 1 |
| Araujo, N; Armand, JP; de La Motte Rouge, T; Dessen, P; Galluzzi, L; Harel-Belan, A; Harper, F; Kroemer, G; Lazar, V; Olaussen, KA; Pierron, G; Pinna, G; Ripoche, H; Robert, T; Soria, JC; Tasdemir, E; Wong, TW; Zermati, Y | 1 |
| Chang, JW; Cheung, YC; Chou, CL; Hsieh, JJ; Hsu, T; Huang, SF; Wang, HM | 1 |
| Jänne, PA; Liu, W; Makrauer, FL; Odze, RD; Qamar, AA | 1 |
| Brahmer, JR; Hann, CL | 1 |
| Chan, G; Pilichowska, M | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Jackman, D; Jänne, PA; Johnson, BE | 1 |
| Bareschino, MA; Ciardiello, F; Gridelli, C; Maione, P; Rossi, A; Schettino, C | 1 |
| Balikó, Z; Sárosi, V | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Davies, AM; Lara, PN | 1 |
| Davies, A; Gandara, D; Ho, C; Mack, P | 1 |
| Carrión, RP; Gracián, AC; Hernandez, PS | 1 |
| Brun, L; Colin, G; Copin, MC; Lafitte, JJ; Makris, D; Marquette, CH; Scherpereel, A | 1 |
| Thatcher, N | 1 |
| Al Hammadi, A; Gerstein, W; Tangri, N | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Huang, MY; Huang, YJ; Liu, SF; Wang, CJ | 1 |
| Long, J; Thotathil, Z | 1 |
| Azzoli, CG; Ginsberg, MS; Kris, MG; Liu, V; Miller, VA; Travis, W; White, DA; Zakowski, MF | 1 |
| de Gunst, MM; Gallegos-Ruiz, MI; Giaccone, G; Rodriguez, JA | 1 |
| Hirsch, FR | 1 |
| Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM | 1 |
| Pan, M; Santamaria, M; Wollman, DB | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Moldvay, J | 1 |
| Balak, M; Chmielecki, J; Gong, Y; Jiang, X; Pao, W; Politi, K; Somwar, R | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Besse, B; Italiano, A; Planchard, D; Soria, JC | 1 |
| Fekrazad, MH; Jones, DV; Ravindranathan, M | 1 |
| Schalock, PC; Zug, KA | 1 |
| Conklin, E; Dwyer-Nield, LD; Eckhardt, SG; Fritz, JM; Gustafson, DL; Iwata, KK; Kane, S; Malkinson, AM; Redente, EF; Shroyer, RJ; Tucker, C; Zerbe, LK | 1 |
| Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A | 1 |
| Amoroso, D; Baldari, M; Bearz, A; Bettoli, V; Cammilluzzi, E; Crinò, L; De Marinis, F; Di Pietro, FA; Gridelli, C; Grossi, F; Innocenzi, D; Maione, P; Micali, G; Piantedosi, FV; Scartozzi, M | 1 |
| Cai, D; Carlson, NE; Deng, J; Letai, A; Perera, S; Shapiro, GI; Shimamura, T; Wong, KK | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST | 1 |
| Balak, M; Bean, J; Brennan, C; Broderick, S; Chang, WC; Chitale, D; Gazdar, A; Gerald, W; Huang, SF; Ladanyi, M; Miller, V; Motoi, N; Pao, W; Pass, H; Riely, G; Rusch, V; Shih, JY; Szoke, J; Viale, A; Wang, L; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Knabl, A | 1 |
| Dizdar, O; Gököz, O; Yalçin, B; Yalçin, S | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B | 1 |
| Danesi, R; Giaccone, G; Giovannetti, E; Lemos, C; Nannizzi, S; Peters, GJ; Ricciardi, S; Rodriguez, JA; Smid, K; Tekle, C | 1 |
| Miller, VA | 1 |
| Costa, DB; Kobayashi, S | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Belani, C; Ramalingam, S | 1 |
| de Marinis, F; Grossi, F | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Curiel, DT; Dent, P; Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J | 1 |
| Ding, K; Pater, J; Seymour, L; Shepherd, FA; Whitehead, M | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Gipps, M; Goldberg, A; Grenader, T | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Dohadwala, M; Dubinett, SM; Elashoff, D; Figlin, RA; Gardner, BK; Inge, L; Krysan, K; Mao, J; Rajasekaran, A; Reckamp, KL; Sharma, S | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG | 1 |
| Fong, T; Govindan, R; Morgensztern, D | 1 |
| Brueckl, WM; Hahn, EG; Murray, S; Schoeberl, A; Wiest, GH; Wirtz, RM | 1 |
| Stewart, DJ | 1 |
| Gerber, PA; Homey, B | 1 |
| Carbone, DP; Heelan, RT; Heller, G; Herbst, RS; Johnson, DH; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Patel, JD; Riely, GJ; Sandler, AB; Tsao, A; Zakowski, MF | 1 |
| Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Shih, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Argiris, A; Basu, S; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; Johnson, DH; Kaiser, K; Patel, JD; Sandler, A; Villaflor, VM | 1 |
| Chalfe, N; Plestina, S; Samarzija, M; Zuljević, E | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Toschi, L; Trisolini, R | 1 |
| McDermott, U; Settleman, J; Sharma, SV | 1 |
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Chen, LK; Huang, H; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Chang, GC; Chang, WC; Chen, CH; Chen, HC; Chen, YM; Chu, NM; Chung, CY; Ho, ML; Hsia, TC; Hsieh, RK; Huang, MS; Kao, WY; Kuo, HP; Lai, RS; Lin, MC; Lin, ZZ; Perng, RP; Su, WC; Tsao, CJ; Wang, JL; Yang, CH; Yu, CJ; Yu, CT | 1 |
| Hainsworth, JD; Lin, M; O'Neill, V; Spigel, DR | 1 |
| Lazzari, G; Lovecchio, M; Palazzo, C; Silvano, G | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Cruz Hernández, JJ; Delgado Fernández, C; Mezquita Pérez, L; Navarro Martín, M; Rodríguez Sánchez, C | 1 |
| Clark, GM; Ding, K; Seymour, L; Shepherd, FA; Wheatley-Price, P | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Black, CC; Dmitrovsky, E; Gribble, GW; Honda, T; Lamph, WW; Liby, K; Liu, X; Risingsong, R; Royce, DB; Sporn, MB; Sporn, TA; Williams, CR; Yore, MM | 1 |
| Buhl, R; Fischer, B | 1 |
| Buchler, T; Joseph, T; Lai, C; Lee, SM | 1 |
| Akita, H; Kinoshita, I | 1 |
| Albanell, J; Baselga, J | 1 |
351 review(s) available for erlotinib hydrochloride and Lung Neoplasms
| Article | Year |
|---|---|
REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Treatment Outcome | 2021 |
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Topics: Adenocarcinoma of Lung; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Erlotinib plus bevacizumab versus erlotinib alone in patients with
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2022 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; HIV Infections; Humans; Lung Neoplasms; Male | 2023 |
EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2023 |
The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Prospective Studies; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2023 |
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
Topics: Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2023 |
Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Characterising acquired resistance to erlotinib in non-small cell lung cancer patients.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; DNA Repair; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Neutropenia; Odds Ratio; Patient Safety; Progression-Free Survival; Protein Kinase Inhibitors | 2019 |
Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Progression-Free Survival; Pyrrolidinones; Quinolines; Randomized Controlled Trials as Topic | 2020 |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors | 2020 |
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Digestive System Diseases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye; Eye Diseases; Female; Gastrointestinal Tract; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors | 2020 |
Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Male; Meningeal Neoplasms; Mutation; Patents as Topic; Progression-Free Survival; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinolines | 2021 |
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; United States | 2021 |
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Topics: Acrylamides; Administration, Oral; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Randomized Controlled Trials as Topic | 2021 |
Efficacy and safety of anti-angiogenic drugs combined with erlotinib in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2021 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
Topics: Biopsy; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Response Evaluation Criteria in Solid Tumors; Salvage Therapy | 2021 |
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2017 |
Overview of current systemic management of EGFR-mutant NSCLC.
Topics: Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Molecular Targeted Therapy; Mucositis; Paronychia; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2018 |
Imaging on Lung Cancer and Treatment with Targeted Therapy.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arginine Vasopressin; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mutation; Tomography, X-Ray Computed | 2018 |
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non-small cell lung cancer: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Progression-Free Survival | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2018 |
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Economics, Pharmaceutical; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2019 |
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction | 2019 |
Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Disease-Free Survival; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolinones | 2019 |
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines | 2013 |
Erlotinib in the first-line treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Lung cancer in 2013: state of the art therapy for metastatic disease.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Maintenance Chemotherapy; Molecular Targeted Therapy; Pemetrexed; Receptor Protein-Tyrosine Kinases; Taxoids | 2013 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Targeted therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pyrazoles; Pyridines; Quinazolines | 2013 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
[Hemolytic anemia under erlotinib treatment].
Topics: Aged, 80 and over; Anemia, Hemolytic; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
[New developments in treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Imaging; Quinazolines | 2013 |
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis | 2014 |
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Erlotinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2014 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Proteomics; Quinazolines | 2014 |
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography Scanners, X-Ray Computed | 2014 |
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines | 2014 |
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve | 2014 |
Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Eyelid Diseases; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma | 2014 |
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2014 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Platinum Compounds; Quinazolines | 2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Stomatitis | 2015 |
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines | 2015 |
EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Experience with erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2015 |
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Smoking; Treatment Outcome; Young Adult | 2015 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Leukopenia; Lung Neoplasms; Neutropenia; Protein Kinase Inhibitors; Risk Factors | 2015 |
A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking | 2015 |
The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Smoking; Treatment Outcome | 2016 |
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Palliative Care; Radiation Pneumonitis; Tomography, X-Ray Computed | 2016 |
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Retrospective Studies | 2016 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Middle Aged; Native Hawaiian or Other Pacific Islander; Neoplasm Staging; Smoking; Survival Analysis | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Intestinal Perforation; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Radiography, Thoracic; Stomach Diseases; Tomography, X-Ray Computed | 2016 |
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Ramucirumab; Taxoids | 2017 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall Survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Quinazolines | 2017 |
Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Dosage Calculations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
New insights in drug development for the non-small cell lung cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2008 |
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Medical Oncology; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Management of targeted molecular therapies toxicities in thoracic cancerology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Delivery Systems; Erlotinib Hydrochloride; France; Humans; Lung Neoplasms; Palliative Care; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2008 |
[Targeted therapies for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Gene Targeting; Humans; Lung Neoplasms; Patient Selection; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2008 |
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2008 |
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids | 2009 |
Predictive biomarkers for EGFR therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines | 2009 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Economics of treatments for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2009 |
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bias; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids; Young Adult | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Platinum Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Investigational agents in the management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphoma; Male; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Survival Rate | 2009 |
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Growth Factor; Sequence Deletion; Treatment Outcome | 2009 |
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking; Smoking Cessation | 2010 |
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2010 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Molecular diagnostics in lung carcinoma for therapy stratification].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
Topics: Animals; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Small Cell Lung Carcinoma; Structure-Activity Relationship | 2010 |
[KRAS status versus EGFR status in lung cancer therapy].
Topics: DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2009 |
Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Topics: Adenocarcinoma; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Topics: BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Clinical Trials, Phase II as Topic; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Histone Chaperones; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Nuclear Proteins; Quinazolines; RNA, Messenger | 2010 |
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Time Factors | 2010 |
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Discovery; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance chemotherapy in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2010 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
[EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; White People | 2011 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
[Consolidation therapy in advanced non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Prognosis; Quinazolines; Risk Assessment | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Reviewing the safety of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2011 |
[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR pathway in advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2011 |
[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quinazolines; Salvage Therapy | 2011 |
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2011 |
[Adverse effects of new biological therapies for non-small-cell bronchial cancer].
Topics: Angiogenesis Inhibitors; Biological Products; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Interdisciplinary Communication; Lung Neoplasms; Neoplasm Staging; Patient Care Team; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2011 |
[A simple view on lung cancer biology: The EGFR pathway].
Topics: Adenocarcinoma; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance | 2011 |
[Indication of EGFR kinase inhibitors should be refined].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2011 |
Tissue sampling in lung cancer: a review in light of the MERIT experience.
Topics: Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Practice Guidelines as Topic; Precision Medicine; Quinazolines; Tissue and Organ Harvesting; Tissue Array Analysis | 2011 |
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor | 2011 |
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Quinazolines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2012 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2011 |
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 2011 |
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2012 |
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2012 |
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Targeted therapy for lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2012 |
Clinical and economic review of erlotinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Taxoids | 2013 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
[Molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; Cetuximab; Clinical Trials as Topic; Depression, Chemical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines | 2003 |
Erlotinib (Tarceva): an update on the clinical trial program.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2003 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Tumor Cells, Cultured | 2003 |
[Non-small cell lung cancer: 1) Molecular-target therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: preclinical investigations.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transplantation, Heterologous | 2003 |
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Patient Selection; Predictive Value of Tests; Quinazolines | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Therapeutic implications of epidermal growth factor receptor in lung cancer].
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2004 |
[Lung cancer: molecular targeting therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gene Targeting; Genetic Therapy; Humans; Imatinib Mesylate; Indoles; Lung Neoplasms; Piperazines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Trastuzumab | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
[New advance of the molecular targeting agents in advanced non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lung Neoplasms; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4; Trastuzumab | 2003 |
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2004 |
Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Metaphor; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Recent developments related to the EGFR as a target for cancer chemotherapy.
Topics: Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in non-small cell lung cancer: a review.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2005 |
Perspectives on novel therapies for bronchial carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A | 2005 |
Medical treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib hydrochloride.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Factors predicting response to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines | 2005 |
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2005 |
Targeted therapies for non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2005 |
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Survival Analysis | 2006 |
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genetic Therapy; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
EGFR inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines; Treatment Failure | 2005 |
[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines; Survival Rate | 2005 |
[Erlotinib. A new option for non-small cell lung cancer].
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Targeting HER1/EGFR in cancer therapy: experience with erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
Where next for gefitinib in patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
Predicting the outcome of chemotherapy for lung cancer.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Mutation; Nuclear Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Smoking; Thioredoxins; Treatment Outcome; Y-Box-Binding Protein 1 | 2006 |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction | 2006 |
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Denmark; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Structure, Tertiary; Quinazolines; Signal Transduction | 2006 |
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Topics: Antineoplastic Agents; Biological Products; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Protein Kinase Inhibitors; Quinazolines | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Synergism; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Vascular Endothelial Growth Factor A | 2006 |
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Smoking | 2005 |
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Topics: Antineoplastic Agents; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Second-line therapeutic options in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Defining clinically relevant molecular subsets of lung cancer.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Erlotinib in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2007 |
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Salvage therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
[New biological treatments for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biopsy; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Mutation; Patient Selection; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.
Topics: Bronchoscopy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Ultrasonography | 2007 |
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Medical Oncology; Mutation; Quinazolines; ras Proteins; Smoking | 2007 |
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Bevacizumab in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Erlotinib in non-small cell lung cancer treatment: current status and future development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines; Treatment Outcome | 2007 |
The place of targeted therapy in the patient management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
Erlotinib in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2007 |
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Considerations for second-line therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Quinazolines; Trastuzumab; Treatment Outcome | 2006 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
[Non-small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Advances in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Targeting epidermal growth factor receptor in lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2002 |
464 trial(s) available for erlotinib hydrochloride and Lung Neoplasms
| Article | Year |
|---|---|
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2022 |
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Ramucirumab | 2022 |
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Ramucirumab | 2022 |
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Retrospective Studies | 2022 |
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors | 2022 |
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypertension; Lung Neoplasms; Mutation; Ramucirumab | 2022 |
Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
Topics: Afatinib; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; ErbB Receptors; Erlotinib Hydrochloride; Esomeprazole; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors | 2022 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Ramucirumab; Tumor Suppressor Protein p53 | 2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dermatitis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Ramucirumab | 2023 |
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Ramucirumab | 2023 |
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras) | 2023 |
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Progression-Free Survival; Survival Rate | 2019 |
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
Topics: Adenocarcinoma of Lung; Aged; Aged, 80 and over; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Predictive Value of Tests; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Ramucirumab; Survival Rate | 2019 |
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2020 |
Overall Survival with Osimertinib in Untreated,
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors | 2020 |
Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Protein Kinase Inhibitors | 2020 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Frail Elderly; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Pleural Effusion, Malignant; Pleurodesis; Prognosis; Survival Rate | 2020 |
Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
Topics: Aged; Animals; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Drug Interactions; Erlotinib Hydrochloride; Esomeprazole; Female; Humans; Lung Neoplasms; Male; Middle Aged; Milk; Proton Pump Inhibitors | 2021 |
Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors | 2020 |
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Naphthoquinones; Prognosis; Protein Kinase Inhibitors; Survivin | 2020 |
Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life | 2020 |
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Patient Reported Outcome Measures; Progression-Free Survival; Proportional Hazards Models; Quality of Life; Ramucirumab | 2020 |
Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male | 2021 |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genes, erbB-1; Hong Kong; Humans; Injections, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Republic of Korea; Taiwan; Treatment Outcome | 2020 |
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quality-Adjusted Life Years; Ramucirumab | 2020 |
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; China; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2021 |
Clinical trial evaluating efficacy and safety of pemetrexed based chemotherapy regimen versus ramucirumab plus erlotinib in Chinese patients with lung cancer: A preliminary investigation.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Ramucirumab; Time Factors | 2020 |
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Response Evaluation Criteria in Solid Tumors; Survival Rate; United States; Young Adult | 2021 |
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
Topics: Aged; Benzamides; California; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Isoindoles; Lactates; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies | 2021 |
The Influence of Intervening on the Pharmaceutical Consultation Targeting Outpatients with Advanced Non-small Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Ambulatory Care; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Therapy Management; Middle Aged; Pharmacists; Professional Role; Referral and Consultation; Retrospective Studies | 2021 |
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Topics: Acrylamides; Aged; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ramucirumab | 2021 |
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Ramucirumab | 2021 |
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Ramucirumab | 2021 |
Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quality of Life | 2021 |
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Random Allocation; Survival Analysis; Treatment Outcome | 2021 |
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Japan; Lung Neoplasms; Quality of Life; Survival Analysis | 2022 |
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyridines; Treatment Outcome | 2017 |
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intention to Treat Analysis; International Cooperation; Lung Neoplasms; Male; Middle Aged; Mutation; Proof of Concept Study; Response Evaluation Criteria in Solid Tumors | 2017 |
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Antineoplastic Agents; Caffeine; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Dried Blood Spot Testing; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Midazolam; Middle Aged; Models, Biological; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Prospective Studies; Protein Kinase Inhibitors; Substrate Specificity; Tandem Mass Spectrometry; Treatment Outcome | 2017 |
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome | 2017 |
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Evaluation of the VeriStrat
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Hematologic Tests; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis; Treatment Outcome | 2017 |
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Reported Outcome Measures; Platinum Compounds; Quality of Life; Survival Analysis | 2018 |
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Platinum Compounds; Pyrazines; Receptors, Somatomedin | 2017 |
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cigarette Smoking; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged | 2017 |
Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinacrine | 2018 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2018 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Fatigue; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pyrrolidinones; Quinolines | 2018 |
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Ramucirumab; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines; Survival Analysis; Treatment Outcome | 2018 |
[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Humans; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Pemetrexed; Protein Kinase Inhibitors | 2018 |
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Progression-Free Survival; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2018 |
OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Massachusetts; Protein Kinase Inhibitors; Quinazolines | 2018 |
Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Survival Rate; Treatment Outcome | 2018 |
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; Follow-Up Studies; Genetic Testing; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Treatment Outcome; White People | 2018 |
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab | 2018 |
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; United States | 2018 |
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Topics: Afatinib; Aged; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2018 |
Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Lung Neoplasms; Male; Proton Pump Inhibitors; Retrospective Studies | 2018 |
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Young Adult | 2018 |
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Pyrrolidinones; Quinolines; Reagent Kits, Diagnostic; Retrospective Studies; Young Adult | 2019 |
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors | 2019 |
First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-met; Survival Rate | 2019 |
Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Survival Rate | 2019 |
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Radiosurgery; Survival Rate | 2019 |
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cross-Over Studies; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2019 |
Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Drug Interactions; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinine; Sex Factors | 2019 |
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pemetrexed; Platinum; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2019 |
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Signal Transduction; Time Factors | 2019 |
Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonia; Progression-Free Survival; Protein Kinase Inhibitors; Radiation Injuries | 2019 |
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Survival Rate | 2019 |
Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Topics: Adenocarcinoma; Adult; Aged; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Up-Regulation | 2013 |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Treatment Outcome | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9 | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Quinazolines | 2013 |
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Quinazolines; Retreatment; Risk Factors; Treatment Outcome | 2013 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2013 |
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2013 |
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2013 |
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Vinblastine | 2014 |
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cyclic N-Oxides; Cyclin-Dependent Kinases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indolizines; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pyridinium Compounds; Quinazolines | 2014 |
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Glutamates; Guanine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Quinazolinones; Treatment Failure | 2014 |
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiography; Radiopharmaceuticals; Survival Rate; Time Factors | 2014 |
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2015 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat | 2014 |
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Treatment Outcome | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biotin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chromogranins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oligonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9; Treatment Outcome | 2014 |
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Furans; Humans; Ketones; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2014 |
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Topics: Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Proportional Hazards Models; Quinazolines; Taxoids; Treatment Outcome | 2014 |
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Remission Induction; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Genes, erbB-1; Genes, ras; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2014 |
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Iohexol; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Treatment Outcome; Tumor Burden | 2014 |
Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cranial Irradiation; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recovery of Function; Treatment Outcome | 2014 |
Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neutropenia; Pemetrexed; Quinazolines; Thrombocytopenia; Treatment Outcome | 2013 |
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United States; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Maximum Tolerated Dose; src-Family Kinases; Treatment Outcome | 2014 |
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Carcinoma, Non-Small-Cell Lung; Cooking; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Inhalation Exposure; Life Style; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Disease-Free Survival; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Treatment Outcome; Young Adult | 2015 |
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retreatment; Treatment Outcome | 2014 |
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Treatment Outcome | 2014 |
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Colorado; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Risk Factors; Texas; Time Factors; Treatment Outcome | 2014 |
Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2015 |
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 2015 |
Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2015 |
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China; Deoxycytidine; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Thymidine Phosphorylase; Treatment Outcome | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome | 2015 |
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Tri
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Safety; Treatment Outcome; Withholding Treatment | 2015 |
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Incidence; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Tandem Mass Spectrometry; Time Factors; Tissue Distribution | 2015 |
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Asian People; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proto-Oncogene Proteins c-met; Treatment Outcome | 2015 |
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome | 2015 |
[Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, erbB-1; Humans; Intercalating Agents; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum Compounds; Treatment Outcome | 2015 |
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Survival Rate | 2015 |
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome | 2015 |
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Retrospective Studies; Time-to-Treatment; Treatment Failure | 2015 |
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Broadly Neutralizing Antibodies; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Receptor, ErbB-3; Treatment Outcome; Young Adult | 2015 |
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Cross-Over Studies; Erlotinib Hydrochloride; Fasting; Female; Food-Drug Interactions; Humans; Lung Neoplasms; Male; Middle Aged; Postprandial Period; Protein Kinase Inhibitors; Quinazolines | 2015 |
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Dinoprostone; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models | 2015 |
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Disease Progression; Disease-Free Survival; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Ointments; Pancreatic Neoplasms; Protein Kinase Inhibitors; Republic of Korea; Treatment Outcome | 2016 |
A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Outcome | 2015 |
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
[Oligoprogression].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure | 2015 |
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Broadly Neutralizing Antibodies; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neuregulin-1; Prospective Studies; Receptor, ErbB-3; Retrospective Studies; Translational Research, Biomedical; Treatment Outcome | 2015 |
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality-Adjusted Life Years | 2015 |
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinolones; Receptors, Vascular Endothelial Growth Factor; Retreatment; Treatment Outcome | 2015 |
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Survival Rate | 2015 |
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrrolidinones; Quinazolines; Quinolines; Young Adult | 2015 |
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Electroretinography; Erlotinib Hydrochloride; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lung Neoplasms; Male; Middle Aged; Retina; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Visual Field Tests; Visual Fields | 2015 |
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Rate; Taxoids | 2015 |
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Erysipelas; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2015 |
"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Forced Expiratory Volume; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Nicotinic Agonists; Respiratory Function Tests; Smoking; Smoking Cessation; Treatment Outcome; Varenicline | 2015 |
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Models, Theoretical; Protein Kinase Inhibitors | 2015 |
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 2015 |
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2015 |
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Treatment Outcome; Young Adult | 2015 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides | 2015 |
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutati
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Palliative Care; Prognosis; Proto-Oncogene Proteins p21(ras); Salvage Therapy; Survival Rate; Young Adult | 2016 |
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Depsipeptides; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2015 |
Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Steroids; Survival Rate; Young Adult | 2016 |
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Minocycline; Prospective Studies; Protein Kinase Inhibitors | 2016 |
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).
Topics: 3' Untranslated Regions; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; ras Proteins; Taxoids | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
Topics: Adolescent; Amino Acid Sequence; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; ErbB Receptors; Erlotinib Hydrochloride; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Neuregulin-1; Phosphorylation; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, ErbB-2; Receptor, ErbB-3; Tomography, X-Ray Computed | 2016 |
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors | 2016 |
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proteomics | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolinones | 2016 |
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Somatomedin; Young Adult | 2016 |
Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Carbonated Beverages; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Drug Monitoring; Erlotinib Hydrochloride; Esomeprazole; Female; Food-Drug Interactions; Gastrointestinal Absorption; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Male; Middle Aged; Netherlands; Protein Kinase Inhibitors; Proton Pump Inhibitors | 2016 |
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome | 2016 |
Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Male; Observer Variation; Positron-Emission Tomography; Radiography, Thoracic; Reproducibility of Results | 2016 |
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Europe; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quality-Adjusted Life Years | 2016 |
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erloti
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Doxycycline; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2016 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome | 2016 |
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins p21(ras); Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2016 |
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quality of Life; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
[Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?]
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Precision Medicine; Predictive Value of Tests; Research Design; Treatment Outcome | 2016 |
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2016 |
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors | 2016 |
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Prospective Studies; Protein Kinase Inhibitors | 2016 |
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2016 |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Treatment Outcome | 2016 |
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Retreatment; Smokers; Treatment Outcome | 2016 |
A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Pyrazoles; Pyrimidines; Survival Rate | 2017 |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Disease-Free Survival; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Research Design; Treatment Outcome | 2017 |
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate | 2017 |
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Papillary; Crizotinib; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazoles; Pyridines; Survival Rate; Tissue Distribution | 2017 |
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Body Height; Body Mass Index; Body Weight; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors | 2017 |
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Topics: Aged; Anilides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines | 2016 |
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Ramucirumab; Research Design; Young Adult | 2017 |
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate | 2017 |
Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Smoking; Taxoids | 2016 |
An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2017 |
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Young Adult | 2017 |
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds | 2016 |
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Taxoids | 2017 |
Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Prognosis; Sex Factors; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2017 |
A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Pemetrexed; Prospective Studies; Treatment Outcome | 2016 |
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation, Missense; Pulse Therapy, Drug | 2017 |
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2017 |
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Broadly Neutralizing Antibodies; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-3 | 2017 |
Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neuregulin-1; Survival Analysis; Treatment Outcome | 2017 |
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Ontario; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors | 2008 |
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Ethnicity; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Time Factors; Treatment Outcome | 2008 |
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Erlotinib Hydrochloride; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2008 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Environmental Exposure; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Particulate Matter; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines | 2008 |
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Smoking; Treatment Outcome | 2009 |
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Germany; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2008 |
Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.
Topics: Aged; Bosnia and Herzegovina; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy | 2008 |
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2009 |
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2009 |
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure; Treatment Outcome | 2009 |
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Prognosis; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2009 |
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Transforming Growth Factor alpha; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Treatment Failure | 2010 |
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2009 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; STAT3 Transcription Factor | 2009 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis | 2010 |
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines | 2010 |
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Time Factors | 2011 |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Quinazolines | 2010 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival; Treatment Outcome | 2011 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors | 2010 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients].
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2010 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome | 2010 |
[Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2010 |
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2010 |
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome | 2011 |
Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sex Characteristics; Survival Rate; Treatment Outcome | 2011 |
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay | 2010 |
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Research Design; Southwestern United States; Treatment Outcome | 2010 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Quinazolines | 2010 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Heptanoic Acids; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2011 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines | 2011 |
Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Demography; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Radiography; Radionuclide Imaging; Smoking; Time Factors; Treatment Outcome | 2011 |
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mu
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Genes, ras; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Survival Rate; Taxoids; Treatment Outcome | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Japan; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Research Design; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2011 |
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2012 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Growth Factor; Survival Analysis | 2011 |
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Vimentin | 2011 |
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2011 |
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Guidelines as Topic; Health Care Costs; Humans; Lung Neoplasms; Models, Economic; Platinum; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2011 |
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2011 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Receptor, IGF Type 1 | 2011 |
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2012 |
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines | 2012 |
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Retrospective Studies; Treatment Outcome | 2012 |
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Docetaxel; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Time Factors | 2012 |
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Research Design; Salvage Therapy; Survival Rate | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2012 |
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Quinazolines | 2012 |
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines; Quinazolines | 2012 |
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States | 2012 |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Smoking | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2012 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Frail Elderly; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2013 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2012 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome | 2012 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Esophagitis; Esophagus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy, Conformal; Remission Induction; Tracheoesophageal Fistula; Treatment Failure | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate | 2012 |
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Po
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis | 2012 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2012 |
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2013 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2012 |
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis | 2013 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Emollients; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymecycline; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Skin; Sunscreening Agents; Treatment Outcome | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2001 |
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis | 2005 |
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
FDA drug approval summary: erlotinib (Tarceva) tablets.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Topics: Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Failure; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost of Illness; ErbB Receptors; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome | 2006 |
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Aged; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis | 2006 |
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2006 |
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Tablets | 2006 |
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Vinblastine; Vinorelbine | 2007 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Topics: Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Half-Life; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 2008 |
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemokines, CC; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Matrix Metalloproteinase 9; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1 | 2008 |
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2008 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Peptic Ulcer; Predictive Value of Tests; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
[Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Salvage Therapy; Sex Factors; Smoking; Taiwan | 2008 |
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Female; Humans; In Vitro Techniques; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis | 2008 |
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies | 2008 |
1641 other study(ies) available for erlotinib hydrochloride and Lung Neoplasms
| Article | Year |
|---|---|
Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Fusion; High-Throughput Nucleotide Sequencing; Humans; Injections, Spinal; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Metastasis; Pemetrexed; Septins | 2022 |
Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer.
Topics: Aged; Biopsy; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Cardiotoxicity; Disease Progression; Dyspnea; Erlotinib Hydrochloride; Female; Follow-Up Studies; Heart Failure; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors | 2021 |
Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC.
Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Humans; Hydrazones; Lung Neoplasms; Models, Molecular; Mycobacterium tuberculosis; Quinazolines; Structure-Activity Relationship; Tuberculosis | 2021 |
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
Topics: Afatinib; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Membrane Glycoproteins; Methyltransferases; Mice; Mice, Nude; Nerve Tissue Proteins; Receptors, Notch; RNA, Long Noncoding; Signal Transduction | 2021 |
An intelligent hypoxia-relieving chitosan-based nanoplatform for enhanced targeted chemo-sonodynamic combination therapy on lung cancer.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chitosan; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy | 2021 |
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Drug Therapy; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2021 |
Nano-Particulated Erlotinib Compound System in Alleviation of Lung Cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Nanoparticles; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer | 2021 |
Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Down-Regulation; Erlotinib Hydrochloride; Fluorouracil; Humans; Lung Neoplasms; Neoplasms, Squamous Cell; p38 Mitogen-Activated Protein Kinases; Rad52 DNA Repair and Recombination Protein | 2021 |
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Topics: Acrylamides; Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Failure | 2021 |
Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
Topics: Afatinib; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Iron Compounds; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Triazoles | 2022 |
Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Topics: Acrylamides; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors | 2021 |
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Eosinophilia; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
Topics: Binding Sites; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Docking Simulation; Oligopeptides; Protein Domains; Protein Kinase Inhibitors; Thermodynamics | 2022 |
Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Progesterone receptor membrane component 2 expression leads to erlotinib resistance in lung adenocarcinoma cells.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Receptors, Progesterone; Signal Transduction | 2021 |
Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liposomes; Lung Neoplasms; Nanoparticles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quality of Life; Quercetin | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines | 2021 |
A New Series of Indeno[1,2-
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles | 2022 |
Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Dramatic Improvement of Severe Cicatricial Ectropion after Discontinuing Long-Term Erlotinib Therapy in a Patient with Lung Cancer
Topics: Carcinoma, Non-Small-Cell Lung; Corneal Perforation; Ectropion; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Toxic Optic Neuropathy | 2022 |
Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Peptides; Protein Kinase Inhibitors; Receptors, Progesterone | 2022 |
Clinical profile and initial treatment of non-small cell lung cancer: a retrospective cohort study at the Uganda Cancer Institute.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Uganda | 2021 |
Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
Topics: Alkaloids; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation | 2022 |
Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.
Topics: Animals; Cachexia; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Head and Neck Neoplasms; Humans; Ligands; Lung Neoplasms; Mice; Parathyroid Hormone-Related Protein; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck | 2022 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medicare; Mutation; Protein Kinase Inhibitors; United States | 2022 |
Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Snake Venoms; Transforming Growth Factor beta1 | 2022 |
FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Muscle Proteins; Mutation; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; SKP Cullin F-Box Protein Ligases; Ubiquitination | 2022 |
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship; Thalidomide | 2022 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia | 2022 |
APE1 shRNA-loaded cancer stem cell-derived extracellular vesicles reverse Erlotinib resistance in non-small cell lung cancer via the IL-6/STAT3 signalling.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA-(Apurinic or Apyrimidinic Site) Lyase; Erlotinib Hydrochloride; Extracellular Vesicles; Humans; Interleukin-6; Lung Neoplasms; Neoplastic Stem Cells; RNA, Small Interfering; STAT3 Transcription Factor | 2022 |
Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles | 2022 |
Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2022 |
Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Effects of miRNA-149-5p and Platelet-Activating Factor-Receptor Signaling on the Growth and Targeted Therapy Response on Lung Cancer Cells.
Topics: Biological Phenomena; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs | 2022 |
Microwave-assisted synthesis, spectroscopic characterization, and biological evaluation of fused thieno[2,3-d]pyrimidines as potential anti-cancer agents targeting EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Microwaves; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2023 |
5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report.
Topics: Acne Vulgaris; Aminolevulinic Acid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Photochemotherapy; Photosensitizing Agents; Skin Diseases | 2022 |
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.
Topics: Afatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Integrin beta3; Lung Neoplasms; Protein Kinase Inhibitors | 2022 |
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Indoles; Lung Neoplasms; Mutation; Nucleic Acids; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Retrospective Studies | 2022 |
Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: A synergistically promising approach for cell proliferation prevention and ROS-Mediated apoptosis activation.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Carriers; Erlotinib Hydrochloride; Humans; Lipids; Lung Neoplasms; Nanostructures; Particle Size; Reactive Oxygen Species; Resveratrol | 2022 |
Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Morpholinos; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Isoforms; Signal Transduction | 2022 |
The Marine-Derived Macrolactone Mandelalide A Is an Indirect Activator of AMPK.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fibroblasts; Glioblastoma; Humans; Lung Neoplasms; Macrolides; Mammals; Mice; Phosphorylation | 2022 |
Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.
Topics: Aniline Compounds; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2022 |
The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glycolysis; Histone Deacetylases; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Sirtuins; Xenograft Model Antitumor Assays | 2022 |
Heat shock protein 90 inhibitor 17-AAG down-regulates thymidine phosphorylase expression and potentiates the cytotoxic effect of tamoxifen and erlotinib in human lung squamous carcinoma cells.
Topics: Antineoplastic Agents; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung; Lung Neoplasms; Pyrimidine Nucleosides; RNA, Small Interfering; Tamoxifen; Thymidine Phosphorylase | 2022 |
New Anticancer Theobromine Derivative Targeting EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship; Theobromine | 2022 |
Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Reactive Oxygen Species; Transaminases | 2022 |
Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs.
Topics: Adenocarcinoma of Lung; Algorithms; Antineoplastic Agents; Computational Biology; CTLA-4 Antigen; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; RNA, Long Noncoding | 2022 |
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2022 |
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Topics: Algorithms; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Retrospective Studies | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |
Ocellatuperoxides A-F, Uncommon Anti-Tumoral
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Circular Dichroism; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Mollusca; Peroxides; Pyrones; RNA | 2022 |
Presumed erlotinib-induced bilateral corneal ulcers in a dog with lung tumor.
Topics: Animals; Cornea; Corneal Ulcer; Dog Diseases; Dogs; Erlotinib Hydrochloride; Lung Neoplasms; Male; Tears | 2023 |
Prevalence, Treatment Patterns, and Outcomes of Individuals with
Topics: Afatinib; Alberta; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Platinum; Prevalence | 2022 |
A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells.
Topics: Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Advanced Lung Cancer Patients' Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quebec | 2022 |
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Rats; Retrospective Studies; Tyrosine Kinase Inhibitors; Zinc | 2023 |
Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles.
Topics: Animals; Antagomirs; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Nanoparticles; Xenograft Model Antitumor Assays | 2023 |
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Taiwan; Tyrosine Kinase Inhibitors | 2023 |
Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Retrospective Studies; Tyrosine Kinase Inhibitors | 2022 |
Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transcription Factors; Xenograft Model Antitumor Assays | 2023 |
Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quality of Life | 2023 |
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Topics: Afatinib; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mouth Neoplasms; Pyruvate Kinase; Quercetin; Squamous Cell Carcinoma of Head and Neck | 2023 |
Liposomal form of erlotinib for local inhalation administration and efficiency of its transport to the lungs.
Topics: Administration, Inhalation; Bronchodilator Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Erlotinib Hydrochloride; Humans; Liposomes; Lung; Lung Neoplasms; Nebulizers and Vaporizers; Particle Size; Respiratory Aerosols and Droplets | 2023 |
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Tetracyclines | 2023 |
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2023 |
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ferroptosis; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; RNA, Long Noncoding; Sesquiterpenes | 2023 |
A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Janus Kinase 2; Lung Neoplasms; Mutation; Phosphoglycerate Mutase; Protein Kinase Inhibitors; Signal Transduction | 2023 |
Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high-resolution population-level analysis.
Topics: Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quebec; Social Determinants of Health | 2023 |
Erlotinib-induced dry eye.
Topics: Dry Eye Syndromes; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2023 |
Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort.
Topics: Brazil; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Tumor Suppressor Protein p53 | 2023 |
Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
Rapid high performance liquid chromatography method for erlotinib quantification in vitro: Application to study the effect of resveratrol on metabolism and cellular uptake of erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Microsomes, Liver; Rats; Resveratrol | 2023 |
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
Antitumor effects of erlotinib in combination with berberine in A431 cells.
Topics: Animals; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2023 |
Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy.
Topics: Dendrimers; Drug Delivery Systems; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms | 2023 |
EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Topics: Afatinib; Amino Acids; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2023 |
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; Lung Neoplasms; Prodrugs; Protein Kinase Inhibitors | 2023 |
High glucose enhances the aggressiveness of lung adenocarcinoma via activating epidermal growth factor receptor/signal transducer and activator of transcription 3 pathways.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Humans; Hyperglycemia; Lung Neoplasms; Mice; STAT3 Transcription Factor | 2023 |
Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Quantitative and qualitative analyses of drug adsorption on silver nanoparticle monolayers: QCM, SERS, and TEIRA nanospectroscopy studies.
Topics: Adsorption; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metal Nanoparticles; Quartz Crystal Microbalance Techniques; Silver; Spectrum Analysis, Raman | 2023 |
Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lysine; Mammals; Protein Kinase Inhibitors | 2023 |
Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinolines | 2023 |
Regulation of epidermal growth factor receptor tyrosine kinase inhibitor resistance via Ambra1-mediated autophagy in non-small cell lung cancer.
Topics: Actins; Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Beclin-1; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; RNA; Tyrosine Kinase Inhibitors | 2023 |
Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Zinc Finger E-box-Binding Homeobox 1 | 2023 |
First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Ramucirumab | 2023 |
BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phospholipase C gamma; Stomach Neoplasms | 2023 |
Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nanomedicine | 2023 |
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Taiwan | 2019 |
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Topics: Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Topics: Animals; Autophagy; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice, Nude; Phosphorylation; Proto-Oncogene Mas | 2020 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
Darkening and eruptive nevi during treatment with erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Melanoma; Nevus, Pigmented; Protein Kinase Inhibitors; Skin Neoplasms | 2019 |
[Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population].
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2019 |
Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Lung Neoplasms; Mutation; RNA, Long Noncoding; Survival Analysis; Transcriptome | 2019 |
Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Tumor Cells, Cultured | 2019 |
BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Marrow; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Insulin-Like Growth Factor Binding Protein 2; Leptin; Lung Neoplasms; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Receptor, IGF Type 1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Are neutralising anti-VEGF or VEGFR2 antibodies necessary in the treatment of EGFR-mutated non-small-cell lung cancer?
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Ramucirumab; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; France; Gefitinib; Humans; Liquid Biopsy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation | 2020 |
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sequence Deletion | 2019 |
Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genetic Fitness; Genotype; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation | 2020 |
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas.
Topics: Adenocarcinoma of Lung; Aldehyde Dehydrogenase 1 Family; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Reactive Oxygen Species; Retinal Dehydrogenase | 2019 |
Complete remission of membranous nephropathy in a patient with lung adenocarcinoma treated with erlotinib.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Follow-Up Studies; Glomerulonephritis, Membranous; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2020 |
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Health Resources; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; United States | 2019 |
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Progression-Free Survival | 2019 |
Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2019 |
Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Mutation; Pemetrexed; Phosphorylation; Protein-Tyrosine Kinases; Random Allocation; Receptor Protein-Tyrosine Kinases; Reference Values; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Reply to A. Tateishi et al.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2020 |
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures | 2020 |
Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Tomography, Optical Coherence; Uveitis, Anterior | 2019 |
Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Taiwan; Treatment Outcome; Young Adult | 2020 |
Erlotinib-loaded carboxymethyl temarind gum semi-interpenetrating nanocomposites.
Topics: A549 Cells; Drug Carriers; Drug Liberation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nanocomposites | 2020 |
Response to a combination of erlotinib and bevacizumab therapy after immune checkpoint inhibitor.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Adenosquamous; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Glycyrrhetinic Acid; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2020 |
Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Quinolines | 2020 |
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population.
Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Poly(ester-thioether) microspheres co-loaded with erlotinib and α-tocopheryl succinate for combinational therapy of non-small cell lung cancer.
Topics: A549 Cells; alpha-Tocopherol; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Drug Carriers; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Microspheres; Polymers; Porosity; Protein Kinase Inhibitors; Reactive Oxygen Species | 2020 |
[A case of Sweet syndrome in a patient receiving erlotinib for lung adenocarcinoma].
Topics: Adenocarcinoma of Lung; Dermis; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neutrophil Infiltration; Protein Kinase Inhibitors; Sweet Syndrome; Time Factors | 2020 |
Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hepatocyte Growth Factor; HT29 Cells; Humans; Immunoglobulin Fc Fragments; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Lung Neoplasms; Male; MCF-7 Cells; Mice; Mice, Inbred NOD; Neuregulin-1; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Drug Liberation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Lipids; Lung Neoplasms; Mice; Molecular Structure; Molecular Targeted Therapy; Nanoparticles; Polymers; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2020 |
Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chitosan; Combined Modality Therapy; Drug Carriers; Erlotinib Hydrochloride; Female; Fluorescent Dyes; Gene Transfer Techniques; Humans; Indoles; Infrared Rays; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Photothermal Therapy; Plasmids; Precision Medicine; RNA, Small Interfering; Survivin; Xenograft Model Antitumor Assays | 2020 |
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Mutation; Neutrophils; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2020 |
A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib.
Topics: Adenocarcinoma; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors | 2020 |
Erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2020 |
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Membrane Proteins; NF-kappa B; Protein Kinase Inhibitors; Receptors, Progesterone; Signal Transduction; Wnt Proteins; Wnt Signaling Pathway | 2020 |
Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Male; Propensity Score; Protein Kinase Inhibitors; Quality of Life; Survival Rate; Taiwan; Tertiary Care Centers | 2020 |
Impact of pharmacist's intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Developing Countries; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Errors; Middle Aged; Patient Care Team; Pharmacists; Progression-Free Survival | 2021 |
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Young Adult | 2020 |
Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Erlotinib Hydrochloride; Glucocorticoids; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Nephritis, Interstitial; Prednisolone; Recovery of Function; Withholding Treatment | 2020 |
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calpain; Case-Control Studies; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-met; Survival Rate; Tumor Cells, Cultured | 2020 |
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Topics: Anthracenes; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Phosphoglycerate Mutase; Pseudopodia; Sulfonamides; Up-Regulation | 2021 |
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Datasets as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Liver Neoplasms; Logistic Models; Lung Neoplasms; Models, Genetic; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; RNA-Seq; Signal Transduction; Sorafenib; Transcriptome | 2020 |
[Management of a patient with a double EGFR and MET anomaly by combined treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-met; Treatment Outcome | 2020 |
LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
Topics: Adult; Aged; Animals; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice; Middle Aged; Mutation; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Up-Regulation | 2020 |
Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Molecular Structure; Mutation; Neoplasms, Experimental; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 10; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Tensins; Vorinostat; Xenograft Model Antitumor Assays | 2020 |
Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Ellagic Acid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors | 2020 |
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Tandem Mass Spectrometry | 2020 |
Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Survival Analysis; Transcriptional Activation | 2020 |
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinolines; Software; Thiazoles; Triple Negative Breast Neoplasms | 2020 |
Feasibility of Surgical Resection After Induction Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for N2 Lung Adenocarcinomas.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Remission Induction | 2021 |
GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Lung Neoplasms; Mice, Nude; Phosphoglycerate Kinase; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Proton Pump Inhibitors; Smoking | 2020 |
Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.
Topics: Adolescent; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Netherlands; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult | 2020 |
Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lipids; Lung Neoplasms; Prognosis; Skin Abnormalities | 2020 |
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MicroRNAs | 2021 |
Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Bevacizumab; Carboplatin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Salvage Therapy | 2020 |
Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Ontology; Humans; Lung Neoplasms; Matrix Metalloproteinase 1; Mutation; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Transcriptome | 2020 |
NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells.
Topics: Carbolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; NF-E2-Related Factor 2; Phospholipid Hydroperoxide Glutathione Peroxidase; Protein Kinase Inhibitors; RNA, Small Interfering; Superoxide Dismutase; Up-Regulation | 2021 |
Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy.
Topics: A549 Cells; Animals; Apoptosis; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chitosan; Drug Carriers; Drug Liberation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Nanoparticles; NIH 3T3 Cells; Oligodeoxyribonucleotides; Reactive Oxygen Species; Signal Transduction | 2020 |
Endothelin-1-Mediated Drug Resistance in
Topics: Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelin-1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A; Vasoconstriction; Xenograft Model Antitumor Assays | 2020 |
Necrolytic migratory erythema-like eruption associated with erlotinib in a patient with lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Necrolytic Migratory Erythema; Necrosis | 2020 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
Topics: Administrative Claims, Healthcare; Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Prescriptions; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Testing; Healthcare Disparities; Humans; Kentucky; Lung Neoplasms; Male; Medicaid; Medicare; Middle Aged; Mutation; Poverty; Precision Medicine; Registries; Retrospective Studies; Sex Factors; Survival Analysis; United States; Young Adult | 2020 |
Nevoid melanoma and eruptive nevi from erlotinib.
Topics: Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Melanoma; Nevus; Protein Kinase Inhibitors; Skin Neoplasms | 2020 |
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Topics: Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies | 2020 |
Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations.
Topics: Ado-Trastuzumab Emtansine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2020 |
Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Retrospective Studies; Treatment Outcome | 2020 |
Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoids; Spheroids, Cellular; Tumor Cells, Cultured | 2020 |
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure | 2020 |
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Topics: Aged; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gain of Function Mutation; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Retrospective Studies; Sequence Deletion | 2020 |
When EGFR inhibitor meets autoimmune disease: Severe corneal complications in a patient with Sjögren syndrome after erlotinib treatment.
Topics: Cornea; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Sjogren's Syndrome | 2022 |
Recurrent EGFR-Mutated Non-Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mammography; Mutation; Ramucirumab; Surgical Procedures, Operative; Treatment Outcome | 2020 |
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Renal Insufficiency | 2021 |
Effect of long non
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; RNA, Long Noncoding | 2020 |
Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Databases, Genetic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Interaction Maps; RNA, Long Noncoding; RNA, Messenger; Sex Factors; Transcriptome; Treatment Outcome | 2020 |
Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2020 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolinones | 2021 |
Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2020 |
Genome-scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib-resistant lung cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genome-Wide Association Study; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Neoplasm Proteins; Ubiquitination | 2021 |
Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mutation; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; STAT3 Transcription Factor | 2021 |
Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Cholesterol; Cyclodextrins; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Nanoparticles; Spheroids, Cellular; Treatment Outcome; Tumor Cells, Cultured | 2021 |
Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nanostructures; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2020 |
Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Signal Transduction | 2020 |
Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Factor Xa Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridines; Thiazoles; Venous Thromboembolism | 2021 |
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Topics: A549 Cells; Acrylamides; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Crizotinib; Drug Synergism; Erlotinib Hydrochloride; Female; Genes, erbB-1; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Oncogenes; Piperidines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Ramucirumab; Random Allocation; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Serially pH-Modulated Hydrogels Based on Boronate Ester and Polydopamine Linkages for Local Cancer Therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Borates; Delayed-Action Preparations; Erlotinib Hydrochloride; Esterification; Humans; Hydrogels; Hydrogen-Ion Concentration; Injections; Lung Neoplasms; Male; Mice; Mice, Inbred ICR | 2021 |
LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases.
Topics: Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Histones; Humans; Lung Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; SOXB1 Transcription Factors; Zinc Finger Protein GLI1 | 2021 |
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate | 2021 |
Incidental finding of regressed solitary unilateral choroidal metastasis from lung adenocarcinoma with EGFR exon-19 deletion treated with erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Choroid Neoplasms; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Lung Neoplasms; Middle Aged; Sequence Deletion | 2021 |
Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Cutaneous cytomegalovirus (CMV) infection in a patient with metastasized lung cancer.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Cytomegalovirus Infections; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male | 2021 |
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Caffeic Acids; Computational Biology; Computer Simulation; Dimerization; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylethyl Alcohol; Quinazolines; Withanolides | 2021 |
Eyelash trichomegaly induced by erlotinib for metastatic lung cancer.
Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Eyelashes; Eyelid Diseases; Female; Hair Diseases; Humans; Lung Neoplasms | 2021 |
Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics - Evaluation in biologically relevant in-vitro models.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinacrine | 2021 |
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Topics: Acrylamides; Angiogenesis Inhibitors; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolinones | 2021 |
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hong Kong; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Retrospective Studies | 2021 |
The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2021 |
Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biosensing Techniques; Case-Control Studies; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Vesicles; Feasibility Studies; Humans; Lung Neoplasms; Molecular Targeted Therapy; Signal-To-Noise Ratio | 2021 |
Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.
Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Ontario; Protein Kinase Inhibitors | 2021 |
Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D
Topics: Apoptosis; Autophagy; Caspase 8; Cell Culture Techniques; Cell Death; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mutation; TNF-Related Apoptosis-Inducing Ligand | 2021 |
Design and Synthesis of Non-Covalent Imidazo[1,2-
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinoxalines; Structure-Activity Relationship | 2021 |
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Topics: Autoantigens; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mitosis; Mutation; Phosphorylation; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |
Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatment.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors | 2021 |
Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors | 2021 |
[Establishment of animal models of epidermal growth factor receptor inhibitor-related rashes].
Topics: Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Lung Neoplasms; Mice; Mice, SCID; Models, Animal; Quinazolines; Rats | 2021 |
An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carbazoles; Chromatography, Liquid; Crizotinib; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolinones; Sulfones; Tandem Mass Spectrometry | 2021 |
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Estrogen Receptor β Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
Topics: A549 Cells; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor beta; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; RNA Interference | 2021 |
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Cell Aggregation; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, Reporter; Humans; Hyaluronan Receptors; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Neoplasm Proteins; Neoplastic Cells, Circulating; Neoplastic Stem Cells; RNA; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Response to Oral Erlotinib Monotherapy in a Patient With EGFR-Negative Status in Histology and Progressive Disease on Conventional Chemotherapy.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
[Erlotinib-induced interstitial pneumonia: a case report].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors | 2021 |
Structural and functional changes of catalase through interaction with Erlotinib hydrochloride. Use of Chou's 5-steps rule to study mechanisms.
Topics: Animals; Binding Sites; Carcinoma, Non-Small-Cell Lung; Catalase; Cattle; Erlotinib Hydrochloride; Liver; Lung Neoplasms; Molecular Docking Simulation; Protein Binding; Spectrometry, Fluorescence; Thermodynamics; Tumor Microenvironment | 2021 |
Re-use of erlotinib in a patient using osimertinib after erlotinib, case report.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Combination of two miRNAs has a stronger effect on stimulating apoptosis, inhibiting cell growth, and increasing erlotinib sensitivity relative to single miRNA in A549 lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MicroRNAs | 2022 |
Successful retreatment with erlotinib after erlotinib-related interstitial lung disease.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Remission Induction; Retreatment | 2021 |
[Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].
Topics: Bevacizumab; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors | 2021 |
Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Energy Metabolism; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Humans; Lung Neoplasms; Middle Aged; Mutation; Prospective Studies | 2021 |
Repurposing calcium channel blockers: may be sensible combination with erlotinib for non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Calcium Channel Blockers; Carcinoma, Non-Small-Cell Lung; Drug Repositioning; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2021 |
Erlotinib complexation with randomly methylated
Topics: A549 Cells; Animals; Antineoplastic Agents; beta-Cyclodextrins; Caco-2 Cells; Calorimetry, Differential Scanning; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Liberation; Erlotinib Hydrochloride; Humans; Intestinal Absorption; Lung Neoplasms; Methylation; Mice; Microscopy, Electron, Scanning; Solubility; Treatment Outcome | 2021 |
Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Duplication; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors | 2021 |
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
Topics: Adolescent; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation | 2021 |
Erlotinib and Trametinib in Patients With
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones | 2021 |
An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Messenger | 2021 |
Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intensive Care Units; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Noninvasive Ventilation; Oxygen Inhalation Therapy; Protein Kinase Inhibitors; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Survival Rate | 2022 |
Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glomerulonephritis; Hematuria; Humans; Kidney; Lung; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteinuria | 2022 |
Matrix-assisted laser desorption ionization - mass spectrometry imaging of erlotinib reveals a limited tumor tissue distribution in a non-small-cell lung cancer mouse xenograft model.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Kidney; Liver; Lung Neoplasms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution; Transplantation, Heterologous | 2021 |
Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Humans; Leukocyte Common Antigens; Lung Neoplasms; Male; Neutrophils; Protein Tyrosine Phosphatases; Rats, Sprague-Dawley; Skin | 2021 |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs.
Topics: Adenylate Kinase; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Chloroquine; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Green Fluorescent Proteins; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutant Proteins; Phosphofructokinase-2; Protein Kinase Inhibitors; Sequestosome-1 Protein | 2021 |
ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2021 |
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Feasibility Studies; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Mice; Positron-Emission Tomography; Proto-Oncogene Proteins c-met; Radioisotopes; Resorcinols; Up-Regulation; Zirconium | 2017 |
Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
Topics: Administration, Inhalation; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Delivery Systems; Dry Powder Inhalers; Erlotinib Hydrochloride; Humans; Lipids; Lung Neoplasms; Nanoparticles | 2017 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Signal Transduction | 2017 |
Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.
Topics: Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genomics; Humans; Lung Neoplasms; Mutation; Neurofibromin 2; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2017 |
Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; LIM-Homeodomain Proteins; Lung Neoplasms; MicroRNAs; Nerve Tissue Proteins; Protein Kinase Inhibitors; RNA Interference; Transcription Factors | 2017 |
Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.
Topics: Animals; Benzophenanthridines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Effectiveness of erlotinib in Critical Care Unit in patients with non-small cell lung cancer with EGFR mutation].
Topics: Carcinoma, Non-Small-Cell Lung; Critical Care; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Mutation; Treatment Outcome | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Amplification; Gene Expression; Gene Knockout Techniques; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor, IGF Type 1; Receptors, Somatomedin | 2017 |
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Topics: Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Editing; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Protein Kinase Inhibitors; Thumb | 2018 |
Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrans; Thymidylate Synthase | 2017 |
The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms | 2017 |
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Clone Cells; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genes, erbB-1; Genes, Neoplasm; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Protein Kinase Inhibitors; Retrospective Studies; Sequence Analysis, DNA; Smoking | 2017 |
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Diosgenin; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-6; Lung Neoplasms; Melanthiaceae; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Rhizome; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Cisplatin; Culture Media, Conditioned; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Injections; Ligands; Lung Neoplasms; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2017 |
Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Health Care Costs; Health Expenditures; Humans; Insurance Claim Review; Longitudinal Studies; Lung Neoplasms; Male; Medicaid; Medicare; Medication Adherence; Retrospective Studies; United States | 2017 |
Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Nanoparticulation improves bioavailability of Erlotinib.
Topics: Animals; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Erlotinib Hydrochloride; Excipients; Humans; Lung Neoplasms; Mice, Nude; Nanoparticles; Solubility | 2017 |
Plasma rich in growth factors for the treatment of rapidly progressing refractory corneal melting due to erlotinib in nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents; Blood Transfusion, Autologous; Carcinoma, Non-Small-Cell Lung; Corneal Ulcer; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms | 2017 |
Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polymorphism, Single Nucleotide; Protein Domains; Protein Kinase Inhibitors | 2017 |
Corneal edema with a systemic epidermal growth factor receptor inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Corneal Edema; Dose-Response Relationship, Drug; Drug Substitution; Epithelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2017 |
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Lung Neoplasms; Protein Transport; RNA, Small Interfering; Vinblastine; Vinorelbine | 2017 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Hispanic or Latino; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2017 |
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Survival Analysis; Treatment Failure; Treatment Outcome | 2017 |
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
Topics: Alleles; Amino Acid Substitution; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors | 2017 |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comorbidity; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Registries; Retreatment; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Phenotype; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-akt; Smad Proteins; Time Factors; Transforming Growth Factor beta | 2017 |
In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Transplantation | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Disseminated Intravascular Coagulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2017 |
Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.
Topics: A549 Cells; Animals; Delayed-Action Preparations; Erlotinib Hydrochloride; Glutathione; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Targeted Therapy; Particle Size; Protein Conformation; Tissue Distribution | 2018 |
Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pulse Therapy, Drug | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors | 2017 |
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors | 2017 |
Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer.
Topics: Animals; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hypoxia; Immunohistochemistry; Liposomes; Lung Neoplasms; Mice, Nude; Models, Biological; Oxygen; Tissue Distribution | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Topics: Acetophenones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
Cerebrospinal Fluid Leak Rhinorrhea after Systemic Erlotinib Chemotherapy for Metastatic Lung Cancer: A Familiar Problem from an Unfamiliar Culprit.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Cerebrospinal Fluid Rhinorrhea; Cranial Fossa, Posterior; Endoscopy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningitis; Nasal Cavity; Natural Orifice Endoscopic Surgery; Sella Turcica; Skull Base; Skull Base Neoplasms | 2017 |
Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation | 2017 |
In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Research Design | 2017 |
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Brain Neoplasms; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Treatment Outcome; Tumor Burden | 2018 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone.
Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Dapsone; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Scalp Dermatoses; Treatment Outcome | 2018 |
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Neoplasm Staging; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2017 |
Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging.
Topics: Animals; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Proliferation; Computer Simulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Phenotype; Time Factors; Tumor Microenvironment | 2018 |
Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Rapid onset of conjunctivitis associated with overdosing of erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Conjunctivitis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors | 2018 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
Duodenal Perforation Secondary to Erlotinib Therapy in a Patient With Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Duodenum; Erlotinib Hydrochloride; Female; Humans; Intestinal Perforation; Lung Neoplasms; Middle Aged; Risk Factors | 2017 |
Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Thalidomide | 2018 |
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pneumonectomy; Point Mutation; Postoperative Period; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Exons; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Receptor, Fibroblast Growth Factor, Type 3 | 2017 |
Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Cell Survival; Contrast Media; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Sequence Deletion; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Mistletoe (Viscum album) extract targets Axl to suppress cell proliferation and overcome cisplatin- and erlotinib-resistance in non-small cell lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Plant Extracts; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Viscum album | 2017 |
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
Topics: Acrylamides; Aged; Aniline Compounds; Brain; Carcinoma, Non-Small-Cell Lung; Cerebrospinal Fluid; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors | 2017 |
MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.
Topics: Animals; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mutation; Neovascularization, Pathologic; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
A rare complication of metastatic lung disease treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Pericardium; Tomography, X-Ray Computed; Tongue Neoplasms | 2017 |
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; China; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcriptional Activation; Up-Regulation | 2018 |
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2017 |
Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Remission Induction; Retrospective Studies; Time Factors | 2018 |
Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo.
Topics: Acrylic Resins; Animals; Antineoplastic Agents; Cell Proliferation; Cystamine; Drug Delivery Systems; Drug Stability; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Lipids; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Oleic Acid; Oxidation-Reduction; Particle Size; Tumor Cells, Cultured | 2017 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Protein Kinase Inhibitors | 2018 |
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Rad51 Recombinase; Remission Induction | 2018 |
Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
Topics: A549 Cells; Animals; Antineoplastic Agents; Biological Availability; Drug Compounding; Drug Liberation; Drug Stability; Erlotinib Hydrochloride; Humans; Injections, Intravenous; Lipids; Liposomes; Lung Neoplasms; Nanomedicine; Nanoparticles; Particle Size; Polyethylene Glycols; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Solubility; Technology, Pharmaceutical; Xenograft Model Antitumor Assays | 2018 |
Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Topics: Aged; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glucuronosyltransferase; Humans; Lung Neoplasms; Male; Models, Biological; Polymorphism, Single Nucleotide; Prospective Studies | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Nivolumab; Prognosis | 2018 |
Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catenins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Transcription Factors; Vimentin | 2018 |
PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Mitochondrial Proteins; Neoplasm Metastasis; Protein Kinase Inhibitors; Transforming Growth Factor alpha; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Models, Biological; Phenotype; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
Iron Oxide Nanoparticles Synergize with Erlotinib to Suppress Refractory Non-Small Cell Lung Cancer Cell Proliferation Through the Inhibition of ErbB/PI3K/AKT and PTEN Activation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diffusion; Down-Regulation; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetite Nanoparticles; Nanocapsules; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase | 2017 |
Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Phantoms, Imaging; Tumor Cells, Cultured | 2018 |
Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer.
Topics: Amiodarone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Paralysis; Radiotherapy; Withholding Treatment | 2018 |
Rapid improvement of psoriasis in a patient with lung cancer after treatment with erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Psoriasis; Severity of Illness Index | 2018 |
Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Unknown Primary; Protein Kinase Inhibitors | 2018 |
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell-Free Nucleic Acids; Cohort Studies; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Protein Kinase Inhibitors | 2018 |
Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Signal Transduction; Tumor Burden; Xanthenes; Xenograft Model Antitumor Assays | 2018 |
Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
Topics: Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Mutation; Neurofibromatosis 1; RNA Interference | 2018 |
A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met | 2018 |
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Principal Component Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
EGFR-TKI-induced HSP70 degradation and BER suppression facilitate the occurrence of the EGFR T790 M resistant mutation in lung cancer cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HSP72 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proteolysis; Ubiquitination | 2018 |
Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adrenal Cortex Hormones; Anaplastic Lymphoma Kinase; Carbazoles; Cough; ErbB Receptors; Erlotinib Hydrochloride; Female; Fever; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2018 |
Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nanocapsules; Paclitaxel | 2018 |
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; NF-kappa B; Progression-Free Survival; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Vesicular Transport Proteins | 2018 |
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Gene Expression Profiling; Heterografts; Histones; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutant Proteins; Neoplasm Transplantation; Phosphoglycerate Dehydrogenase; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, RNA; Staining and Labeling; Treatment Outcome | 2018 |
Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Retrospective Studies | 2019 |
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Inflammation Mediators; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Survival Rate | 2018 |
Resistant to Targeted Therapy - Aim for Metabolic Liabilities.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphoglycerate Dehydrogenase | 2018 |
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Tumor Cells, Cultured | 2018 |
Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Crizotinib; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-met | 2018 |
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2018 |
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Lung Neoplasms; Proteomics; Pyrimidines; Sulfonamides | 2018 |
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Republic of Korea; Treatment Outcome; Young Adult | 2018 |
Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors | 2018 |
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Calgranulin B; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Myeloid-Derived Suppressor Cells; Prognosis; Survival Rate | 2018 |
Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.
Topics: A549 Cells; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Treatment Outcome; Up-Regulation | 2018 |
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors | 2018 |
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.
Topics: Adenocarcinoma; Antineoplastic Agents; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Proto-Oncogene Proteins p21(ras); Remission Induction; Survival Analysis; Time Factors | 2018 |
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; ELAV-Like Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Erlotinib-Induced Transverse Fissure-Like Skin Lesions of Fingers.
Topics: Administration, Topical; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fingers; Humans; Lung Neoplasms; Middle Aged; Paronychia; Protein Kinase Inhibitors; Skin Cream; Treatment Outcome | 2016 |
Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer.
Topics: Adult; Aged; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Exosomes; Female; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Neoplasm Transplantation; RNA, Long Noncoding; Up-Regulation | 2018 |
Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells.
Topics: A549 Cells; Aspartic Acid Endopeptidases; Base Sequence; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Sequence Deletion | 2018 |
A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.
Topics: Acrylamides; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Piperazines; Positron Emission Tomography Computed Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy.
Topics: Adenylate Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Sertraline; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; China; Clinical Decision-Making; Cost-Benefit Analysis; Decision Support Techniques; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years | 2018 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Topics: Calcitriol; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liposomes; Lung Neoplasms; Mutation; Nanoparticles; Protein Kinase Inhibitors; Vitamin D3 24-Hydroxylase | 2018 |
In Search of an Oncogene Driver for Squamous Lung Cancer.
Topics: Afatinib; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation | 2018 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Point Mutation; Up-Regulation | 2018 |
Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer.
Topics: Aged; Aged, 80 and over; Bone Marrow; Dose-Response Relationship, Radiation; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Spine; Tomography, X-Ray Computed | 2019 |
Afatinib restrains K-RAS-driven lung tumorigenesis.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Sequence Deletion | 2018 |
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Topics: Animals; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Neoplasm Proteins; RNA, Small Interfering; Survivin; Xenograft Model Antitumor Assays | 2018 |
Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway.
Topics: A549 Cells; Animals; Aspirin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Nitric Oxide; Protein Kinase Inhibitors; Signal Transduction | 2018 |
mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mutation; Protein Kinase Inhibitors; RNA Interference; Survival Analysis | 2018 |
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sequence Deletion | 2018 |
Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Multimodal Imaging; Mutation; Treatment Outcome | 2018 |
HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hyaluronic Acid; Lung Neoplasms; Nanoparticles; Rats; Rats, Sprague-Dawley; Serum Albumin, Human | 2018 |
Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2018 |
An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Piperazines; Treatment Outcome | 2018 |
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species | 2018 |
Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Queensland; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pentacyclic Triterpenes; Protein Kinase Inhibitors; Signal Transduction; Triterpenes | 2018 |
Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines; Vinorelbine | 2018 |
EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nivolumab; Protein Kinase Inhibitors | 2018 |
Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Glycolysis; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Comment on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lactones; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering; Sesquiterpenes | 2018 |
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Folate Receptor 1; Humans; Lipids; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice, Nude; Middle Aged; Nanoparticles; Photochemotherapy; Pleural Neoplasms; Porphyrins; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activation.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Lung Neoplasms; Molecular Docking Simulation; Mutation; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; STAT3 Transcription Factor | 2018 |
EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neuregulin-1; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Signal Transduction | 2018 |
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis; Young Adult | 2018 |
Erlotinib-Guided Self-Assembled Trifunctional Click Nanotheranostics for Distinguishing Druggable Mutations and Synergistic Therapy of Nonsmall Cell Lung Cancer.
Topics: Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbocyanines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Click Chemistry; Copper; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Infrared Rays; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Confocal; Microscopy, Fluorescence; Molecular Targeted Therapy; Mutation; Photochemotherapy; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2018 |
YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Lung Neoplasms; Naphthoquinones; Protein Kinase Inhibitors; Survivin | 2018 |
Iatrogenic pneumopericardium in the setting of carcinomatous pericarditis.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Pericarditis; Pneumopericardium; Protein Kinase Inhibitors; Punctures; Radiography; Ventilators, Negative-Pressure | 2018 |
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Antineoplastic Agents; Cell-Free Nucleic Acids; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Piperazines; Polymorphism, Restriction Fragment Length | 2018 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; United States | 2018 |
Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, SCID; Mutation; Nanoparticles; Water | 2018 |
Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, SCID; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma.
Topics: Acrylamides; Adenocarcinoma; Aged; Aniline Compounds; Crizotinib; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors | 2018 |
Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Halogenation; Humans; Liver; Lung Neoplasms; Mice, Inbred BALB C; Positron-Emission Tomography; Reference Standards | 2019 |
Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Topics: Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclodextrins; Drug Carriers; Drug Liberation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2019 |
Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2018 |
Reply to the comments on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Asian People; Brain Neoplasms; China; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2018 |
CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.
Topics: beta Catenin; Carcinoma, Non-Small-Cell Lung; CD146 Antigen; Cell Movement; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Phenotype; Protein Kinase Inhibitors; Signal Transduction; Up-Regulation | 2019 |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sex Factors; Taiwan; Time Factors | 2019 |
Clinical Drug Response Prediction by Using a Lq Penalized Network-Constrained Logistic Regression Method.
Topics: Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Discovery; Erlotinib Hydrochloride; Female; Gene Expression Regulation; Gene Regulatory Networks; Genome, Human; Humans; Logistic Models; Lung Neoplasms; Male; Models, Biological; Precision Medicine; Sorafenib; Transcriptome | 2018 |
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs).
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Retrospective Studies; Tomography, X-Ray Computed | 2018 |
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Positron-Emission Tomography; Tyrosine | 2019 |
Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells.
Topics: Animals; Antimicrobial Cationic Peptides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cichlids; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fish Proteins; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors | 2018 |
Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Imaging; Mutant Proteins; Mutation; Neoplasm Transplantation | 2019 |
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinogenesis; Cell Line, Tumor; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Transfection; Xenograft Model Antitumor Assays | 2019 |
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Models, Econometric; Pemetrexed; Quality-Adjusted Life Years; Survival Analysis | 2019 |
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Analysis; Treatment Outcome | 2019 |
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Topics: Animals; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazolidines | 2019 |
A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Piperazines; Protein Kinase Inhibitors | 2019 |
Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.
Topics: Acrylamides; Adenocarcinoma; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Oncogene Fusion; Phosphoproteins; Proto-Oncogene Proteins c-met | 2019 |
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis | 2019 |
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Treatment Outcome | 2019 |
Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cells; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neuraminidase; Protein Kinase Inhibitors; Quinazolines | 2019 |
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Treatment Failure; Treatment Outcome | 2019 |
Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Face; Female; Humans; Lung Neoplasms; Radiodermatitis; Skin; Treatment Outcome | 2019 |
Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Terpenes; Transforming Growth Factor beta1 | 2019 |
Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients.
Topics: Aged; Aged, 80 and over; Asian People; Black or African American; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genetic Testing; Healthcare Disparities; Humans; Lung Neoplasms; Male; Medicare; Molecular Targeted Therapy; Protein Kinase Inhibitors; Retrospective Studies; SEER Program; Socioeconomic Factors; United States; White People | 2019 |
Fisetin suppresses migration, invasion and stem-cell-like phenotype of human non-small cell lung carcinoma cells via attenuation of epithelial to mesenchymal transition.
Topics: AC133 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Flavonoids; Flavonols; Humans; Hyaluronan Receptors; Lung Neoplasms; Neoplasm Invasiveness; Phenotype; Stem Cells | 2019 |
Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis: Review of 2 Cases.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Brain; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors | 2019 |
Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Calcium Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Silicates; Solubility; Valproic Acid | 2019 |
Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost Sharing; Drug and Narcotic Control; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Pragmatic Clinical Trials as Topic; Retrospective Studies; Vinorelbine | 2019 |
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors | 2019 |
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Critical Pathways; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Guideline Adherence; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Mutation; Practice Guidelines as Topic; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Failure | 2019 |
Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Integrin beta1; Lung Neoplasms; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; rab GTP-Binding Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Cranial Irradiation; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2019 |
Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Drug Prescriptions; Erlotinib Hydrochloride; Gefitinib; Humans; Interrupted Time Series Analysis; Lung Neoplasms; National Health Programs; Reimbursement Mechanisms; Taiwan | 2019 |
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation Rate | 2019 |
Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.
Topics: Adolescent; Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Time Factors; Young Adult | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Small Cell Lung Carcinoma | 2019 |
EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Survival Analysis; Treatment Outcome | 2019 |
Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2019 |
Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2019 |
Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2019 |
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cohort Studies; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Staging; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 4; Respiratory Mucosa; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
The economic impact of the transition from branded to generic oncology drugs.
Topics: Antineoplastic Agents; Cetuximab; Cisplatin; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Drug Costs; Drugs, Generic; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphoma; Randomized Controlled Trials as Topic; Vinorelbine | 2019 |
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2019 |
The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA (Cytosine-5-)-Methyltransferase 1; Drug Synergism; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sp1 Transcription Factor | 2019 |
Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Proto-Oncogene Proteins c-met | 2019 |
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer.
Topics: Adult; Aged; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors | 2019 |
Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Nitric Oxide; Nitro Compounds | 2019 |
Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Cell Growth Processes; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Mutation; Precision Medicine | 2019 |
A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Multiprotein Complexes; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2019 |
Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Glycolysis; Humans; Lung Neoplasms; Mutation; Phosphofructokinase-2; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction | 2019 |
Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Survival Analysis | 2019 |
[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Survival Rate | 2019 |
Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
Topics: Afatinib; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Multimerization; Treatment Outcome | 2019 |
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Topics: Acrylamides; Adult; Afatinib; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
NEJ026 trial: progression-free survival benefit is not enough.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Progression-Free Survival | 2019 |
NEJ026 trial: progression-free survival benefit is not enough - Author's reply.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Progression-Free Survival | 2019 |
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.
Topics: Animals; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice, Transgenic; Mutation; Oncogenes; Protein Kinase Inhibitors; T-Lymphocytes; Tumor Microenvironment | 2019 |
[A Survey on the Concurrent Administration of Erlotinib and Gastric Acid Suppressing Medications among Doctors:Concern for Drug Interaction].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Gastric Acid; Humans; Lung Neoplasms; Surveys and Questionnaires | 2019 |
Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
Topics: Adolescent; Adult; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Health Expenditures; Health Resources; Humans; Insurance Claim Review; Lung Neoplasms; Male; Middle Aged; Patient Acceptance of Health Care; Protein Kinase Inhibitors; Retrospective Studies; United States; Young Adult | 2020 |
Treatment of EGFR positive lung adenocarcinoma in a heart transplanted patient.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Heart Transplantation; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Mutation | 2019 |
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Middle Aged; Mutation; Piperidines; Pyrazoles; Xenograft Model Antitumor Assays | 2019 |
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Topics: Acrylamides; Alkylating Agents; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ethylnitrosourea; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; Mutagenesis; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
[Fatal interstitial lung disease associated with erlotinib use].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Topics: Aged; Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Mutation; Pemetrexed; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2013 |
Erlotinib-induced hair repigmentation.
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Hair Color; Humans; Lung Neoplasms; Pigmentation; Protein Kinase Inhibitors; Quinazolines | 2014 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Proteome; Proteomics; Quinazolines; Retrospective Studies | 2013 |
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Diagnostic Tests, Routine; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; CD56 Antigen; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Ki-67 Antigen; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2 | 2013 |
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2013 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Erlotinib-induced acneiform eruption].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Erlotinib Hydrochloride; Fluoroquinolones; Humans; Lung Neoplasms; Male; Methylprednisolone; Quinazolines; Quinolizines; Treatment Outcome | 2013 |
Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Systematic Reviews as Topic | 2013 |
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Transdifferentiation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sequence Analysis, DNA; Sequence Deletion | 2013 |
Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemokine CCL5; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-10; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Topics: Animals; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Patient Selection; Pemetrexed; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2013 |
Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Hand-Foot Syndrome; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
A swollen knee in a 77-year-old lung cancer patient receiving antimicrobial therapy for pneumonia.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Erlotinib Hydrochloride; Fatal Outcome; Humans; Knee; Knee Injuries; Lung Neoplasms; Male; Pneumonia; Quinazolines | 2013 |
Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Signal Transduction; Small Cell Lung Carcinoma; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; France; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Survival Rate; Treatment Outcome | 2013 |
Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Topics: Adult; Aged; Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Topics: Animals; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Janus Kinase 1; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
Topics: Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Integrin beta1; Lung Neoplasms; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases | 2013 |
Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-4F; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Quinazolines; RNA Caps; Signal Transduction; Tumor Cells, Cultured | 2013 |
EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2013 |
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines | 2013 |
Erlotinib in the treatment of advanced squamous cell NSCLC.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Insulin; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Transcriptome | 2013 |
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Erlotinib Hydrochloride; Humans; I-kappa B Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference | 2014 |
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoassay; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.
Topics: Bronchoscopy; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Erlotinib Hydrochloride; Humans; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Infections; Thoracic Surgery, Video-Assisted | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Scalp pustules in a patient receiving chemotherapy.
Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2013 |
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Lung Neoplasms; Mutation; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Silybin; Silymarin; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Topics: Acetylation; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mice; Mice, Nude; Propidium; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2013 |
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Inbred BALB C; Models, Biological; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Failure; Treatment Outcome | 2014 |
In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin B1; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Microtubules; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Quinazolines; Quinolines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cytokines; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Mutation; Quinazolines | 2014 |
[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Hedgehog Proteins; Humans; Lung Neoplasms; MicroRNAs; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; Humans; Immunotherapy; Leukocytes, Mononuclear; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Quinazolines | 2013 |
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Predictive Value of Tests; Prognosis; Proteomics; Quinazolines; Severity of Illness Index; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2014 |
Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Retrospective Studies; Stem Cells | 2013 |
Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2013 |
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2014 |
Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction | 2014 |
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Insertional; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Structural Homology, Protein; Translational Research, Biomedical | 2013 |
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; Docetaxel; Drug Dosage Calculations; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2014 |
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Skin; Survival Analysis; Treatment Outcome | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Community Networks; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Pemetrexed; Practice Patterns, Physicians'; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Retrospective Studies; Smoking; Treatment Outcome | 2014 |
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
[Radiosensitizing effect of erlotinib on human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Particle Accelerators; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2013 |
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Tamoxifen; Thymidine Phosphorylase; Time Factors | 2014 |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Receptor, IGF Type 1; RNA, Small Interfering | 2014 |
Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Luteolin; Male; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Frequency; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Random Allocation; Survivin; Xenograft Model Antitumor Assays | 2013 |
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinazolines; Sulfonamides; Transplantation, Heterologous | 2014 |
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Neoplasms, Experimental; Neurofibromin 1; Pyridones; Pyrimidinones | 2014 |
In-depth analysis shows synergy between erlotinib and miR-34a.
Topics: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Quinazolines | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2014 |
Erlotinib induced target-like purpura.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purpura; Quinazolines | 2014 |
Regulatory mechanisms of betacellulin in CXCL8 production from lung cancer cells.
Topics: Apoptosis; Betacellulin; Cell Count; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cycloheximide; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lipopolysaccharides; Lung Neoplasms; Models, Biological; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Necrosis Factor-alpha | 2014 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines; Radiography; Treatment Outcome | 2014 |
EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Topics: Animals; Apoptosis; Aurora Kinase B; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Chromatin; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase C-alpha; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation Tolerance; ras Proteins; Xenograft Model Antitumor Assays | 2014 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy; Taxoids | 2014 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta2; Wound Healing | 2014 |
Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Erlotinib Hydrochloride; Female; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines | 2014 |
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Proliferation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice, Nude; Microtubules; Mitosis; Niacinamide; Paclitaxel; Phosphorylation; Polymerization; Quinazolines; STAT3 Transcription Factor; Sulfonamides; Tubulin; Tumor Suppressor Protein p53; Vincristine | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mice, Transgenic; Mutation; Neoplasms, Experimental; Quinazolines; SOXB1 Transcription Factors | 2014 |
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Integrin alphaVbeta3; Integrin beta3; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-rel; Proto-Oncogene Proteins p21(ras); Quinazolines; ral GTP-Binding Proteins; Randomized Controlled Trials as Topic; ras Proteins; RNA Interference; Signal Transduction; Spheroids, Cellular; Time Factors; Transfection; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
The TAILOR study: to agree or to disagree?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Research Design; Salvage Therapy; Taxoids | 2014 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
Case of erlotinib-induced photosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Dermatitis, Photoallergic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Patch Tests; Protein Kinase Inhibitors; Quinazolines | 2014 |
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A | 2014 |
Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiography; Severity of Illness Index | 2014 |
Small-cell lung cancers in patients who never smoked cigarettes.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Chromogranins; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Rearrangement; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Retinoblastoma Protein; Retrospective Studies; Small Cell Lung Carcinoma; Smoking; Survival Rate; Telomerase; Tumor Suppressor Protein p53 | 2014 |
VeriStrat validated in patients with non-small-cell lung cancer.
Topics: Blood Proteins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2014 |
Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Paclitaxel; Quinazolines | 2014 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2014 |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2014 |
EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cognition Disorders; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2014 |
A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; GPI-Linked Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Comparison is beyond IPASS and OPTIMAL.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; Electrophoresis, Capillary; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolome; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2014 |
Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2014 |
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases | 2014 |
Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2014 |
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Sex Factors; Survival Analysis; Treatment Outcome | 2016 |
Variations in molecular profile in NSCLC can be analyzed using cytological samples: development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient.
Topics: Aged; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion | 2015 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcription, Genetic | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.
Topics: Adenocarcinoma; Anti-Infective Agents; Atovaquone; Chorioretinitis; ErbB Receptors; Erlotinib Hydrochloride; Female; Food Parasitology; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Toxoplasma; Toxoplasmosis, Ocular | 2014 |
Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
Topics: Adenocarcinoma; Aged; Autoantibodies; Autoantigens; Electroretinography; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Infusions, Intravenous; Isoxazoles; Lung Neoplasms; Male; Night Blindness; Paraneoplastic Syndromes, Ocular; Phosphopyruvate Hydratase; Quinazolines; Resorcinols; Retina; Tomography, Optical Coherence; Visual Acuity | 2014 |
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Repetitive Sequences, Nucleic Acid; Risk Factors; Treatment Outcome | 2014 |
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays | 2014 |
Network-based modeling and intelligent data mining of social media for improving care.
Topics: Antineoplastic Agents; Artificial Intelligence; Computer Simulation; Data Mining; Erlotinib Hydrochloride; Health Literacy; Humans; Lung Neoplasms; Meaningful Use; Models, Statistical; Natural Language Processing; Needs Assessment; Patient Education as Topic; Patient Satisfaction; Quality Improvement; Quinazolines; Social Media; Treatment Outcome; Vocabulary, Controlled | 2015 |
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Tomography, X-Ray Computed | 2014 |
EGFR-mutated lung cancer in Li-Fraumeni syndrome.
Topics: Adult; Breast Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Li-Fraumeni Syndrome; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2014 |
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Radiopharmaceuticals; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Metastasis; Quinazolines | 2014 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Intensive Care Units; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Respiration, Artificial; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Monitoring cancer through the blood.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines | 2014 |
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplastic Stem Cells; Quinazolines; Receptor, Notch3; Receptors, Notch; Signal Transduction; Transcription, Genetic | 2014 |
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cohort Studies; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
What new therapeutic targets exist for EGFR-mutant NSCLC?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines | 2014 |
Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2014 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Pulmonary embolism with haemorrhagic pericardial effusion and tamponade: a clinical dilemma.
Topics: Anticoagulants; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Diagnosis, Differential; Drainage; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Pericardial Effusion; Protein Kinase Inhibitors; Pulmonary Embolism; Quinazolines; Treatment Outcome; Vena Cava Filters | 2014 |
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Outcome | 2014 |
Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pakistan; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
[Safety of reintroduction of erlotinib at low doses following hand-foot syndrome induced by erlotinib treatment for a Pancoast-Tobias tumour].
Topics: Aged, 80 and over; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Pancoast Syndrome; Protein Kinase Inhibitors; Quinazolines; Retreatment | 2014 |
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction; Thiophenes; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2015 |
Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Cysts; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Pneumothorax; Protein Kinase Inhibitors; Quinazolines; Rupture, Spontaneous | 2014 |
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.
Topics: Animals; Cell Culture Techniques; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Myristoylated Alanine-Rich C Kinase Substrate; Phosphatidylinositol 3-Kinase; Phosphatidylinositol Phosphates; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins | 2015 |
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiosurgery | 2014 |
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Topics: Antigens, CD; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Vimentin | 2014 |
Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Mass Spectrometry; Phosphopeptides; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2015 |
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Imidazoles; Lung Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolines; ras Proteins; TOR Serine-Threonine Kinases | 2014 |
The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Chromones; Cytoplasm; Diketopiperazines; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Morpholines; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; CpG Islands; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Phenotype; Prognosis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2014 |
Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sodium; Treatment Outcome | 2014 |
Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Molecular; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2015 |
The failure of figitumumab: the danger of taking shortcuts in drug development.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male | 2015 |
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2014 |
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; White People | 2015 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Receptor, Notch1; Tumor Suppressor Protein p53 | 2014 |
ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2015 |
A case of new onset keratosis pilaris after discontinuation of erlotinib.
Topics: Abnormalities, Multiple; Antineoplastic Agents; Darier Disease; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
Topics: Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Taiwan; Tuberculosis, Pulmonary | 2015 |
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
A 'shock-ing' endoscopic finding on esophagogastroduodenoscopy.
Topics: Adenocarcinoma; Antineoplastic Agents; Endoscopy, Digestive System; Erlotinib Hydrochloride; Esophagus; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Necrosis; Quinazolines | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Nicotine; Nicotinic Agonists; Receptor Cross-Talk; Receptors, Nicotinic; Smoking; Xenograft Model Antitumor Assays | 2015 |
Oncologists push beyond new lung cancer genomic testing guidelines.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic | 2015 |
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Forkhead Transcription Factors; Humans; Lung Neoplasms; Membrane Proteins; Proto-Oncogene Proteins; SOXB1 Transcription Factors | 2015 |
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Radiography; Small Cell Lung Carcinoma | 2015 |
Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; Treatment Outcome | 2015 |
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib | 2015 |
Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MicroRNAs | 2015 |
Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
Topics: Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transforming Growth Factor beta; Up-Regulation | 2015 |
Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mice; Molecular Chaperones; Oligonucleotides; Xenograft Model Antitumor Assays | 2015 |
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2015 |
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique, Indirect; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Quinazolines | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Nude; Misonidazole; Molecular Targeted Therapy; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2016 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Remission of advanced EGFR-positive lung adenocarcinoma after short and intermittent erlotinib therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors | 2015 |
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Studies as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Proteomics; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Onartuzumab in lung cancer: the fall of Icarus?
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Design; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine | 2015 |
Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.
Topics: Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Pyrrolidines; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Tubulin Modulators | 2015 |
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Synergism; Erlotinib Hydrochloride; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Resveratrol; Ribosomal Protein S6 Kinases; Signal Transduction; Stilbenes; Survivin; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2015 |
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2015 |
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Hypoxia; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Reproducibility of Results; Transcriptome; Treatment Outcome | 2015 |
SELPHI: correlation-based identification of kinase-associated networks from global phospho-proteomics data sets.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Humans; Internet; Lung Neoplasms; Peptides; Phosphoprotein Phosphatases; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Software | 2015 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Blotting, Western; Broadly Neutralizing Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterografts; Humans; Lung Neoplasms; Mice; Neuregulin-1; Real-Time Polymerase Chain Reaction; Receptor, ErbB-3; RNA, Small Interfering; Transfection | 2016 |
Erlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-3; Regression Analysis; Signal Transduction; Structural Homology, Protein; Thermodynamics | 2015 |
Regulation of metastatic ability and drug resistance in pulmonary adenocarcinoma by matrix rigidity via activating c-Met and EGFR.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomechanical Phenomena; Cell Line, Tumor; Collagen Type I; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Fibrosis; Humans; Indoles; Integrins; Lung; Lung Neoplasms; Mechanotransduction, Cellular; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sulfones | 2015 |
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Topics: Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Retrospective Studies | 2015 |
Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.
Topics: Adult; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Conscious Sedation; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Frameshift Mutation; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Pain Management; Pain, Intractable; Palliative Care; Quinazolines; Radiography | 2015 |
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2015 |
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Isoflavones; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Naphthyridines; Principal Component Analysis; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
A pilot study of conformal radiotherapy combined with erlotinib-based multimodality therapy in newly diagnosed metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Radiotherapy, Conformal; Survival Rate | 2015 |
Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Transcriptome | 2015 |
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2015 |
Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Nude; Photochemotherapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Platinum Compounds; Population Groups; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models.
Topics: Acrylamides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines | 2015 |
Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cost-Benefit Analysis; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Germany; Humans; Lung Neoplasms; Models, Economic; Mutation; Neoplasm Invasiveness; Precision Medicine; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2015 |
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Decision Making; Drug Utilization; Erlotinib Hydrochloride; Female; Gefitinib; Hospital Administration; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; National Health Programs; Ownership; Quinazolines; Residence Characteristics; Taiwan | 2015 |
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterocyclic Compounds, 3-Ring; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Retreatment; Treatment Outcome | 2015 |
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Survival; Dinoprostone; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Human Umbilical Vein Endothelial Cells; Humans; Integrin alpha6; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice, Nude; Prostaglandin-E Synthases; Prostatic Neoplasms | 2015 |
LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Energy Metabolism; Erlotinib Hydrochloride; Female; Flow Cytometry; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2016 |
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male | 2015 |
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomimetics; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2015 |
[Study on Inhibitory Effect of Aqueous Extract of Taxus Chinensis var. mairei Combined Erlotnib on A549 Xenograft in Nude Mice and Its Mechanism].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclooxygenase 2; Drugs, Chinese Herbal; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Heterografts; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Taxus; Transplantation, Heterologous | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression; Humans; Inhibitory Concentration 50; Isoenzymes; Lung Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Purines; Pyrimidinones; Quinazolinones; Triazines | 2015 |
Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Live Birth; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Twin; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report.
Topics: Afatinib; Carcinoma, Large Cell; Cell Differentiation; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Spheroids, Cellular | 2015 |
[Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Crizotinib; Culture; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Molecular Targeted Therapy; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Surveys and Questionnaires | 2016 |
Radiation-Refractory Brain Metastases in Patients with Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2015 |
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2015 |
Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Signal Transduction; Tyrosine; Xenograft Model Antitumor Assays | 2015 |
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET....
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines | 2015 |
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Survival Rate | 2015 |
[Targeted therapy for solid tumors in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2015 |
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
Topics: Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Genetic Testing; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Pyrimidines; Pyrroles | 2015 |
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; SOXB1 Transcription Factors; Spheroids, Cellular; Stem Cells; Transcription Factors; Tumor Cells, Cultured; Zinc Finger Protein GLI1 | 2015 |
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Young Adult | 2015 |
Gene mutation characteristics of nonsmall-cell lung carcinoma patients with wild-type epidermal growth factor receptor and sensitivity to Tarceva therapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Analysis of Epidermal Growth Factor Receptor Mutations in Serum Among Japanese Patients Treated With First-Line Erlotinib for Advanced Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Survival Rate | 2016 |
Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bone Neoplasms; Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Keratomileusis, Laser In Situ; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Spinal Neoplasms | 2016 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Cell Line, Tumor; Cetuximab; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines | 2016 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2015 |
Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mutation; Polymerase Chain Reaction; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2016 |
Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2015 |
Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.
Topics: Adoptive Transfer; Animals; Antineoplastic Agents; Blotting, Western; Calcium-Binding Proteins; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Humans; Immunohistochemistry; Immunotherapy; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Receptors, Notch; Recombinant Fusion Proteins; T-Lymphocytes | 2015 |
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States | 2015 |
An Autopsy Case of Two Distinct, Acquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung Adenocarcinoma: Small Cell Carcinoma Transformation and Epidermal Growth Factor Receptor T790M Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autopsy; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male | 2015 |
Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenon's triamcinolone without erlotinib cessation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Glucocorticoids; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Staging; Tenon Capsule; Triamcinolone Acetonide; Uveitis, Anterior | 2015 |
Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug-drug interaction.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Drug Interactions; Erlotinib Hydrochloride; Female; Homozygote; Humans; Lung Neoplasms; Middle Aged; Pharmacogenetics; Protein Kinase Inhibitors; Rhabdomyolysis | 2015 |
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Casein Kinase I; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2015 |
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Hospitals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Smoking | 2015 |
Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Microscopy, Electron, Transmission; Nanoparticles; Phosphatidylcholines; Phosphatidylethanolamines; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Tumor Stem Cell Assay | 2016 |
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Theoretical; Mutation; Mutation Rate; Protein Kinase Inhibitors | 2015 |
Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hospitals, University; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Risk Factors; Salvage Therapy; Time Factors; Treatment Failure | 2015 |
Adjuvant TKIs in NSCLC: what can we learn from RADIANT?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male | 2015 |
Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Signal Transduction; Thyroid Nuclear Factor 1; Transcription Factors; Up-Regulation | 2015 |
Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Iodine; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Reproducibility of Results; Tomography, X-Ray Computed | 2016 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
Topics: Apoptosis; Benzophenanthridines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Flow Cytometry; Glutaminase; Humans; Lung Neoplasms; Mitochondria; Protein Kinase Inhibitors; RNA Interference; Time Factors | 2016 |
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Topics: Base Sequence; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Amplification; Humans; Inhibitory Concentration 50; Lung Neoplasms; Molecular Sequence Data; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2015 |
Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; MicroRNAs; Molecular Sequence Data; Protein Biosynthesis; Protein Kinase Inhibitors; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2015 |
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cholecalciferol; Drug Eruptions; Erlotinib Hydrochloride; Female; Genotype; Humans; Inflammation; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Quality of Life; Retrospective Studies | 2016 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Effects of kinase insert domain receptor (KDR) gene silencing on the sensitivity of A549 cells to erlotinib.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Silencing; Humans; Lung Neoplasms; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Female; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Xenograft Model Antitumor Assays | 2016 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Panobinostat | 2015 |
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Treatment Outcome | 2016 |
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-met | 2015 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation | 2016 |
Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Treatment Outcome | 2016 |
An unusual response with long term survival using erlotinib in NSCLC lung with brain metastases.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Survival Rate | 2016 |
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Protein Kinase Inhibitors; Receptor, EphA2; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |
Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2016 |
Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Precision Medicine; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2016 |
TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lung Neoplasms; MAP Kinase Signaling System; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Transforming Growth Factor beta1 | 2016 |
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-mdm2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
[Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Treatment Outcome | 2016 |
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Treatment Outcome | 2016 |
Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Staging; Xenograft Model Antitumor Assays | 2016 |
Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Carcinoma, Non-Small-Cell Lung; Dealkylation; Disease Progression; Disease-Free Survival; Drug Dosage Calculations; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Germany; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Severity of Illness Index | 2016 |
Quantitative and Simplified Analysis of 11C-Erlotinib Studies.
Topics: Adult; Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Models, Biological; Whole Body Imaging | 2016 |
Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genomics; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Nerve Tissue Proteins; Protein Kinase Inhibitors; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bundle-Branch Block; Carcinoma, Non-Small-Cell Lung; Cardiomyopathy, Dilated; Cisplatin; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pacemaker, Artificial; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Stroke Volume; Treatment Outcome | 2016 |
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Tumor Cells, Cultured | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolinones; Random Allocation; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2016 |
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biological Assay; Cell Proliferation; DNA Mutational Analysis; Erlotinib Hydrochloride; Exome; Female; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Metabolic Networks and Pathways; Models, Biological; Mutation; Pleural Effusion, Malignant; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Resolution of vocal fold leukoplakia during erlotinib treatment for lung cancer.
Topics: Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidental Findings; Laryngeal Neoplasms; Leukoplakia; Lung Neoplasms; Male; Vocal Cords | 2016 |
miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; MicroRNAs; Neoplasm Transplantation; Protein Kinase Inhibitors; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction | 2016 |
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastric Acid; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hypoalbuminemia; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Serum Albumin; Treatment Outcome | 2016 |
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome; Tumor Burden | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2016 |
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
The impact of autophagy on cell death modalities in CRL-5876 lung adenocarcinoma cells after their exposure to γ-rays and/or erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Chloroquine; DNA Breaks, Double-Stranded; DNA Repair; Erlotinib Hydrochloride; Gamma Rays; Humans; Lung Neoplasms | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; RNA, Small Interfering; Transcription Factor CHOP | 2016 |
Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Genes, erbB-1; Humans; Imatinib Mesylate; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rectal Neoplasms | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Decision-Making; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Reproducibility of Results; Sensitivity and Specificity; Sequence Analysis, DNA | 2016 |
Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Proteome; Proteomics; Retrospective Studies | 2016 |
In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Microtubule-Associated Proteins; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases | 2016 |
Metastasized lung cancer suppression by Morinda citrifolia (Noni) leaf compared to Erlotinib via anti-inflammatory, endogenous antioxidant responses and apoptotic gene activation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cell Line, Tumor; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Morinda; Neoplasm Metastasis; Plant Extracts; Plant Leaves; Xenograft Model Antitumor Assays | 2016 |
Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2016 |
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Brain Chemistry; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Unusual progressive neurological syndrome in epidermal growth factor receptor-mutated lung adenocarcinoma, diagnosed at autopsy as invasive meningeal carcinomatosis.
Topics: Adenocarcinoma; Coma; Dysarthria; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mental Disorders; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Sequence Deletion | 2016 |
miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Humans; Insulin-Like Growth Factor I; Lentivirus; Lung Neoplasms; Male; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.
Topics: Animals; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Lung Neoplasms; Mice, SCID; Mutation; Phosphorylation; Pyrimidines; Xenograft Model Antitumor Assays | 2016 |
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Dosage Calculations; Drug Synergism; Erlotinib Hydrochloride; Female; Indoles; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling.
Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CRISPR-Cas Systems; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockout Techniques; HEK293 Cells; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Phosphoproteins; Protein Interaction Domains and Motifs; Protein Stability; RNA, Small Interfering; Signal Transduction; Tankyrases; Transcription Factors; Ubiquitin-Protein Ligases; YAP-Signaling Proteins | 2016 |
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Interleukin-8; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phenotype; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Efficient Microscale Basic Reverse Phase Peptide Fractionation for Global and Targeted Proteomics.
Topics: Cell Line, Tumor; Chemical Fractionation; Chromatography, Reverse-Phase; Drug Resistance; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Miniaturization; Neoplasm Proteins; Proteome; Proteomics | 2016 |
TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Interaction Maps; Protein Kinase Inhibitors; Signal Transduction | 2016 |
Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Practice Patterns, Physicians'; United States | 2016 |
Drug companies settle claim of misleading doctors on cancer survival data.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Communication; Compensation and Redress; Drug Industry; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Scientific Misconduct; United States | 2016 |
Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Smoking; Survival Analysis | 2016 |
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Xenograft Model Antitumor Assays | 2016 |
YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphoproteins; Transcription Factors; YAP-Signaling Proteins | 2016 |
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Pemetrexed; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2016 |
Hepatoid adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Pneumonia; Tomography, X-Ray Computed | 2016 |
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Nude; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Assay; Biphenyl Compounds; Bronchi; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Survival; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Lignans; Lung Neoplasms; Magnolia; Mice; Molecular Docking Simulation; Nitrosamines; Plant Extracts; RNA, Small Interfering | 2016 |
Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Time Factors; Treatment Outcome | 2016 |
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.
Topics: Antineoplastic Agents; B7-H1 Antigen; Cell Line, Transformed; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2016 |
Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Trees; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Health Care Costs; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Republic of Korea | 2016 |
Calls to suspend European sales of erlotinib for lung cancer.
Topics: Antineoplastic Agents; Drug and Narcotic Control; Drugs, Generic; Erlotinib Hydrochloride; Europe; Humans; Lung Neoplasms; Therapeutic Equivalency | 2016 |
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Immunological; Cetuximab; Clodronic Acid; Cytokines; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, Synthetic; Humans; Lung Neoplasms; Macrophage Activation; Macrophages, Alveolar; Mice; Mice, Transgenic; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Recombinant Fusion Proteins; Smoking; Uteroglobin | 2017 |
Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Liver; Liver Neoplasms; Lung Neoplasms; Models, Theoretical; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Retrospective Studies | 2016 |
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Corpus Callosum; Cranial Irradiation; Decompression, Surgical; Diagnosis, Differential; Erlotinib Hydrochloride; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Metastasectomy; Parotid Neoplasms; Radiotherapy, Adjuvant | 2016 |
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Maximum Tolerated Dose; Research Design | 2017 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hypoxia; Lung Neoplasms; Prodrugs; Tumor Microenvironment | 2016 |
Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Mutation; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2016 |
Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Mutation | 2016 |
Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Quinazolines; Survival Analysis; Tumor Escape | 2016 |
Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphorylation; Polyubiquitin; Protein Kinase Inhibitors; Protein Stability; Proteolysis; Ubiquitination | 2016 |
[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Translocation, Genetic | 2017 |
Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
Topics: Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Insurance, Health; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Young Adult | 2016 |
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Xenograft Model Antitumor Assays | 2016 |
Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-8; Lung Neoplasms; Mutation; Phenotype; Receptors, Death Domain; Signal Transduction; Time Factors | 2016 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anilides; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Treatment Outcome | 2016 |
Management Difficulties in a Patient with EGFR-mutation Positive Lung Adenocarcinoma and Cerebral Metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Remission Induction; Salvage Therapy; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2017 |
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Radiation-Sensitizing Agents; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Reactive Oxygen Species | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
[Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorectal Neoplasms; Drug Eruptions; Erlotinib Hydrochloride; Fluorouracil; Folliculitis; Humans; Irinotecan; Lung Neoplasms; Male | 2017 |
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Topics: Amphiregulin; Anaplastic Lymphoma Kinase; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Microtubule-Associated Proteins; Mutation; Pleural Effusion; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Serine Endopeptidases; Xenograft Model Antitumor Assays | 2017 |
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP3A; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Seizures; Treatment Outcome | 2016 |
PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Diffusion; Drug Carriers; Drug Delivery Systems; Erlotinib Hydrochloride; Humans; Hydrodynamics; Hydrogen-Ion Concentration; Lipids; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanocapsules; Nanoparticles; Neoplasm Transplantation; Particle Size; Peptides; Polyethylene Glycols; Surface Properties | 2017 |
Targeted therapy of multiple liver metastases after resected solitary gastric metastasis and primary pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gastrectomy; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Positron Emission Tomography Computed Tomography; Stomach Neoplasms | 2016 |
TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.
Topics: Auranofin; Carcinoma, Non-Small-Cell Lung; Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Tumor Suppressor Proteins | 2016 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome | 2016 |
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Onartuzumab ineffective in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Pemetrexed; Population Groups; Young Adult | 2017 |
Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Guideline Adherence; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis; United States; United States Department of Veterans Affairs; Veterans; Young Adult | 2017 |
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Lung Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-met; Triazines | 2017 |
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Long Noncoding | 2017 |
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Neoplasm Staging; Protein Kinase Inhibitors; Taiwan | 2017 |
Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Benzeneacetamides; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Glutaminase; Glutamine; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Radiopharmaceuticals; RNA Interference; Thiadiazoles; Transplantation, Heterologous | 2017 |
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; North America; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Surveys and Questionnaires | 2017 |
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Radiosurgery; Retrospective Studies; Salvage Therapy; Survival Rate | 2017 |
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
A multi species evaluation of the radiation dosimetry of [
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Isotope Labeling; Lung Neoplasms; Macaca mulatta; Mice; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radiometry; Swine; Tissue Distribution | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2017 |
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Treatment Failure | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
A double-edged sword: Should stage IV non-small cell lung cancer patients be informed of their cancer diagnosis?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anxiety; Awareness; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Prognosis; Quality of Life; Stress, Psychological; Truth Disclosure; Young Adult | 2017 |
Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cattle; Cell Line, Tumor; Cell Survival; Erlotinib Hydrochloride; Humans; Lung; Lung Neoplasms; Models, Molecular; Serum Albumin, Bovine | 2017 |
Celecoxib-erlotinib combination treatment enhances radiosensitivity in A549 human lung cancer cell.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle Checkpoints; Combined Modality Therapy; Cyclooxygenase 2; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Oncogene Protein v-akt; Phosphoinositide-3 Kinase Inhibitors; Radiation Tolerance | 2017 |
Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Lung Neoplasms; Mutation; NADPH Oxidase 2; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Small Interfering | 2017 |
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2017 |
Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method.
Topics: A549 Cells; Administration, Inhalation; Aerosols; Antineoplastic Agents; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Dry Powder Inhalers; Emulsions; Erlotinib Hydrochloride; Humans; Lipids; Lung Neoplasms; Nanoparticles; Particle Size; Solubility; Time Factors; Tissue Distribution | 2017 |
MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Movement; Cell Proliferation; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Topics: Adenocarcinoma; Cerebrospinal Fluid; Diagnosis, Differential; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2008 |
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Topics: Amino Acid Substitution; Apoptosis; Arginine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leucine; Lung Neoplasms; Mitochondria; Mutation; Oxidative Phosphorylation; Protein Structure, Quaternary; Protein Transport; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering | 2008 |
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines | 2008 |
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment | 2008 |
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genes, erbB-1; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis | 2008 |
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Codon, Nonsense; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
Topics: Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung Neoplasms; Mesoderm; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Electrospray Ionization; Thiophenes; Transforming Growth Factor beta; Tumor Cells, Cultured | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Trichomegaly induced by erlotinib.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed | 2008 |
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2008 |
[Targeted therapies. New hopes, new challenges].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A | 2008 |
Non-small cell lung cancer-smokers or non-smokers, does it matter?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Newer opportunities in systemic therapy of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiotherapy; Treatment Outcome | 2008 |
Rosaceiform eruption induced by erlotinib.
Topics: Acneiform Eruptions; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate | 2008 |
[Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"].
Topics: Adult; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Male; Multiple Pulmonary Nodules; Pericardial Effusion; Protein Kinase Inhibitors; Quinazolines; Smoking; Treatment Outcome | 2009 |
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Oncogene Protein v-akt; Quinazolines; Time Factors; Tumor Cells, Cultured | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2008 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Topics: Amino Acid Substitution; AMP-Activated Protein Kinase Kinases; Animals; Chlorocebus aethiops; COS Cells; ErbB Receptors; Erlotinib Hydrochloride; Focal Adhesion Kinase 1; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation, Missense; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Growth Factor; Sulfonamides | 2009 |
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Salvage Therapy; Treatment Failure | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
[Hand-foot syndrome: A new side effect of erlotinib].
Topics: Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Erythema; Foot Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Syndrome | 2008 |
Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disseminated Intravascular Coagulation; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thrombocytopenia | 2009 |
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dideoxynucleosides; Down-Regulation; Early Detection of Cancer; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Lung Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclosporine; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2009 |
Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated non-small cell lung cancer (NSCLC) patients.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhalation Exposure; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2009 |
[Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Utilization; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents; Cell Proliferation; Cone-Beam Computed Tomography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, p53; Genes, ras; Lung Neoplasms; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; Quinazolines; Tumor Burden | 2009 |
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking | 2009 |
Erlotinib for the treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2009 |
A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Risk Assessment | 2009 |
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Caspase 12; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transcription Factor CHOP; Tunicamycin | 2009 |
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Tissue Distribution; Transplantation, Heterologous | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
Arsenic activates EGFR pathway signaling in the lung.
Topics: Adult; Aged; Amphiregulin; Analysis of Variance; Arsenic; Arsenites; Biomarkers; Bronchi; Cells, Cultured; Cyclin D1; Cycloheximide; EGF Family of Proteins; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; Middle Aged; Nails; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Compounds | 2009 |
Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Quinazolines; Thromboxane B2; Treatment Outcome | 2009 |
[Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2008 |
[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction; Treatment Failure; Young Adult | 2008 |
ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Staging; Palliative Care; Quinazolines; Radiotherapy Dosage | 2009 |
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Depsipeptides; Drug Synergism; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Xenograft Model Antitumor Assays | 2009 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Erlotinib-induced pustular eruption.
Topics: Acneiform Eruptions; Administration, Cutaneous; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythromycin; Gels; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
Topics: Animals; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Immunoprecipitation; Indoles; Luciferases; Lung Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; RNA, Small Interfering; Sulfonamides; Xenograft Model Antitumor Assays | 2008 |
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2009 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Survival; Depsipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Cluster Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Gene Expression; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2009 |
Persistent hair growth during treatment with the EGFR inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Hair; Hair Color; Humans; Hypertrichosis; Lung Neoplasms; Neoplasm Proteins; Paronychia; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
Topics: Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Metabolome; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2009 |
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lung Neoplasms; Lysosomes; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quantum Dots; Quinazolines; Signal Transduction | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Analysis of ErbB receptors in pulmonary carcinoid tumors.
Topics: Adult; Aged; Base Sequence; Carcinoid Tumor; Cell Proliferation; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Polymorphism, Single Nucleotide; Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2009 |
Erlotinib and bevacizumab have synergistic activity against melanoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, SCID; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Topics: Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost Control; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Sensitivity and Specificity; Taxoids | 2008 |
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed | 2009 |
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tumor Cells, Cultured; Vincristine | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Proteins; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Persistent corneal epithelial defect associated with erlotinib treatment.
Topics: Aged; Cataract Extraction; Corneal Diseases; Epithelium, Corneal; Erlotinib Hydrochloride; Female; Humans; Keratitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Staphylococcal Infections; Staphylococcus epidermidis | 2009 |
Role of tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2009 |
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Lung Neoplasms; Middle Aged; Quinazolines | 2009 |
Assessment of erlotinib in chemoresponse assay.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2009 |
Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
Topics: Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Proteins; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Exons; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2009 |
Erlotinib for the treatment of relapsed non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical | 2009 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Injections, Intraocular; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vitreous Body | 2009 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors; Treatment Outcome | 2009 |
Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Stability; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2009 |
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Online Systems; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Registries | 2009 |
Lung cancer trials probe effects of maintenance therapy, targeted agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Respiration; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Glycoproteins; Mitochondria; NADPH Oxidase 2; NADPH Oxidases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Personalized medicine and inhibition of EGFR signaling in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Screening for epidermal growth factor receptor mutations in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sex Distribution; Survival Analysis; Young Adult | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking | 2009 |
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Topics: Afatinib; Amphiregulin; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Models, Animal; Drug Resistance, Neoplasm; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Transplantation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Insurance, Health, Reimbursement; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2010 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Lung Neoplasms; Male; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction | 2009 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; Community Health Services; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors | 2009 |
Clinical significance of the KRAS mutation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2009 |
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Guidelines as Topic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome | 2009 |
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Erlotinib-induced skin manifestations.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
A case of bullous dermatitis induced by erlotinib.
Topics: Adenocarcinoma; Dermatitis; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases, Vesiculobullous | 2009 |
Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2009 |
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2010 |
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
Topics: Budgets; Carcinoma, Non-Small-Cell Lung; Cost Control; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Economic; Protein Synthesis Inhibitors; Quinazolines | 2010 |
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed | 2011 |
[Lung cancer: an update in 2010].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Treatment of lung cancer.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Trichomegaly secondary to erlotinib.
Topics: Adenocarcinoma; Aged; ErbB Receptors; Erlotinib Hydrochloride; Eyebrows; Eyelashes; Humans; Hypertrichosis; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2010 |
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Alopecia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Topics: Adenocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Economics and the new generation of targeted therapies for non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; United States | 2010 |
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Hospitalization; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2010 |
[Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
Topics: Adenocarcinoma; Aged; Erlotinib Hydrochloride; Female; Humans; IgA Vasculitis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation | 2010 |
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2009 |
[Maintenance treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Network meta-analysis: importance of appropriate trial selection.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Confidence Intervals; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meta-Analysis as Topic; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Taxoids | 2010 |
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Osteoblasts; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Cancer: drug-tolerant insurgents.
Topics: Biological Evolution; Cell Line, Tumor; Cisplatin; Clone Cells; Drug Resistance, Neoplasm; Drug Tolerance; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Biological; Quinazolines; Retinoblastoma-Binding Protein 2; Selection, Genetic | 2010 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Serious hematologic complications following erlotinib treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk | 2010 |
Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seasons; Vaccination | 2010 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytochromes b5; Cytoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Membrane Proteins; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Receptors, Progesterone; RNA Interference | 2010 |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2010 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Markov Chains; Neoplasm Staging; Pemetrexed; Placebos; Quinazolines; Remission Induction; Survival Rate; Treatment Outcome | 2010 |
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bronchi; Cell Line, Tumor; Cetuximab; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Quinazolines; RNA, Small Interfering; Signal Transduction | 2010 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Face; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured | 2010 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
Serum concentrations of Erlotinib at a dose of 25 mg daily.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Bilateral anterior uveitis secondary to erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Uveitis | 2010 |
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenopus Proteins | 2010 |
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Proliferation; Enzyme Inhibitors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Protein Binding; Quinazolines; Ribonuclease, Pancreatic; Sulfhydryl Compounds; Tumor Cells, Cultured | 2010 |
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Methylation; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Ubiquitin-Protein Ligases | 2011 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Topics: Animals; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta | 2010 |
Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Topics: Adenocarcinoma; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; International Normalized Ratio; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thromboembolism; Warfarin | 2010 |
Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equipment Design; Equipment Failure Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hydrogels; Lung Neoplasms; Peptides; Protein Array Analysis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2011 |
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase IV as Topic; Compassionate Use Trials; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Topics: Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Dermatologic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Isotretinoin; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
[Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines | 2010 |
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.
Topics: Antineoplastic Agents; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Piperidines; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
Topics: Alternative Splicing; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Lung Neoplasms; Mutation; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Serine-Arginine Splicing Factors; Signal Transduction | 2010 |
[TARCEVA Clinical Registry].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Registries | 2010 |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Array Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2010 |
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2010 |
Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Topics: Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Transforming Growth Factor alpha | 2010 |
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Peptide Fragments; Peptide Mapping; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2011 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Long-lasting drop in perfusion of a non-small cell lung cancer induced by monotherapy with the epithelial growth factor receptor inhibitor erlotinib persisting despite tumor progression at remote sites.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2010 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking; Young Adult | 2010 |
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Mutation, Missense; Quinazolines; Sequence Deletion | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Lung cancer: recent advances.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Mutation; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Translocation, Genetic | 2011 |
Erlotinib and pantoprazole: a relevant interaction or not?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Quinazolines | 2010 |
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Furans; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Repair; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Genes, BRCA1; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Treatment Outcome | 2011 |
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss | 2011 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Survival Rate | 2011 |
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines | 2011 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
More on aprepitant for erlotinib-induced pruritus.
Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines | 2011 |
Is FISH floating or still swimming in the lung cancer ocean?
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Meta-Analysis as Topic; Molecular Diagnostic Techniques; Mutation; Quinazolines; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
Screening for EGFR mutations in lung cancer, a report from India.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; India; Lung Neoplasms; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Sequence Deletion; Sex Factors | 2011 |
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
[A case of lung cancer with skin metastases responding to erlotinib].
Topics: Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2011 |
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; fas Receptor; Genes, erbB-1; Humans; I-kappa B Proteins; Lung Neoplasms; Models, Biological; Mutant Proteins; Mutation; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2011 |
"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Topics: Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Lung Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcription Factor AP-2 | 2011 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.
Topics: Bronchi; Butadienes; Cell Line, Tumor; Cyclin D1; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hyperplasia; Luciferases; Lung Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Nitriles; Organ Culture Techniques; Quinazolines; RNA, Small Interfering | 2011 |
Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Taiwan; Treatment Outcome | 2011 |
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2011 |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2011 |
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; bcl-X Protein; Biphenyl Compounds; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mice; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Sulfonamides; Transplantation, Heterologous | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Salvage with erlotinib plus bevacizumab: not in NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Palmar bullous blistering induced by erlotinib.
Topics: Adenocarcinoma; Blister; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Retreatment; Treatment Outcome | 2011 |
Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outpatients; Protein Kinase Inhibitors; Quinazolines | 2011 |
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Technology Assessment, Biomedical; Treatment Outcome | 2011 |
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Confocal; Microscopy, Electron; Microtubule-Associated Proteins; Phagosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2011 |
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Markov Chains; Medical Oncology; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sensitivity and Specificity | 2012 |
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
[Erlotinib in non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Ascites; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Prednisolone; Quinazolines | 2011 |
Papulopustular eruptions in a 32-year-old woman after lung cancer treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Dermatologic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Metronidazole; Mupirocin; Quinazolines | 2011 |
Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
The use of erlotinib in daily practice: a study on adherence and patients' experiences.
Topics: Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Culture; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Informed Consent; Lung Neoplasms; Medication Adherence; Multicenter Studies as Topic; Patient Selection; Patients; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design | 2011 |
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic | 2011 |
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2012 |
Recovery from carcinomatous meningitis by erlotinib.
Topics: Adenocarcinoma; Aged; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Spectrophotometry, Ultraviolet | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[Management of patients with resistance to EGFR-TKI].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2011 |
Erlotinib-induced rash spares previously irradiated skin.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2011 |
Drug-induced effects on erlotinib metabolism.
Topics: Adenocarcinoma; Aged; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2011 |
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lung Neoplasms; Membrane Potential, Mitochondrial; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sirolimus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lung Neoplasms; Mutation; Neoplasms, Second Primary; Organoplatinum Compounds; Quinazolines; Thyroid Neoplasms; Transcriptional Activation; Treatment Failure; Treatment Outcome | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2011 |
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Cetuximab; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2011 |
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment | 2011 |
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Topics: Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2011 |
Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Topics: Aged; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors | 2011 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.
Topics: Aged; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2011 |
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Congresses as Topic; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United Kingdom | 2011 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2011 |
Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Computer Simulation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Lymphoma; Mice; Mice, Transgenic; Models, Theoretical; Oncogenes; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Quinazolines; Tumor Cells, Cultured | 2011 |
Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Radiography | 2011 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance.
Topics: Carcinoma, Non-Small-Cell Lung; Decision Making; Decision Support Techniques; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Middle Aged; Pharmacopoeias as Topic; Protein Kinase Inhibitors; Quinazolines; State Medicine; Tape Recording; United Kingdom | 2011 |
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morphine; Quinazolines; Receptors, Opioid, mu | 2011 |
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Rearrangement; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2011 |
[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Treatment Outcome | 2011 |
Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Granuloma, Pyogenic; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tracheal Diseases | 2011 |
Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; British Columbia; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Taxoids | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2011 |
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2011 |
[New 'targeted therapy' for lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Treatment Outcome | 2011 |
Erlotinib in metastatic bronchopulmonary mucoepidermoid carcinoma.
Topics: Adult; Carcinoma, Mucoepidermoid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mediastinal Neoplasms; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Splenic Neoplasms | 2011 |
Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Laboratory Techniques; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Services; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Office Visits; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Taxoids; United States | 2012 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
Pneumocystis jiroveci Pneumonia in an Atypical Host.
Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bevacizumab; Breast Neoplasms; CD4 Lymphocyte Count; Clinical Trials, Phase I as Topic; Dexamethasone; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Paclitaxel; Pneumocystis carinii; Pneumonia, Pneumocystis; Quinazolines; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoembryonic Antigen; Drainage; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleura; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tissue Polypeptide Antigen; Treatment Outcome | 2012 |
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Erlotinib Hydrochloride; Female; France; Germany; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Spain | 2012 |
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2011 |
Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Quinazolines | 2010 |
Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression.
Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; Protein Kinase Inhibitors; Quinazolines; RANK Ligand | 2012 |
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azabicyclo Compounds; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured | 2012 |
Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
Topics: Adenocarcinoma; Adult; Afatinib; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.
Topics: Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Invasiveness; Prognosis; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Transfection | 2012 |
The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Optimising therapy for EGFR-addicted NSCLC: just the start.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Vimentin; Young Adult | 2012 |
Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate | 2012 |
Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
Subacute transient encephalopathy induced by erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Confusion; Erlotinib Hydrochloride; Female; Humans; Irritable Mood; Lethargy; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seizures; Unconsciousness; Urinary Incontinence | 2011 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Inbred BALB C; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed | 2012 |
[Efficacy of combination therapy with EGFR-TKI and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKI].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2012 |
A case of choroidal metastasis of lung cancer successfully treated with erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Choroid Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis | 2012 |
A study of electrochemical biosensor for analysis of three-dimensional (3D) cell culture.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Count; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Collagen; Drug Combinations; Electrochemical Techniques; Erlotinib Hydrochloride; Gels; Humans; Laminin; Lung Neoplasms; Proteoglycans; Quinazolines; Spheroids, Cellular | 2012 |
Retrospective study of erlotinib in patients with advanced squamous lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
Topics: Antigens, CD; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines; Tumor Stem Cell Assay | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Carcinomatous meningitis in a post-operative patient with lung adenocarcinoma for which erlotinib was effective - a case report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Membrane Potentials; Patch-Clamp Techniques; Phlorhizin; Protein-Tyrosine Kinases; Quinazolines; Radiation Dosage; Sodium-Glucose Transport Proteins; Tumor Cells, Cultured | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Crizotinib; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Amplification; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, SCID; Mutation, Missense; Oncogene Proteins, Fusion; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
A case of rapid improvement of severe psoriasis during molecular-targeted therapy using an epidermal growth factor receptor tyrosine kinase inhibitor for metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Comorbidity; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Colorectal Neoplasms; Corneal Perforation; Ectropion; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Keratoplasty, Penetrating; Lung Neoplasms; Male; Middle Aged; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Visual Acuity | 2012 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
Topics: Adult; Biopsy; Bronchoscopy; Cell Transformation, Neoplastic; Diagnosis, Differential; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis.
Topics: Aged; Antitubercular Agents; Dermatomyositis; Diagnosis, Differential; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; Tuberculosis, Pulmonary | 2012 |
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Purpuric drug eruption and alopecia induced by erlotinib.
Topics: Adenocarcinoma; Aged; Alopecia; Dermis; Drug Eruptions; Erlotinib Hydrochloride; Humans; Leg; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptors, Tumor Necrosis Factor; Signal Transduction; Tumor Cells, Cultured; TWEAK Receptor | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Transcription, Genetic; Trifluoperazine; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Puncture | 2011 |
Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Onycholysis; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2011 |
[A case of a corneal disorder after lung cancer treatment with erlotinib].
Topics: Corneal Diseases; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival Rate | 2012 |
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Genes, erbB-1; Humans; Janus Kinase 2; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Management of non-small cell lung cancer: focus on erlotinib. Foreword.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dideoxynucleosides; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Sequence Deletion | 2012 |
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Topics: Adult; Aged; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Linear Models; Lung Neoplasms; Multivariate Analysis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease-Free Survival; Ephrins; Epithelial Cells; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multivariate Analysis; Mutation, Missense; Neoplasm Invasiveness; Occludin; Proportional Hazards Models; Quinazolines; Receptor, EphA4 | 2012 |
A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Topics: Alleles; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single-Stranded Conformational; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2012 |
Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Tumor Burden | 2012 |
KRAS wild-type lung cancer: a moving target in an era of genotype migration.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Follow-up of erlotinib related uveitis.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Uveitis; Visual Acuity | 2012 |
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography; Treatment Outcome | 2012 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Salvage Therapy | 2013 |
[Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Topics: Aged; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2012 |
Analysis of chemotherapy and molecular therapy efficiency in advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
[EGFR mutations in patients with advanced NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2012 |
Erlotinib-associated dermatological toxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Quinazolines | 2013 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering | 2012 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Quinazolines | 2012 |
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry | 2013 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Theoretical; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution; Tumor Cells, Cultured | 2012 |
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dihematoporphyrin Ether; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Photochemotherapy; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2012 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lung Neoplasms; Quinazolines; Taxoids; Tubulin | 2012 |
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2012 |
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2012 |
Erlotinib in patients with advanced lung squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
[Personalised treatment of lung cancer].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Positron-Emission Tomography; Precision Medicine; Quinazolines | 2012 |
Erlotinib-induced bullous pemphigoid.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Pemphigoid, Bullous; Quinazolines | 2012 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2013 |
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Topics: Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Who should receive EGFR tyrosine-kinase inhibitors?
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure; Tumor Burden | 2013 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cytochrome P-450 CYP2D6; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[The TULUNG clinical registry].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Czech Republic; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Registries | 2012 |
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; RNA Interference; TOR Serine-Threonine Kinases; Ubiquitin-Conjugating Enzymes | 2012 |
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proteins; Proteomics; Quinazolines; Survival Analysis | 2013 |
Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Models, Statistical; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
Topics: Adult; Base Sequence; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed | 2013 |
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.
Topics: Calibration; Chromatography, High Pressure Liquid; Edetic Acid; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Quinazolines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
First-line erlotinib inferior to chemo in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2012 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Topics: Acrylamides; Amino Acid Substitution; Animals; Area Under Curve; Base Sequence; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; RNA Interference; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; England; Erlotinib Hydrochloride; Humans; Inappropriate Prescribing; Lung Neoplasms; Polypharmacy; Prevalence; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Cell Survival; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Stability; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2013 |
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2013 |
EGFR mutations in squamous cell lung cancer in never-smokers.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Epidural Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Smoking; Thoracic Vertebrae | 2013 |
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Neuroendocrine; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2013 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Topics: Adenocarcinoma; Animals; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta2; Tumor Cells, Cultured | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Topics: Adult; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Family Health; Fatal Outcome; Female; Germ-Line Mutation; Humans; In Situ Hybridization; Lung; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Squamous Cell; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; LIM Domain Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; Signal Transduction | 2013 |
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Thoracic Diseases; Treatment Outcome | 2013 |
Erlotinib plus parenteral nutrition: an opportunity to get through the hardest days of advanced non-small cell lung cancer with cancer anorexia-cachexia syndrome.
Topics: Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Parenteral Nutrition; Quinazolines; Syndrome | 2013 |
A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Sample Size; Software | 2013 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
Early-stage lung cancer findings end a debate, put focus on next steps.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Quinazolines; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Congresses as Topic; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Societies, Medical; United States | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
[Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Survival Rate | 2004 |
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2004 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Survival Analysis; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
FDA Oncology Committee debates Iressa's status following negative trial results.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
Will lung cancer targeting hit its mark?
Topics: Antineoplastic Agents; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2005 |
Targeting EGFR in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2005 |
Erlotinib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Placebos; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
New approaches in the management of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2006 |
Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelium; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Genes, Neoplasm; Humans; Immunohistochemistry; Lung Neoplasms; Mesoderm; Mutation; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vimentin | 2005 |
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2005 |
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
An acneiform eruption due to erlotinib: prognostic implications and management.
Topics: Acneiform Eruptions; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2006 |
Assessing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paraffin Embedding; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Survival Analysis | 2006 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Neoplasms; Male; Molecular Biology; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Smoking | 2006 |
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Humans; Lung Neoplasms; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
[A new medication for lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2005 |
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2006 |
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF | 2006 |
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film | 2006 |
Erlotinib: optimizing therapy with predictors of response?
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Gene Amplification; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2006 |
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A | 2006 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines | 2006 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2006 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-3; Lung Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2 | 2006 |
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2006 |
Pulmonary fibrosis in a patient treated with erlotinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2005 |
Follicular rash during therapy with erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Facial Dermatoses; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptors, Somatomedin; RNA, Messenger; Signal Transduction; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
Erlotinib-induced breast cancer regression.
Topics: Adult; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines; Radiography; Remission Induction | 2006 |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Discriminant Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Reproducibility of Results; Tumor Cells, Cultured | 2006 |
Should every lung cancer patient be tested for EGFR mutation?
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Pharmacogenetics; Quinazolines | 2006 |
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2006 |
Paired drugs give advanced lung cancer a double punch.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Sulfonamides | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[New medications; erlotinib].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dermatitis, Phototoxic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cetuximab; DNA, Complementary; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2007 |
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Clairvoyance or reliable prediction of the future?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2007 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
[Lung cancer: targeted therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Significant drug interaction: phenytoin toxicity due to erlotinib.
Topics: Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Seizures | 2007 |
Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2007 |
An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2007 |
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Topics: Active Transport, Cell Nucleus; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; S Phase; Up-Regulation | 2007 |
Erlotinib-associated acute pneumonitis: report of two cases.
Topics: Acute Disease; Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Glucocorticoids; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Shock, Septic | 2007 |
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Topics: Alleles; Amino Acid Substitution; Animals; Cell Survival; Cells, Cultured; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Peptide Fragments; Phosphorylation; Point Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retroviridae; Sequence Deletion | 2007 |
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Rectal Neoplasms; Rosacea | 2007 |
Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2007 |
Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Agents; Brachiocephalic Veins; Carcinoma, Non-Small-Cell Lung; Cyanosis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Superior Vena Cava Syndrome; Syncope; Tomography, X-Ray Computed; Venous Thrombosis | 2007 |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines | 2007 |
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering | 2007 |
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2007 |
Fulminant hepatic failure secondary to erlotinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Failure, Acute; Liver Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2007 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |
[Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Optimizing targeted therapy in patients with lung cancer with a performance status of 2.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinazolines; Tomography, X-Ray Computed | 2007 |
Epidermal growth factor receptor inhibitor-related folliculitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Fatal Outcome; Hematoma, Subdural; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2008 |
Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer.
Topics: Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic | 2007 |
Pulmonary toxicity associated with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.
Topics: Bacterial Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Luminescent Proteins; Lung Neoplasms; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Point Mutation; Polymorphism, Genetic; Quinazolines; Sequence Deletion | 2007 |
EGFR inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2007 |
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2007 |
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hungary; Immunohistochemistry; Lung Neoplasms; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2007 |
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-Associated Death Protein; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Mice; Mutation; Quinazolines; Sensitivity and Specificity | 2007 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2007 |
Response of intracranial metastases to erlotinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2007 |
Acneiform reaction to erlotinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Sex Factors | 2008 |
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment | 2008 |
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Lung Neoplasms; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Small Interfering; Signal Transduction | 2007 |
Erlotinib-associated alopecia in a lung cancer patient.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2007 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines | 2007 |
[TRUST study: general practice relevant data on erlotinib in NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Topics: Acne Vulgaris; Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2007 |
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Cell Cycle; Cell Death; Cell Extracts; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Folic Acid Antagonists; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Morpholines; Pemetrexed; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2008 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Green Fluorescent Proteins; Humans; Interleukins; Lung Neoplasms; MAP Kinase Signaling System; Mutant Proteins; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Quinazolines; Recombinant Fusion Proteins; Tumor Stem Cell Assay | 2008 |
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors | 2008 |
Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
Topics: Bacteremia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin; Staphylococcal Infections | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
Topics: Adult; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2008 |
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome | 2008 |
Images in clinical medicine. Erlotinib-induced hair alterations.
Topics: Erlotinib Hydrochloride; Hair Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure | 2008 |
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2008 |
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
[Efficacy of erlotinib on advanced non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2008 |
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Topics: Acute Disease; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Pain Management; Palliative Care; Quinazolines; Radiotherapy; Shock; Spinal Cord Compression | 2008 |
[Acneiforme rash in woman with pulmonary adenocarcinoma].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Lung; Lung Neoplasms; Mice; Nicotinic Acids; Oleanolic Acid; Protein Kinase Inhibitors; Quinazolines; Tetrahydronaphthalenes | 2008 |
Bilateral eardrum perforation after long-term treatment with erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tympanic Membrane Perforation | 2008 |